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ABSTRACT 
A glycoprotein can exist as a spectrum of glycosylated forms, where each protein molecule may 
be associated with an array of oligosaccharide structures. The overall range of glycoforms can 
have a variety of different biophysical and biochemical properties. As a result of this 
'microheterogeneity' there is a need for the synthesis of homogeneously glycosylated proteins 
for analytical purposes. The synthesis of novel glycoproteins through the selective reaction of 

















Through site-directed mutagenesis, whereby the natural asparagine glycosylation sites can be 
exchanged for cysteine, it was possible to selectively glycosylate proteins at predetermined sites. 
This provided a general method for the synthesis of homogeneously glycosylated proteins. We 
chose the glycoprotein hormone erythropoietin as a model system since the N-glycans at residues 
24, 38 and 83 are essential for in vivo biological activity. 
Using a modified recombinant erythropoietin gene (prepared in Chapter 2) we optimized protein 
expression, and over-expressed and purified Hisio-WThEPO, His i o-Asn24Cys, Hisio-Asn38Cys, 
His i o-Asn83Cys and His i o-Asn38/83CyshEPO's in yields of 13mgL from E. co/i. This 
allowed us to probe the structure of rhEPO using techniques such as NMR spectroscopy and 
electrospray MS (Chapter 3). Having access to larger quantities of EPO, we were also able to 
develop on-line LC-ESI-MS methods, which allowed us to monitor protein glycosylation 
reactions with glycosyl 13-N-iodoacetamides and map the position of the glycosylation site. 
The synthesis of relevant iodoacetamides was attempted and simple glycosyl iodoacetamides and 
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EXPLANATORY NOTES 








Erythropoietin is the protein under study in this thesis. The wild type protein 
comprises 166 amino acids (molecular weight-18389). Our expressed Hisio-tagged 
species have an additional 21 amino acids fused to the N-terminus of wild type 
erythropoietin (molecular weight=209 17): 
GHHHHHHHHHHSSGHIEGRHM-EPO 
To maintain the native human erythropoietin residue numbering, unless otherwise 
stated, the polyhistidine tag residues are assigned negative numbers (-21G to —1M). 
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Principles of Pro te in 
Glycosylation and The Role 
of the Bound 
Oligosaccharides. 
CHAPTER 1 
IJVTRODUCTION: General Principles of Protein Glycosylation. 
The importance of oligosaccharides is now well appreciated' 2.  Cell growth and 
differentiation, viral and bacterial infection, leukocyte adhesion to inflamed 
endothelium and tumour cell metastasis are a few examples of the vast array of 
processes governed by carbohydrate-receptor interactions. It was the ability to 
accurately sequence the oligosaccharide moieties of glycoproteins that revealed their 
complexity and diversity in structure. However, despite the large number of 
glycoproteins known, the types of covalent bond between the protein and 
carbohydrate show relatively little variation. The two variants which are most 
prevalent throughout eukaryotes are N-linked, characterised by a f-N-glycosidic 
linkage between N-acetyl glucosamine and the amide group of certain asparagine 
residues in the sequence Asn-X-SerlThr, and 0-linked, characterised by a proximal 
a-0-glycosidic linkage between N-acetyl galactosamine and the hydroxyl groups of 









2 	 NH 3 
Figure 1.1: (1) -N-glycosidic linkage to asparagine in N-linked glycoproteins, (2) and (3) (x-0- 
glycosidic linkages to serine and threonine respectively. R= oligsaccharide chain. 
2 
CHAPTER 1 
1.1 Biosynthesis of N-Linked Glycoproteins. 
N-linked glycoproteins are constructed on the lumenal side of the endoplasmic 
reticulum (Figure 1.2) where a single multimeric enzyme, oligosaccharyl transferase 
(OST), catalyses the co-translational transfer of a common lipid linked tetradeca 
saccharide (GlcNAc 2Man9Glc 3 ) to an 
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Figure 1.2: Biosynthesis of N-linked glycans. 
invariably not tolerated. 
asparagirie residue on a nascent 
polypeptide. How OST does this has 
been, and still is, a matter of intense 
debate 45. The consensus sequence: 
Asn-X-Ser/Thr (where X is any ammo 
acid except proline) required for 
recognition by the enzyme has been 
extensively studied in vitro in attempts 
to establish the specificity of the 
enzyme. Studies on the model peptide 
(4) has shown that modification of the 
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(4) 
Glutamine and N-methyl asparagine in place of asparagine are not substrates for OST 
but thioasparagine (carbonyl oxygen is substituted with sulfur) is. The third amino 
acid (Ser/Thr) is as invariable and only substitution with cysteine shows low, but 
measurable, levels of glycosyl acceptor activity. Conformational requirements are 
also important as the peptide to be glycosylated is believed to form an Asx turn 
(Figure 1.3) which allows the hydroxyl group of serine or threonine to activate the 









Figure 1.3 : Asparagine amide group activation by the hydroxyl group of serine or threonine 4 . 
As not all consensus sequences are glycosylated, occupation of the sites may also be 
influenced by the manner of folding during biosynthesis ie: the accessibility of 
potential sites to OST. After glycosylation, the glycoprotein is translocated to the 
Golgi apparatus where it is subjected to the host cell's complement of glycosidases 
and glycosyltransferases. This is where the resulting heterogeneity occurs and is a 
result of the differing rate constants of particular glycosyltransferases and 
glycosidases and overall time spent in each post-translational compartment 6 ' 7 . The 
major subgroups of mammalian oligosaccharides from N-linked glycoproteins are 
shown below: 
GkNAc(3I-4) 	 Fuc(cxl-6) 
Sia((x2-6)Gaj31-4) GkNAc(I3l-6) 
Sia(ct2-6)Gahj3l-4) GIcNAc(131-4) Man(cd6) \ 
Sia((x2-6)GakP1-4) GkNAc(J3l-2) 	
Man(3l-4) G1cNAc(131-4) GIcNAc —Asn A. 





Man(3l-4) GNAc(I3l-4) G1cNAc —Asn B 
/ 
Maal-2)Maa1-2) 	Man(l-3) 
Man(al-6)I 	 I Maia1-6) 	 I 
Marcil-3)I I 
S(a2-3ak 1-4) GNAc( 1-4) Man((x 1-3) 
an() GNAc(13l-4) GIcNAc —Asn C 
GkNAc(131-2)I 
GIcNAc(31-4) 	 Fuc(al-6) 
Figure 1.4: The major subgroups of mammalian Winked oligosaccharides. A. complex type, B. 
High mannose type and C. Hybrid type. The structures within the boxes are always conserved, 
outside the boxes, the structures are variable. 
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Although all members of these classes share a characteristic core pentasaccharide 
adjacent to the peptide, the outlying glycoforms vary widely and account for 
glycoproteins enormous diversity in structure and variation in biophysical and 
biochemical properties. 
1.2 Biosynthesis of 0-linked Glycoproteins. 
The synthesis of 0-linked oligosaccharides occurs entirely by post-translational, 
sequential addition of nucleotide linked monosaccharides to the protein 8 '9 . Unlike in 
N-glycoproteins, there is no clear consensus sequence and protein domains likely to 
be glycosylated are generally rich in serine and threonine but, as with N-glycans, the 
presence of the glycosylation site is not sufficient for glycosylation and 
conformational restraints may inhibit glycosylation at specific sites. 
The glycans of 0-linked glycoproteins comprise five main core structures 10  and, 
again, structural diversity comes from the variation in terminal sugars which are 
generally cc-linked N-acetylneuraminic acid (sialic acid), fucose, galactose, N-acetyl 
glucosamine and N-acetly galactosamine. 
	
Sia((x2-3)INAca 	Serf Thr 
Sia((x2-3)1(f3 1-3) 	_ 
1NAca____ Serf Thr 
Sia(ct2-6)" 
1NAc(aI3) \ 
QtI(13 1 -4)IcNAc(l3 1 -3)th1(3 1-4)tkNAc(3 1 -3)thl(f3 1-3) 
Fuc((xl-2) / 	 a6)" i1NAca 	Serf Thr 
Sia(2-  
Fuc(aI-2)1(1-3)acNAc(I31-3)ckilNAca 	Serf Thr 
th1( 1-4)cilcNAc(13 1-3) 
Sia(ci2-3)thl(1314)\ 	 / thiNAca 	Serf Thr 
GIcNAc(13 1-6) 
Fuc((t 1-3)" 
Figure 1.5: Core structures of mammalian 0-linked glycans' ° 
The structures of 0-linked glycoproteins are diverse and even within a single protein 
can exhibit considerable microheterogeneity. 
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1.3 The Biological Roles of Oligosaccharides in Glycoconjugates. 
In recent years the biological role of the bound oligosaccharide has been 
comprehensively reviewed' ,2 . Despite some observations suggesting important 
biological roles for the oligosaccharide moiety, a single common theory has not, to 
the present day, emerged to explain the diversity in oligosaccharide structure, as the 
importance of the bound oligosaccharide can vary from seemingly trivial to vital for 
the development, growth, function and survival of the organism. Below are but a 
few examples of the effects that the presence of sugars can have on glycoproteins'. 
1.3.1 Structural, Protective and Stabilising. 
As previously mentioned, N-glycosylation relies on the presence of an Asx turn motif 
(5) for recognition by OST4. It is believed that glycosylation of this motif perturbs 
the conformation towards a 3-tum (6) and the bias towards a n-turn is greatest when 
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Figure 1.6: Glycosylation of the Asx turn causes a conformational change which results in the 
formation of a n-turn. 
In fact 30% of all glycosylation sites result in sites that fold ultimately into -tums 
and it has been suggested that the IV-acetyl group of the proximal G1cNAc residue 
plays a key role sprouting from a steric interaction which hinders rotation about the 
glycosidic bond. Furthermore, a slightly truncated form of the initial 
tetradecasaccharide is a ligand for calnexin, a key chaperone protein in the 
endoplasmic reticulum and may therefore play a direct role in aiding the folding 
process ' 2 . This helps to explain observations that many proteins which have been 
engineered to lack N-glycans fail to be secreted from the endoplasmic reticulum or 
6 
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perform their biological functions in vivo. If unfolded, misfolded, or aggregated they 
would most likely be targeted for destruction by intracellular proteases. 
0-linked glycosylation, though post-translational, has also been shown to have 
structural implications for proteins. 0-linked glycosylation reduces the tendency for 
peptides to form a-helices and can hinder supercoiling of a-helices ' 3 . A less 
common form of glycosylation, but one which is gaining great interest is the 0-
linked -GlcNAc to serine or threonine and this has the tendency to change protein 
conformations by inducing a turn structure and may play a signalling role, not 
unsimilar to protein phosphorylation 14 . 
The increase in steric bulk or surface charge imparted by large glycans through a 
coating of oligosaccharides on glycoproteins may also serve to protect the protein 
from recognition by proteases or antibodies and prevent aggregation thus increasing 
circulatory half life' 5" 6 . 
1.3.2 Receptor and Masking Functions. 
This is a highly specific, usually polyvalent, interaction dependent on the identity of 
the terminal monosaccharide and the stereochemistry about its anomeric linkage to 
the underlying sugar chain. This type of interaction has been extensively reviewed 17 
and some important processes dictated by it include: 
Bacterial and viral infection: Bacterial and viral surface lectins, adhesins and 
hemagglutinins mainly bind to the host cells sialic acids on cell surface glycoproteins 
and glycolipids. Infection may also be initiated by bacterial or viral lectins 
interacting with heparin, heparan sulfate, galactose, fucose or N-acetyl galactosamine 
in the extracellular matrix or presented on the cell surface 17 . 
Recognition of antibody coated antigen by macrophages: Macrophages bind 
mannose residues on the Fc section of antibodies, but only act polyvalently. Only 
when antigens are coated with antibodies and many Fc fragments interact with 
7 
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receptors on the surface is the macrophage activated and an immune response 
induced" , ". 
Hyperacute rejection in xenographic transplantation: 
The enzyme a-i ,3-galactosyltransferase is active in the Golgi apparatus of non 
primate mammals and new world monkeys and transfers galactose from UDP-Gal to 
N-acetyl lactosamine (Gal 1 -4G1cNAc-R) on glycoproteins and glycolipids to form 
the cc-Gal epitope' 9. The enzyme has become inactivated in humans and old world 
monkeys and, in fact, 1% of all circulating human IgG is raised against the (X-Gal 
epitope. The cc-Gal epitope has become the major immunological obstacle for 
transplantation of non-primate mammalian organs into human recipients as anti-Gal 
induces attack by blood monocytes and macrophages and fixes complement, 
inducing complement mediated lysis of xenograft cells. 
1.3.3 Modulators of Biological Activity. 
The presence of bound oligosaccharides have a tendency to 'tune' the biological 
activity of the adjacent protein. This effect is most pronounced in glycosylated 
growth factors where some cell surface receptors for such factors acquire their 
binding function in a glycosylation dependant manner. In the case of the cytokine, 
granulocyte macrophage colony stimulating factor (GM-CSF), the fully 
deglycosylated form is known to be the most active. However, natural GM-CSF, 
which exists as a range of glycoforms exhibits substantial differences in binding 
affinity and signal transduction" 20. Many unglycosylated growth factors are 
expressed from multi-copy genes which are clustered together on chromosomes. It 
has been argued that this process allows for maximum diversification, providing a 
spectrum of eg. a-interferons which have slightly different structural features which 
may be able to interact with different targets, leading to different effects. Glycoform 
variants of single-copy genes may also act through providing charge and size 
heterogeneity therefore not confining diversity to the protein structure. 
8 
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1.3.4 Regulatory Functions. 
This is an extension of two previously discussed roles for oligosaccharides bound to 
proteins 1 " 7 ' 20. Many proteins, particularly cytokines, perform their biological 
functions in a glycosylation dependant manner and have a finite circulatory half-life 
whether or not they have interacted with their target receptor. 'Aged' glycoproteins 
are then targeted for clearance from the body by hepatic cells in the liver. 
Cytokines are usually highly sialylated on the oligosaccharides non-reducing ends. 
The presence of branched (bi-tri and tetra antennary) oligosaccharides display many 
sialic acid residues on the proteins surface. As highly sialylated molecules and cells 
(eg. erythrocytes) circulate, they are exposed to sialidases on the surface of 
endothelial cells and in the blood which trim back the sialic acid and expose terminal 
galactose residues. The presence of asialoglycoprotein receptors recognise the 
processed glycoproteins with exposed terminal f3-galactoside residues in mammalian 
plasma proteins. The result is that the glycoprotein can be cleared from the 
circulation and the oligosaccharides are serving as a timing device which regulates 
the half-life of proteins in the plasma. They also do this by increasing the overall 
size of circulating proteins and consequently reduce the rate of glomerular filtration. 
1.3.5 Cell-Cell Recognition. 
Since cell surfaces are densely coated with sugars it has been predicted that 
oligosaccharides must be the determinants of cell-cell interactions. We have already 
met this type or interaction above. 'Aged' erythrocytes become desialylated 
exposing terminal galactose residues, signalling their demise as they are recognised 
by receptors on hepatic cells which remove them from circulation. The best 
characterised cell-cell interactions are those which occur during the inflammatory 
response 17 . When tissue is damaged by injury, cytokines are expressed locally which 
initiate the inflammatory response by inducing the expression of E- and P-selectin 
(carbohydrate binding proteins) on the surface of endothelial cells 21 . Neutrophils 
(the major class of white blood cells) are then attracted to the site of inflammation by 
a mechanism termed rolling, which describes the sialyl Lewis X (7)(SLeX;  expressed 












inflammation. 	Additionally, L- 
Selectin expressed on the surface of 
neutrophils binds SLeX  on the surface 
of endothelial cells. Further, sheer 
resistant, adhesion is also mediated by 
integrins which are activated by further glycosylation dependant cell adhesion 
molecules (CAM's) such as MAdCAIVI-1 and G1yCAM-1 prior to extravasion 22 . 
1.4 The Study of the Role of the Oligosaccharides: Glycoproteins and 
Neoglycoproteins. 
It has never been more truly said than for the role of the bound oligosaccharides on 
glycoproteins that for every rule there is an exception. Common features of the 
above that have fuelled interest into the role of the bound oligosaccharide are that 
they can mediate specific recognition events or modulate biological processes. 
Consequently they provide further functional diversity which is essential for the 
development and survival of cells, tissues, organs and species. 
The study of glycoproteins is complicated by the fact that they exist in various 
glycosylated forms, or 'glycoforms', in which each glycosylation site may be 
associated with one of several possible oligosaccharide sequences. Therefore, a 
glycoprotein may be a heterogeneous mixture of protein molecules which vary only 
in the structure of the oligosaccharide. As a result of this microheterogeneity the 
overall range of glycoforms may have a range of different physical, biochemical and 
biological properties and their presence may constitute a subtle and sophisticated 
mechanism of biological control. The importance of glycoforms has been recognised 
in the case of tissue plasminogen activator, a recombinant fibrinolytic agent in which 
the glycoforms show differing fibrin-dependant plasminogenolytic activities, and 
thus the United States patent office has ruled that glycoforms must be specified in 
patents. As a result of the difficulties in characterising natural glycoproteins there 
has been increasing interest in the synthesis of homogeneously glycosylated proteins, 
ie. glycoproteins containing oligosaccharide sidechains of defined structure, for 
10 
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analytical purposes. The ability to prepare single glycoforms of proteins allows one 
to probe the structure-activity relationships (SAR's) of glycoproteins, elucidate 
carbohydrate-lectin interactions, define fine structural requirements and possibly 
optimise their biological activity 23 ' 24 . 
So, how can the synthesis of homogeneously glycosylated proteins be achieved? 
Proteins are macromolecules composed of many residues with nucleophilic and 
electrophilic functional groups therefore the problem is mainly one of obtaining regio 
and stereoselective glycosylation. 
1.5 Strategies for the Synthesis and Study of Glycoproteins. 
• 1.5.1 Mutagenic Deletion of the Glycosylation Site. 
A crude method for the study of the biological role of the oligosaccharide moiety of 
glycoproteins is to isolate the gene which encodes for the protein and delete the 
glycosylation sites (either completely or sequentially) by recombinant DNA 
technology and compare the biological activity of the mutant to that of the 
glycosylated wild type 25 . This is usually achieved by mutating the asparagine 
residue (for N-linked glycans) to glutamine or mutating the serine or threonine in the 
Asn-X-Ser/Thr consensus sequence (or in the case of 0-linked glycans) to alanine or 
glycine. The difficulty in analysing products from this type of approach is 
establishing whether changes in biological activity or secretion results from a lack of 
glycosylation, or changes to the protein conformation stemming from the backbone 
mutation. 
• 1.5.2 Expression of Genes in Carefully Chosen Cell Lines. 
Progress has been made towards the use of in vivo techniques such as glycosyl 
engineering. This can exploit the differences in metabolism and glycosylation 
pathways in different organisms and perturb known pathways using modem methods 
in genetics such as gene knock out. The use of the baculovirus-insect expression 
system which has a restricted glycosylation pathway (cannot synthesize complex 
type N-glycans) has been useful in this respect 26.  Co-expression of specific glycosyl 
11 
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transferases can effect the synthesis of specific glycoforms. However, the structures 
of the bound oligosaccharides still tend to be heterogeneous in nature and many 
glycoforms result. 
idiD is a Chinese hamster ovary (CHO) cell mutant, which is deficient in the 4-
epimerase enzyme required to convert glucose into UDP-Galactose and UDP N-
acetyl galactosamine 27. When glucose is provided as the only sugar source in the 
growth medium, the organism is unable to synthesize galactose and N-acetyl 
galactosamine and this has an enormous effect on the glycosylation of the expressed 
protein (Figure 1.7). 
Sia(a2-3) [cl(31-4) cNAc(31-3)] 
m1314 	
cNAc(3l-6) 	 Fuc(al-6) 
Sia(a2-3) [1(f3l-4) G!cNAc(131-3)] 	l(l314) OlcNAc(131-2) Man(ctl6)\ 
	 I 
Man(131-4) kNAc(I3l-4) acNAc —An 
Sia(a2-3) [cl(01-4) cicNAc(01-3)] 	cl(01-4) ?3cNAc(314) Man(ctl-3)" 
0 	lU31-4)kNAc(0l-2) 
Sia(a2-3)l(31-3) 
:cNAccr—:— Ser/Thr -Gal 	 Sia(a2-6)/ 
-Gal 	-GaINAc 
Figure 1.7: Representative N- and 0-linked oligosaccharides that are obtained as a result of gene 
expression of recombinant human erythropoietin (EPO) in ldlD cells in the presence or absence of Gal 
or Ga1NAc 27 . 
The defect can be reversed by the addition of galactose or N-acetyl galactosamine to 
the growth medium, providing a versatile method for the expression of proteins with 
defined, truncated glycans, which may then be extended by enzymatic means. 
• 1.5.3 Enzymatic Synthesis. 
The ability to construct a homogeneous glycoprotein from the 'naked', 
deglycosylated protein (eg. expressed in Escherichia coli) is a most attractive 
approach. The advantages are that glycosylation can be achieved in vitro using 
glycosyltransferases in a regio and stereoselective manner using unprotected 
carbohydrates under mild, aqueous conditions 28 . 
12 
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1.5.3.1 Enzymatic Synthesis off-linked Glycoproteins. 
The problems associated with enzymatic N-linked glycans/glycoproteins are obvious. 
They are constructed on the lipid bilayer of the ER linked to dolichol phosphate. The 
substrate for OST is Dol-PP-GlcNAc2Man9Glc3. And the lipid tether is essential for 
the enzymatic transfer of sugar to protein. The result is that substrates for OST and 
the glycosyltransferases involved in the tetradecasaccharide assembly are incredibly 
complex and not simple nucleotide sugar donors of 0-linked glycosylation. The 
tetradecasaccharide is also constructed by membrane bound glycosyltransferases and 
consequently it has been difficult to isolate, purify and characterise these proteins 
and few are known. The most common methods for enzymatic synthesis of N-linked 
homogeneous glycoproteins begin with a mature heterogeneously glycosylated 
protein 29. Endo-glycosidases are then employed to cleave the majority of the 
oligosaccharides leaving only homogeneous regions of the conserved core structure 
(Figure 1.8)30 . 
Glycosyl 
Endo H 	 Transferases 
Figure 1.8: Wong and co-workers synthesised specific glycoforms of RNAse B by first removing the 
N-linked glycan with an endoglycanase (Endo H). Sialyl Lewis X was then built up on the truncated 
glycoprotein30 . 
Specific oligosaccharides can then be built up using selected glycosyltransferases 
and nucleotide sugars. This method fails however to deal with heterogeneity 
associated with glycosylation site occupancy. But glycoproteins which differ to such 
large extents can usually be separated by capillary electrophoresis (CE) or size 
exclusion chromatography 29'31 . 
1.5.3.2 Enzymatic Synthesis of 0-linked Glycoproteins. 
As 0-linked glycosylation is a post translational process where 0-glycosides are 
formed from sugar-nucleotides this is more straight forward than for N-linked 
glycoproteins. Until recently, a major limitation was the expense of the sugar 
13 
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nucleotides but ingenious methods have been developed for their regeneration". For 
a fully enzymatic synthesis however, proteins are usually required with the first one 
or two sugars in place. Fortunately methods for bringing this about are known: 
trimming back mature glycoprotein glycans with exoglycosidases, expression of 
glycoproteins in ldlD cells as described above, using inhibitors of 0-linked 









J Glycans C-11 
OH 	OH 
H 
 *NHAC 	 (8) 0",~01 
Figure 1.9: Homogeneously glycosylated proteins can be obtained after expression of glycoproteins 
in the presence of 0-glycosylation inhibitors or by cleaving the heterogeneous portion of the glycan. 
• 1.5.4 In Vitro Translation. 
This method for the synthesis of glycoproteins was developed by Hecht and co-
workers. Although this method requires mutated mRNA, tRNA which is recognised 
sufficiently by the proteins biosynthetic machinery so as to suppress a stop codon 
and is acylated with the desired amino acid derivative, they have demonstrated the 
incorporation of several unnatural amino acids and glycoamino acids into proteins at 
the desired sites 35 . This methodology has escaped attention due to the complexity of 
starting materials and the current inability to scale reactions up. 
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• 1.5.5 Chemical Synthesis. 
Chemical synthesis is potentially the most versatile strategy for the synthesis of 
homogeneous glycoproteins. It allows one to produce both natural and unnatural 
linkages between the carbohydrate moiety and the protein and explore the effects of 
altering the oligosaccharide structure. Chemical syntheses of homogeneous 
glycoproteins generally fall into one of two categories. 
1.5.5.1 Total Synthesis of Homogeneous Glycoproteins. 
The total synthesis of large glycoproteins is a very ambitious goal. In contrast to 
peptide synthesis, glycopeptide synthesis requires the protection of many more 
functional groups, reversibly and with maximum selectivity. Furthermore, the 
glycosidic linkage must be formed stereoselectively and prevented from anomerising 
throughout the synthesis. For peptide synthesis, high efficiency must be achieved in 
each of the coupling steps and in solid phase methodology the addition of excess 
reagent can drive reactions to near quantitative. Advances in carbohydrate 
chemistry363 and protecting group strategies 44-46  has made the synthesis of large 
oligosaccharide structures possible. Despite this, the synthesis of small 
glycopeptides (<20amino acids) still poses a significant challenge but has been met 
by a handful of groups4753 . Developments in solid phase oligosaccharide and 
glycopeptide chemistry47 ' 54 has also improved the efficiency and purity in which 
glycopeptides can be prepared 5559. Although the convergent coupling of tailor made 
glycans to a peptide scaffold is an appealing strategy, it has only been successful in 
the construction of N-linked glycopeptides (Figure 1.10). Extension of this to 0-
linked glycoproteins has been hindered by problems endemic to the formation of 
sugar-peptide glycosidic bond. 0-linked glycans are then usually incorporated as 
glycoamino acids during sequential solid phase peptide synthesis (SPPS). 
15 
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Figure 1.10: Natural and unnatural glycopeptide structures which have been synthesised to be 
incorporated into synthetic peptides. All, except the glycosyl amine, are incorporated into sequential 
SPPS as a-N-Fmoc protected glycoamino acids. 
The molecular weight restrictions of SPPS are a significant issue, only a few groups 
have synthesised peptides over 100 amino acids in length and SPPS tends to become 
inefficient for peptides over 50 amino acids in 1ength' 65 . Most naturally occurring 
glycoproteins are substantially larger and the total synthesis of a full-length 
glycoprotein is yet to be reported. 
The most likely solution to this problem will be through convergent methods of 
protein synthesis such as native ligation or expressed protein ligation 6669 . This will 
ultimately allow the convergent coupling of smaller and more attainable synthetic 
glycopeptides to synthetic or recombinant peptide fragments. 
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Small, synthetic glycopeptides are not however without their uses and much of our 
understanding of the structural consequences of protein glycosylation has come from 
studies with small synthetic glycopeptide fragments" 1314 
1.5.5.2 Chemoenzymatic Synthesis of Homogeneous Glycoproteins. 
Recombinant DNA technology has allowed for the isolation of 'naked', 
deglycosylated proteins. Expression of the gene encoding for the glycoprotein of 
interest in non-glycosylating organisms such as E. co/i (which lack the biological 
machinery for glycosylation) allows one to selectively glycosylate proteins at 
specific amino acid residues with activated oligosaccharides. This facilitates the 
synthesis of neoglycoproteins which are novel glycoproteins designed for analytical 
purposes. Much of the pioneering work in this field by Lee and co-workers indicated 
that a protein-carbohydrate linkage formed by coupling activated oligosaccharides to 
proteins should be specific, covalent and stable under physiological conditions. They 
should be formed under conditions which do not degrade the oligosaccharide, and 
should not contain bulky or highly interactive groups which may interfere non-
specifically in vivo. However, most methods currently available do not adhere to 
these specifications since they are very non-specific with respect to a single amino 
acid side chain. Consequently, they may: 
• introduce bulky aromatics or long spacer arms which may hinder the necessary 
protein-carbohydrate interactions. 
• produce antigenic, unnatural glycosidic linkages. For example glycosyl amines 
react with the carboxyl groups of both aspartic and glutamic acid thus N-
glycosides of glutamine are formed and these linkages are not present in nature. 
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Figure 1.11: Activated carbohydrates which result in the formation of neoglycoproteins with 
unnatural sugar-protein linkages. These activated saccharides target specific amino acid residues and 
can be used to modify recombinant or synthetic peptides in the absence of protecting groups. 
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Some examples, which underscore the power and versatility of the semi-synthetic or 
chemoenzymatic approach to glycoprotein/ neoglycoprotein synthesis, are discussed 
below: 
One of the most striking uses of neoglycoproteins has been in the investigation of 
their ability to raise the humoral immune response against tumors displaying the 
GloboH breast cancer antigen (9). The fully synthetic Globo H antigen was prepared 
by Danishefsky and co-workers as an allyl glycoside 77. Ozonolysis of the allylic 
double bond afforded an aldehyde which was reductively aminated by the g-amino 
group of lysine residues on the carrier protein keyhole limpet hemocyanin (with 150 
carbohydrate units per protein!). 
NH-KLH 
Globo H antin (9) 
High loading on the carrier protein allowed polyvalent display of the antigen as 
would be expected on the cell surface. Neoglycoproteins were used to immunize 
mice and isolated antibodies were shown to bind to the surface of human Globo H 
positive tumour cells78 '79 . This vaccine is now undergoing clinical trials. 
An elegant neoglycopeptide synthesis was also reported by Lee and co-workers who, 
in contrast to the previous example, used oligosaccharides from natural sources and a 
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Finally, utilising endo--N-acetyl-glucosaminidase (Endo-A) and an oiigosaccharide 
isolated from soybean agglutinin, they were able to prepare the C- glycopeptide (12) 
via transgiycosyiation 60 . 
Manal -2  Mana 1 
Mana 1-6 	 H Tyr lie Mn Ala Ser NH2 
Manal -2  Mana  1-3 	 -4GlcNAl -4GicNAc i—CH2 
Mana 1-2  Mana 1-2 Maria 1-3 	 12 
This demonstrates that it is possible to introduce synthetically complex high mannose 
type homogeneous glycans using glycosidases (in reverse) in high concentrations of 
organic solvents. 
Convergent approaches will be the future of synthetic glycoprotein assembly. 
Convergent methods in protein synthesis are now well established and convergent 
methods of oligosaccharide elongation have also been investigated (Figure 1.1 
Figure 1.12: Galactose oxidase oxidises the 6-position of Ga1NAc to the C6 aldehyde which can then 
be coupled to saccharides with hydroxylamine derivatives at the reducing end. The Ga1NAc-Ser/Thr 
linkage is introduced as a glycoamino acid, preserving the native sugar-protein linkage. 
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A novel approach for the synthesis of homogeneous glycoproteins was first reported 
by Davis and Flitsch in 1991 0 and subsequently by Wong and co-workers 71 . The 
use of glycosyl iodoacetamides as the activated carbohydrate moiety affords the 
selective derivatisation of the thiol groups of free cysteines at pH8 (where thiols are 
the strongest nucleophiles) (Figure 1.13). 
OH 0 	 NH 2 
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Figure 1.13: Selective chemical glycosylation of the free thiol of reduced glutathione using glycosyl 
iodoacetamides. 
The resulting thioether linkage is clearly very similar to the natural asparagine 
linkage (Figure 1.14). Indeed, the conformation of the bound monosaccharide in 
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Figure 1.14: The novel thioether linkage (A) for homogeneous glycoprotein synthesis is identical to 
the natural sugar-asparagine linkage (B)except it is extended by a CH 2S unit. 
Since this method of homogeneous glycoprotein synthesis is very selective, and in 
nature free cysteine residues are relatively rare, the advantages of this approach are 
obvious. By mutating the asparagine glycosylation sites to cysteine by site directed 
mutagenesis, the desired glycoprotein can be prepared providing the mutation does 
not greatly affect the tertiary structure of the protein. Furthermore, iodoacetamides 
tend not to react with the 'oxidised' cysteine present in disulfide bridges, expanding 
the scope of this method to proteins with no free cysteine residues assuming the 
correct disulfide bonds form during the refolding process. In contrast, most available 
glycosylation methods (Figure 1.11) afford derivatisation of lysine residues which 
are a far more common constituents of proteins. 
In summary, an ideal homogeneous glycoprotein synthesis would involve the 
production of a mutated protein backbone (for selective chemical glycosylation), or 
construction of oligosaccharides on singly glycosylated proteins using glycosyl 
transferase enzymes. Unfortunately, many of the required enzymes have yet to be 
isolated, so selective chemical glycosylation (perhaps followed by 










1.6 Ervthropoietin: A Model Protein for Glycosylation Studies. 
Erytbropoietin (EPO) is a glycoprotein hormone synthesised by the adult kidney and 
foetal liver. In adults, mature EPO is secreted as a heavily glycosylated protein 
where glycosylation comprises 40% of its molecular weight. On secretion, it 
migrates to the bone marrow where it acts specifically on erytbroid progenitor cells, 
stimulating erythropoiesis through binding to the extracellular domain of the EPO 
receptor (EPOR), triggering intracellular signalling events including phosphorylation 
of the receptor and activation of the JAK-STAT, RAS and P 13 kinase pathways. 
Present at concentrations in the picomolar range in human serum, EPO regulates the 
number of circulating erythrocytes and ultimately controls the transport of oxygen 
(carried by red blood cells (RBC's)) throughout the body. Serum EPO 
concentrations are controlled by a classic feedback mechanism whereby elevated 
serum oxygen level downregulate EPO expression and hypoxia results in elevated 





Figure 1.15: On secretion from the kidney, EPO acts on a number of specific cells along the erythroid 
progenitor cascade: Initial interaction with plunpotential hematopoietic stem cells, burst forming unit-
erythroid (BFU-E), and colony forming unit-erythroid (CFU-E) allows further differentiation (aided 




In addition to being one of the first recombinant therapeutics, recombinant human 
EPO (rhEPO) has also become one of the most successful and valuable recombinant 
therapeutics for the treatment of anaemia resulting from chronic renal failure, 
negating the need for regular blood transfusions for patients on dialysis. In such 
disease states the kidneys are no longer capable of synthesising EPO and hence 
anaemia results from reduced RBC production. 
Since it's approval in 1989, EPO's use has become more widespread and has been 
extended for the treatment of anaemia associated with cancer and AIDS. Of course, 
treatment with rhEPO does rely on the presence of functional erythroid progenitor 
cells and accordingly has little affect in patients where anaemia is associated with the 
absence or destruction of these cell types. The clinical use of EPO has sparked huge 
interest in the cytokine field, examining the roles -and potential therapeutic uses of 
cytokines in virtually every organ system of the body. It is perhaps unsurprising that 
the majority of approved cytokines fall into the categories of immunological and 
hematopoietic regulators: interferon-y for chronic granulomatous disease, Interferon-
a-2-b for hepatitis and interferon43- 1-b and interferon-3- 1-a for multiple sclerosis 
amongst others81 . 
rhEPO, marketed by Amgen Inc. (California) as EPOGEN ® or PROCRIT® contains 
Epoeitin alfa which exists as a heterogeneous mixture of rigorously characterised 
glycoforms with as many as 58 different N-linked glycans associated with one 
sample82 '83 . Indeed the glycoform composition of EPO has been known to differ 
between samples from plasma and urine, between samples obtained under different 
pathophysiological conditions, between samples of purified uhEPO and between 
samples of rhEPO synthesised in different cell lines. EPO's differing in glycoform 
composition have been shown to differ in immunological and biological properties. 
Although deglycosylated versions of EPO fail to be biologically active in vivo, they 
retain biological activity in vitro demonstrating that the oligosaccharides, though not 
essential for receptor binding, perhaps affect the proteins stability, solubility, tissue 
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specific targeting and in vivo biological activity. This has prompted investigations 
into the roles of the oligosaccharide moiety 80 . 
The carbohydrate structures of EPO expressed in Chinese Hamster Ovary (CHO) 
cells have been thoroughly characterised (Figure 1.16) and have been found to be 
identical to those found in hEPO 8284 . 
Gal( 1-4) G1cNAc( 1-2) Man(a 1-6) 	 Fuc(a 1-6) 
1± 
Man(3 1-4) G1cNAc(3 1-4) GLcNAc —Asn 
Gal(1-4) GlcNAc(1-2) Man(al-3) 





Ga1(1-4) GlcNAc(1-2) 	 / Man(1-4) G1cNAc(1-4) GIcNAc —Asn 
Gal(31-4) GlcNAc(1-2) Man(al-3) 
Ga1( 1-4) G1cNAc(3 1-2) Man(a1-6) 	 Fuc(c'L 1-6) 
1± 
Gal(31-4) G1cNAc(131-4) 	
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Ga1-4) GkNAc(1-2) / l(  
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Ga3l-4) GNAc(1-2) / 	 I ± 
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Figure 1.16: Core structures of the N-linked glycans found on EPO derived from CHO cells. 
Due to the heterogeneity of rhEPO it has (until very recently 85) evaded complete 
structural analysis by X-ray crystallography and multidimensional NMR 
spectroscopy. The major problems associated with structural assignment have been 
associated with the molecular properties of rhEPO: As a mature glycoprotein it is 
very heterogeneous and fails to crystallise, as a deglycosylated species it is unstable 
and only poorly soluble86 . 
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Troubles aside, many imaginative approaches have been used to investigate EPO's 
tertiary structure. The primary structure was solved in 1986 by Goldwasser and co-
workers 87  who purified urinary human EPO (uhEPO) from patients with aplastic 
anaemia. From this work they were able to establish that EPO had two disulfide 
bonds, between C7 and C161 (linking the C and N terminus), and between C29 and 
C33 as well as determine the protein sequence. Furthermore they identified that EPO 
was N-glycosylated at N24, N38 and N83 and O-glycosylated at S126. CD 
spectroscopy also intimated that the protein was highly cc-helical. Based on 
sequence analysis of purified uhEPO it was possible to probe for the human EPO 
gene; which was later identified, cloned, and over-expressed in CHO cells 88 . 
Although little was known about the 3D structure, EPO was presumed to have a 4-
anti-parallel cc-helical bundle fold, as a result of weak sequence homology with other 
cytokines with solved structures such as growth hormone, the interleukins (2-7), G-
CSF and GM-CSF. Additionally, this theory was founded on the fact that they all 
bound to the extracellular domains of receptors with similar structural motifs. This 
information was used to predict the tertiary structure 89 . One example is shown 
below90 (Figure 1.17). 
Figure 1.17: EPO (white) dimerises the extracellular domain of the EPO receptor (EPOR), 








The structure of EPO was also probed with monoclonal antibodies raised against 
specific EPO epitopes and they were evaluated for their ability to neutralise the 
activity of rhEPO. These results identified which residues were on the surface of the 
Figure 1.18: Model structure of hEPO, the disulfide 
bonds are shown in yellow. The glycosylation sites are 
also shown. 
protein and which residues were 
involved in receptor binding 
providing further evidence for the 
4-anti-parallel a-helical bundle 
Ibid91 . At a later date the active 
site of EPO was mapped more 
thoroughly showing that the active 
site was discontinuous and spread 
over many residues throughout the 
protein and that interaction with 
the receptor may be dependant on 
electrostatic interactions between 
exposed basic side chains and the 
IPOR. Key residues for receptor 
hinding were identified as 11-15, 
44-51, 100-108 and 14715192. 
Throughout this analysis one could 
he excused for believing that the 
peptide backbone alone constitutes 
the requirements for biological 
activity. Of course, this is not the 
case as EPO is completely inactive in vivo in the absence of glycosylation and in 
cases where glycosylation is prohibited or inhibited the protein fails to undergo 
normal secretion. 
1.6.1 The Role of Disulfide Bonds. 
It has been established that the disulfide bonds in EPO help stabilise the structure, 
although they are not believed to be neccessary for establishing the correct fold. 
Indeed it is the topology of the fold that brings the correct cysteine residues into 
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contact. It may then be considered surprising that the alkylation of the thiol groups 
after reduction results in the irreversible loss of biological activity 80 '90 . Analysis of 
alkylated EPO with conformation sensitive antibodies has shown that disruption of 
the disulfide bonds causes a conformational change. These apparently contrasting 
observations may indicate that the fold is stabilised during synthesis (by chaperones) 
but is ultimately unstable and is readily lost. Disruption of the C29-C33 disulfide has 
less affect on the biological activity of EPO than disruption of the C7-C 161 disulfide 
which results in the loss of biological activity 93 . 
1.6.2 Role of Sialylation. 
The 0- and N-linked glycans of hEPO and rhEPO are mainly bi- and tetra-antennary, 
capped with sialic acid at the non-reducing end. Removal of sialic acid residues 
using sialidases exposes terminal galactose residues, causing rapid clearance of EPO 
from the circulation 94 . The requirement for sialylation is clearly to reduce the rate of 
clearance and desialylated EPO is biologically inactive in vivo, presumably for this 
reason as removal of sialic acid does not affect protein conformation and desialylated 
EPO is fully active in vitro. 
1.6.3 Role of 0-Linked Glycosylation. 
Tetra antennary 0-linked glycans predominate in rhEPO and uhEPO. When 0-
linked glycans were removed enzymatically or EPO was expressed in ldlD cells 27 
(lacking 0-linked glycans) no difference in biological activity was observed relative 
to CHO derived EPO. Ser126Gly mutations had severe effects on protein secretion 
but this was considered more likely to have resulted from structure destabilisation 
caused by the mutation rather than the absence of 0-linked glycans 95 . 
1.6.4 Role of N-Linked Glycans. 
The N-linked glycans on EPO have been studied most intensively and for a long time 
were considered key in administering the biological activity of EPO. Numerous 
studies were conducted and indicated that the highly branched N-linked glycans 
served as anchors for sialic acid which increases circulatory half-life 25 '27 '9497 , 
allowing EPO to reach it's target organs. It is difficult to argue that the N-glycans 
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play a crucial structural role as the solved 
BCloop NMR structure of E. coli derived 
MK1ysEPO (where all N-glycosylation 
sites were exchanged for lysine) still folds 
into a 4-antiparallel helical bundle (Figure 
1.19). The lysine residues were 
introduced to increase the solubility of E. 
coli derived EPO. It also became apparent 
AB loop that the receptor binding sites residues: 
11-15 and 100-108, and 44-51 and 147- 
151 were brought together in the tertiary 
CO loop NH2 
	structure to form two biologically active 
COOH 
'patches' which give rise to EPO's 
Figure 1.19: Solved NMR structure of 
MK1ysEPO86. 	 bivalency and ability to dimerise it's 
receptor. 	Interestingly however, in the 
absence of N-linked glycans, normal EPO secretion is prevented in BHK cells. In 
fact, while N24 glycosylation is not necessary for normal secretion, the absence of 
N24 glycosylation actually increases the rate of secretion. In summary, these 
findings suggest that N-glycosylation of EPO may affect the biosynthesis and 
secretion of EPO in eukaryotic cells, affect tissue specific targeting or influence the 
ability of EPO to bind it's receptor. Glycans may also prevent EPO from interacting 
non-specifically with other cytokine receptors. The role of the glycans may become 
much clearer when the X-ray crystal structure of the co-complex between EPO and 
the extracellular domain of EPOR is disclosed in July 199985. 
EPO is therefore an ideal protein for glycosylation studies with glycosyl 
iodoacetamides. It is a biologically relevant protein where the N-linked glycans at 
asparagine residues 24, 38 and 83 contribute significantly to its biological activity in 
vitro (where the full pentasaccharide core is required for full biological activity) and 
in vivo. The presence of two disulfide bonds give the methodology a complex setting 
in which to be evaluated: How will the introduction of a fifth, sixth or seventh 
cysteine residue affect the structure or the manageability of the protein. For 
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example, the presence of four cysteine residues allows three possible disulfide 
bonded structures: 
SH 
HN P\  
All are not of equal energy and the most stable would be expected to predominate, 
this is presumably the native folded structure. 
30 
CHAPTER 1 
1.7 Project Aims. 
The general aim of this project was to develop the cysteine targeting iodoacetaniide 
methodology to effect the synthesis of homogeneos glycoforms of recombinant 
human erythropoietin. This involved the over expession, purification and 
characterisation of wild type (WT) and specific Asn—*Cys mutant EPO's from E. 
coli. Refolding of our samples would then follow, hopefully exposing a thiol group 
from a single cysteine residue for glycosylation studies using glycosyl 
iodoacetamides. Once we had established that the correct sugar-protein linkage had 
been formed (Figure 1.11) we aimed to determine, unambiguously, that the correct 
site (cysteine residue) had been modified. 
Previous work in the group resulted in the construction of many EPO containing 
vectors, encoding EPO genes with asparagine—*cysteine mutations. Specifically, 
genes encoding N24C-hEPO, N38C-hEPO, and N38/83C-hEPO were prepared 
(N38/83C was prepared unintentionally: N38C DNA was used as the template DNA 
in the mutagenesis reaction for the synthesis of N83C-hEPO instead of WTcDNA). 
A number of expression systems were then evaluated for their ability to over-express 
WThEPO and cysteine mutants but al/failed to provide sufficient quantities of EPO 
to study protein glyco.sylation using standard biophysical techniques such as NMR 
spectroscopy or mass spectrometry. However, the highest yields of EPO (1.OmgL) 
were obtained using the pET expression system, where the proteins were expressed 
as N-terminal fusions with a decahistidine tag. Previously, EPO samples were 
expressed, identified by their approximate molecular weights (SDS-PAGE) and the 
fact that they were detected by a monoclonal antibody raised against a continuous N-
terminal epitope. Glycosylation was then detected using horse radish peroxidase 
conjugated lectins that bind N-acetyl glucosamine in a western blot-type analysis. 
From this type of analysis however, a number of issues remained unresolved: 
Was the reaction quantitative? 
Were any other amino acid side-chains modified? 
Was the correct cysteine residue modified? 
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So, the specific aims of this project were: 
To optimise the expression of Hisio-WT and cysteine mutant EPO's from E. coli 
using the pET system, particularly, the pET 1 6b constructs provided by 
predecessors. Failing this, to investigate further expression systems. 
To refold and characterise, as fully as possible, the E. coli derived Hisio-fused 
proteins. 
Develop methods for the efficient synthesis of relevant or model glycosyl 
iodoacetamides. 
Establish methods that will enable us to monitor and evaluate protein 
glycosylation. 
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Prokaryotic Expression 






2. Optimisation of a Prokaryotic Expression System for Recombinant Human 
Erythropoietin. 
The expression of erythropoietin in eukaryotic systems such as Chinese hamster 
ovary (CHO) and baby hamster kidney (BHK) cells has been well 
documented 25 '88 '98'99. For our purposes however, we required erythropoietin in a 
deglycosylated form so that we might specifically glycosylate it after expression and 
elucidate the roles played by specific oligosaccharides in administering in vivo 
biological activity. This was achieved by expressing EPO in E. coli, a prokaryotic 
organism which lacks the biosynthetic machinery for protein glycosylation. 
Erythropoietin expression in E. coli from cDNA has been achieved as both the native 
peptide sequence 10° and as a fusion protein, whereby the gene of interest is inserted 
immediately downstream of a highly expressed gene encoding a cleavable fusion 
protein. The fused sequence (which may be on the N or C terminus of the target 
protein) may serve to protect the target protein from damaging proteases in the host 
organism, and aid solubility or purification of the protein of interest. To date, EPO 
has been expressed in E. co/i as a fusion protein with 0-galactosidase 101 , f3-
lactamase' °2 , glutathione S-transferase' 03 , thioredoxinA 104, and a decahistidine 
tag89' 104 . 
Bill and Flitsch first reported on the expression of WThEPO and cysteine mutants as 
fusions with glutathione-S-transferase using the pGEX-2T expression system. 
Although purification of the target fusion protein was greatly simplified, the yield of 
fusion protein was low (Table 2.1) and the target protein was obtained from the 
fusion in poor yield after preparative SDS-PAGE and electro elution. Boisell and co-
workers were then to report on the expression of EPO as a decahistidine tagged 
fusion protein using the commercially available pET expression system, which 
increased yields of fusion protein and also increased efficacy of purification due to 
the affinity of the polyhistidine tag for Ni 2 . Further investigations 104 on the 
expression of WThEPO and cysteine mutants as His10-fusion proteins were then 
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undertaken. Indeed, it appeared that the pET system was the preferred method for 
efficient expression of rhEPO and cysteine mutants (Table 2.1). 
Parent Vector Fusion Protein Cleavage site Yield per 1 liter induced culture 
pGEX-2T GST-hEPO Thrombin hEPO : 25ig 
C38hEPO : 25tg 
pET-16b His 10-hEPO Factor Xa hEPO: 1 mg 
C38hEPO : 0.6 mg 
C38/83hEPO: 0.4 mg 
pTrxFus TrxA-hEPO Enterokinase N/D 
pET-GST GST-hEPO Thrombin hEPO : 40tg 
C38hEPO : 40.tg 
C38/83hEPO : 20j.tg 
Table 2.1 Summary of previous EPO expression work conducted within the group. TrxA= 
thioredoxin. The pET system provided the highest yield of EPO. 
2.1 The pET System. 
In pET vectors"' (commercially available from Novagen, Madison, USA), genes to 
be expressed are brought under the control of strong bacteriophage 17 transcription 
signals where transcription is induced by providing a source of T7 RNA polymerase 
in the host cell' 06 . This highly active enzyme can transcribe RNA chains five times 
faster than E. coli RNA polymerase and is very selective since the promoter signals 
are rarely encountered in DNA unrelated to T7 DNA. Consequently the hosts own 
bacterial RNA polymerase does not induce transcription and hence translation. T7 
RNA polymerase is provided by the host cell specifically engineered to carry a 
chromosomal copy of the ADE3 lysogen. Ultimately, the hosts expression of 17 
RNA polymerase is controlled by a 1acUV5 promoter which is induced by 13- 
 isopropyl thiogalactoside (IPTG) and as a result (as is generally the case with genes 
expressed under the control of the lac promoter) some background expression can be 
observed. This is only problematic however, when the target protein is sufficiently 
toxic to the host. Protein expression is therefore induced by the addition of IPTG. 
Novagen have made available a range of vectors which express target proteins with 
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N or C-terminal tags to aid protein identification and purification. One of the more 
popular fusion proteins is the enzyme cleavable (thrombin or factor X proteases) 
His-tag where a polyhistidine tag simplifies the purification of target proteins due to 









Figure 2.1: Decahistidine tagged proteins are immobilized on Ni" chelating resins through their 
imidazole side chains. 
2.2. Expression Studies Using pET16b-EPO Constructs. 
In previous work", the yield of His 10-fused protein was still poor (1mg per liter at 
best). Unfortunately, a contaminant was found to co-purify with the His 10-EPO 
fusions of similar molecular weight and once again preparative SDS-PAGE had to be 
employed to separate the fusion protein from this unwelcome contaminant. 
However, the pET 1 6b system was generally considered the most efficient expression 
system. Optimisation of the expression conditions for His 10-WT, His 10-C24, His 10-
C38 and His,,,-C38/83 EPO's was then undertaken. As previously noted", 
expression (monitored by SDS-PAGE of the whole cell protein) was not significantly 
altered by changing the temperature at which the cells were induced between 30 and 
37°C. 1mM IPTG was also considered optimal and in line with previous work and 
the manufacturers instructions. However, levels of expression of His 10-EPO's were 
found to vary significantly on altering the host strain of E. coli. In previous work, 
the BL21(DE3) and BL21(DE3)PlysS strains had been employed to facilitate 
expression of the target proteins but SDS-PAGE was to show that B834(DE3), the 
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parental strain of BL21(DE3) appeared to give larger expression levels of His 10-
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Figure 2.2 :SDS-PAGE (left) and western blot analysis (right) of E. coli total cell protein. Expression 
of His 10-C38EPO, 3 hours after induction with IPTG. Lanes: M= molecular weight markers, 1= 
B834(DE3), 2=BL21(DE3) and 3=BL21(DE3)PLysS, C=  control (no induction) 
This was a significant improvement on previous results supplying enough material 
for analytical purposes. Furthermore, it showed that the previously described 
contaminating higher molecular weight band was in fact detectable by a murine anti-
hEPO monoclonal antibody raised against a continuous epitope within the first 24 
amino acids from the N-terminus (Figure 2.3). 
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Figure 2.3: Induction over 3h shows accumulation of higher molecular weight impurity. Observable 
by SDS-PAGE and western blot analysis. C=control (no induction). 
This implied that both species originated from the same DNA and indicated that the 
lower molecular weight band was the desired His 0-EPO species and the upper band 
contained some type of extension. An observation contrasting severely with 
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previous results. Expression of EPO in the presence of PMSF' °7 had no effect on the 
product distribution (approximately 9:1 lower band/upper band (Figure 2.4)) 
implying that the product distribution could not be accounted for by proteolytic 
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Figure 2.4: Ni" affinity purification of His 10-C38hEPO gave rise to two species. M= MWt markers, 
L=loaded cell free extract, W=50mM imidazole wash, numbers refer to fraction (1 .Oml) number, 
In order to show that the observation was not an artifact of SDS-PAGE the products 
were separated by preparative SDS-PAGE (after attempts to separate the species on 
the column by means of an imidazole gradient had failed) and separated proteins 
were obtained after electro-elution as described in previous work by Karen Sage"'. 
Comparison of the proteins by SDS-PAGE and western blotting convincingly 
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Initial conjecture was verified on obtaining the MALDI-TOF spectrum of the protein 
mixture prior to preparative SDS-PAGE. 
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MM (m/t) 
SPECIES EXPECTED MWt OBSERVED MWt 
Ml 20906 21097 
M2 —* 22864 
* Given that any extension would overwrite a stop codon-what is inserted (if anything) in place of 
stop is unknown and therefore the mass of the extension is unknown. 
Figure 2.6: MALDI-TOF mass spectrum of Ni" affinity purified C38hEPO clearly indicates the 
presence of an extending peptide sequence. 
The MALDI-TOF spectrum (Figure 2.6) clearly depicted two species, one within 
200 amu of the expected His 10-C38EPO species (Ml) and the other some 1767 amu 
larger (M2), confirming some sort of extension. Analysis of the encoding DNA 
(Figure 2.7) led us to assume that perhaps the extension was formed as a result of an 
inefficient stop codon, a phenomenon known to occur as a result of secondary gene 
structure, allowing protein synthesis to continue until the next stop codon is reached. 
Additionally, it has been shown that the efficiency of the stop signal can rely on the 
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identity of the following base. The +1 frame shift is particularly pronounced where a 
TGA stop codon is followed by G 108 , as is the case in our pET16b-WT and cysteine 
mutant genes. A pause, or a frame shift are frequent outcomes of such a 
phenomenon. In fact, calculations were to show that the mass of the extension 
corresponded approximately to the mass the hypothetical protein species produced if 
this was indeed the case. The exact mass of any extension would be difficult to 
predict however since the species which is inserted (if any) in place of the TGA stop 
codon is unknown. 
17 DrmOtar arsm.r *€934.1 
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841 11 	 17 promotar 	 lac operator 	 Xba I. 
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Figure 2.7: The pET 16b multiple cloning site"" 
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A simple experiment that would examine this hypothesis was then devised. The WT 
and cysteine mutant EPO genes are inserted between the Nde I and BamH I 
endonuclease sites of the pET16b multiple cloning site (Figure 2.7). The suspected 
extending sequence was then contained within the following sequence, to the TAA 
stop codon, just beyond the Esp I site. Enzymatic digestion of the pET16b-EPO 
plasmid DNA with Esp I and BarnH I followed by religation should delete the 
majority of the extension. This reaction was performed on the plasmid DNA 
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NOTE: religation ofpETláb destroys 
I both the BamHl and BpullO2 
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Transformation and expression 
Figure 2.8: Deletion of pET16b extending sequence involved a double endonuclease (BamH 
I/Bpu 1102 I) digest. The non-cohesive ends were 'filled-in' using the Kienow fragment of DNA 
polymerase and blunt ended vector was religated and used to transform competent JMIO9 cells. 
This resulted in a new, shorter, extension sequence 
5• 	 3• 
GGA TCT GAG CAA TAA 
Gly Ser Glu Gin Stop 
The resulting products designated pET16b-WTEPO(2) and pET16b-C38EPO(2) 
were then expressed in B834(DE3) cells and the Ni2*  affinity purified products were 
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Figure 2.9: His 10-C38EPO(2) shows no visible signs of an extending sequence by SDS-PAGE when 
compared with the original His 10-C38EPO (right). 
SDS-PAGE showed that the distance between the two protein species (corresponding 
to molecular weight) had decreased and, as expected, the size of the extension had 
been decreased. This result was echoed by analysis of the MALDI-TOF spectrum of 
His 10-C38EPO(2) (Figure 2.10): 
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Figure 2.10: MALDI-TOF mass spectrum of His 10-C38EPO(2). 
Similar results were also obtained with His 10-WTEPO(2). 
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Although this confirmed that the problem had arisen as a result of the inefficient stop 
codon it had not solved that problem. The EPO now being expressed could 
potentially have a four or five amino acid extension and it had lost the ability to be 
manipulated further with ease as a result of the destruction of the BamH I and Esp I 
sites (Figure 2.8). 
2.3 Optimisation of expression. 
A new experiment, involving cassette mutagenesis, was then devised that would 
serve to solve our extension problem and maintain the integrity of the restriction 
endonuclease sites. Fortuitously, a unique Stu I restriction site was observed only 
twenty seven base pairs from the DNA encoding the C terminus of EPO. This 
allowed us to excise only a small DNA fragment from the EPO gene and replace it 
with a synthetic 27mer oligo deoxynucleotide. 
The experiment (outlined schematically in Figure 2.11) involved the cloning in of the 
synthetic duplex, replacing the unsatisfactory C- terminus encoding DNA fragment. 
Figure 2.11: Introduction of a new C-terminal sequence using cassette mutagenesis. 
The synthetic oligonucleotides were chosen carefully to introduce new optimised 
codons for expression in E. coli. (replacing human codons, for which E. coli has not 
been shown to have a high percentage of corresponding tRNA, with optimal E. coli 
codons for the same amino acid) and a new, TAA, stop codon (one more commonly 
found) followed by the original TGA stop codon: 
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Original C-terminal sequence: 
5' 	 3' 
GAG GCC TGC AGG ACA GGG GAC AGA TGA GGATCC 
Glu Ala Cys Arg Thr Gly Asp Mg Stop BamH I 
New, optimised sequence: (codon changes in bold type, endonuclease restriction sites 
in red) 
5 	 3' 
G ', (IC CGT ACC GGT GAC CGT TAA TGA 
C 	 CG GCA TCG CCA CTG GCA ATT ACT 
Glu Ala Cys Mg Thr Gly Asp Mg Stop Stop BamH 1 
and this therefore required the purchase of two synthetic o ligonucleot ides which were 
obtained desalted and deprotected: 
5' 	 3' 
GC CGT ACC GGT GAC CGT TAA TGA 	termed EPOCOPT 1 
and 
5' 	 3' 
1(( TCA TTA ACG GTC ACC GGT ACG GC 	termed EPOCOPT2 
when equimolar quantities of each were melted' in the conventional manner they 
afforded the desired fragment 
5' 	 3' 
(( JGC CGT ACC GGT GAC CGT TAA TGA ( 
G6 ',.CG CGT TGG CCA CTG GCA ATT ACT ('(:1' ,\G 
3' 	 5' 
which served to optimise E. coil expression for this length of DNA, introduce a new 
stop codon followed by the original stop codon and reformed the restriction 
endonuclease sites after insertion to allow further genetic manipulations. After the 
ligation, reaction mixtures were used directly to transform JMI09 cells and the 
resulting colonies were screened. The screening procedure, consisting of two stages, 
was very straightforward: 
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First, transformants were cloned and the DNA was purified and digested with Stu I 
and BamH I. If the plasmid had just closed upon itself without incorporation of the 
synthetic duplex the recognition site for Stu I would have been lost. The BamH I site, 
however, may have been reformed. The DNA resulting from such an unfavourable 
process would not be cleaved with Stu I but will have been cleaved by BamH I. 
Second, the incorporation of the synthetic duplex introduced a new Bs1E II site, 
increasing the number of BsIE II sites in the plasmid from one to two. Therefore 
incorporation of the synthetic duplex would result in a fragment being cleaved from 
the plasmid rather than just linearising when treated with BstE II. 
Seven colonies were screened initially (Figure 2.12). From the first screen only, one 
transformant (number 4) fulfilled the initial criteria of being cleaved by Stu I and 
BamI-1 I enzymes. 
Wi 1 	 P P 	i 	4 i 6 7 R P P 
Figure 2.12: BamH I digest (left) and Stu I digest (right) of transformants. WT=original 
unmodified pETI6b-WT, M=MWt standards, P==transformants where the insert was phosphorylated 
prior to ligation. 
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This DNA was then taken on to the next stage and was shown to be cleaved (not just 
linearised) by BsIE II (Figure 2.13). To confirm that the sequence was correct the 
resulting DNA was sequenced across the inserted region using the pET16b reverse 
primer (Figure 2.7). 
Figure 2.13 Agarose gel shows 
(from left) stu I cut original 
pET 16b-WThEPO (a standard), 
molecular weight markers, BsIE 
II cut WThEPO (standard), and 
BsIE II cut pET 16b-
WThEPO(COPT), followed by 
markers. 
Stu I 	VL  UstE II 
	
IVI 
Now that we had the desired gene, termed pET I 6b-WThEPO(COPT), we were then 
able to manipulate the remaining genes encoding cysteine mutants. This was 
particularly simple and all experiments (outlined schematically in figure 2.14) were 
conducted in parallel: The optimised pET16b-WThEPO(COPT) construct was 
digested with Nco I and Stu I to remove the wild type sequence, while the optimised 
3' end of the gene (from the synthetic duplex) remained attached to the pET 16b-
vector. N24C, N38C and N38/83C EPO pET vectors were also cut Nco I! Stu I, but 
this time the fragments corresponding to the mutant encoding cDNA was purified 
from the endonuclease digestion and these fragments were ligated with the pET 
vector incorporating the optimised C-terminal sequence. Colonies were screened as 
previously and now all genes contained the optimised C-terminal sequence. 
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Figure 2.14 : Sub-cloning of the original pET 16b-C24, C38 and C38/83 cysteine mutants into the 
optimised pET l6b(COPT) plasmid. 
The four new plasmids designated pET 1 6b-WTEPO(COPT), pET 1 6b-
C24EPO(COPT), pET I 6b-C3 8EPO(COPT) and pET 1 6b-C3 8/83EP0(COPT) were 
then fully sequenced across the His 10-EPO encoding region using EPOCOPT 2 
(single strand of the synthetic duplex) as primer. The sequences also confirmed that 
all genes contained the correct optimized sequence. The target proteins were then 
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expressed and as expected only a single product was observed after Ni" affinity 
chromatography (Figure 2.15): 
1 7JI 
T 	- 	- 
Figure 2.15 SDS-PAUE analysis 01 Ni affinity purified His 10-C38hEPO from the optimized 
pET 1 6b-C3 8EPO(COPT) vector. 
The advantages were two fold: 
preparative- SDS-PAGE (a cumbersome technique with limitations concerning the 
quantity of protein that can be loaded on to a gel at any one time) was no longer 
required to purify our proteins. 
100% of the expressed protein has the correct amino acid sequence (no 
extensions) and the yield of protein after Ni" chromatography was in excess of 
1 3mgL' based on extinction coefficient (e = 22430 at 280nm) and Bradfords assay. 
All proteins purified from IL cultures were generally eluted from the column in 
9.Oml buffer that when pooled, provided an approximately 60iM stock solution. 
The expression of His 10-EPO's could also be scaled up in a 10 liter fermenter, but 
with limited reliability. Expression tended to vary from one batch to the next and 
protein yields were never lOx 13mg for a 10 liter culture (7mgL' at best). Notably, if 
the initial inoculation of media with overnight starter culture resulted in a culture 
with OD6 <0.1 then, on occasion, the culture would lyse early on in the fermentation 
and never reach induction OD 6 =0.6. 
The MALDI-TOF mass spectrum (Figure 2.16) showed that the protein expressed 
now was a single species: 
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Figure 2.16: MALDI-TOF mass spectrum of His 10-WThEPO derived from the optimized pET 16b-
WThEPO(COPT) vector. 
Although MALDI-TOF mass spectra were qualitatively very useful, in the absence 
of a delayed extraction MALDI instrument we were not convinced that they would 
provide the required resolution to allow glycoproteins (with mass differences of two 
hundred mass units) to be easily observed. 
2.4 NMR analysis of His 10-WThEPO. 
Having access to much higher quantities of EPO we were interested in looking at 
EPO by NMR. This work was done in collaboration with Dr Emma Beattie. The 
three dimensional structure of human erythropoietin has remained unsolved by 
multidimensional NMR spectroscopy and, until recently", X-ray crystallography due 





containing (' 5NH4 )2SO4 as the only source of nitrogen. The protein was purified 
from inclusion bodies and the Ni 2 affinity purified material was refolded according 
to the protocol developed by Boissel and co-workers". 
However, measured concentrations were low in 2% N-lauroyl sarcosine, 50mM 
tris.HC1; pH8 due to poor solubility. The protein was then precipitated and 
redissolved in fully deuterated 70% MeCN, 0.1% TFA to see whether we could 
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Figure 2.17: 'H-' 5N HSQC spectrum of His 10-WTIiEPO. Spectra were acquired in 70% CD 3CN/D20, 
0.1% CF3COOD. The three tryptophan residues (10.5ppm in the proton dimension) present in EPO are 
clearly observed. 
From this encouraging spectrum, we went on to look at the 'H-' 5N HSQC spectrum 
obtained from a sample refolded against 2% N-lauroyl sarcosine, 50mM tris.HC1; pH 
8, 40p.M CuSO4, The paramagnetic Cu" ions, employed to catalyse oxidative 
disulfide bond formation, were removed by dialysis against refolding buffer free of 
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Figure 2.18: 'H-"N HSQC spectrum of His 10-WThEPO. Spectra were acquired in 2% N-lauroyl 
sarcosine, 50mM tris.HC1; pH 8 
The resulting spectrum (Figure 2.18) was very poor, showing very broad signals and 
little resolution in the ' 5N dimension. This indicated that attempts to refold our 
His 10-wild type protein according to the protocol of Boissel and co-workers" had 
been unsuccessful and the protein had remained unfolded. An identical spectrum 
was also obtained when our E. coli derived protein was refolded against 35% 
glycerol, 40.tM CuSO 4 100 . We later discovered (Chapter 3, 3.1-3.3) that our E. coil 
derived proteins were expressed in an oxidised form, comprising monomeric and 
highly aggregated material. This was surprising as we expected the protein to be in a 
reduced form owing to the reducing conditions (GSH:GSSG >1) in the bacterial 
cytoplasm. Therefore, the refolding process (in the absence of a prior reductive step) 
was likely to have had little affect on the expressed protein. Consequently, a further 
avenue of investigation would be to oxidatively refold the protein after a reductive 
step and re-examine the solution structure of recombinant human EPO by NMR 
spectroscopy. 
Since our attempts to solve the 3D structure of hEPO by NMR, Cheetham and co- 
workers (Amgen Inc) have reported on the NMR structure of erythropoietin 86 . 
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Similarly, they had difficulty in dissolving EPO to the required concentration for 
NMR and mutations of all N-glycosylation sites from asparagine to lysine were made 
resulting in MKLysEPO which was soluble at concentrations in excess of 20mgL'. 
Furthermore, they reported that their MKLysEPO suffered the effects of rapid ' 5N 
and ' 3C relaxation rates, giving poor magnetisation transfer through scalar coupling 
in the NMR experiments used for assignments. This results in broadening of signals 
and poor signal to noise ratio. Their solved solution structure (Figure 2.19) shows 
good agreement with previously determined model structures. 
AS o 
b 
Figure 2.19: Solved solution structures for MKLysEPO (b) and ribbon diagram (a) 86 . 
The NMR structure of the wild type protein, though undoubtedly similar to that 













Electrospray Jonisation Mass Spectrometry (ESI-MS) Analysis. 
Electrospray ionisation mass spectrometry (ESI-MS), a softer ionisation method, has 
found broad applicability in structural biology, particularly in the analysis of primary 
structures of biopolymers such as proteins and nucleic acids. ESI-MS has allowed 
the routine analysis of very large and very labile molecules from small organics to 
large supramolecular assemblies and protein complexes bound by non-covalent 
interactions 
Typically, a sample solution is pumped through a capilliary (PEEK or fused silica) 
whose end is supported by a stainless steel capilliary needle. Charged aerosol 
droplets are electrosprayed by means of an electrical potential (2-5kv) between the 
needle tip and the cylindrical counter electrode and dispersed into the ionisation 
region. Desolvation of macro-ions is assisted the use of a counter current 'drying' 
gas and by heating the probe (Figure 3.1)". 
RF I I an 
I 	Probe 
	
VW 	 a 
Analyser 	 — Sample 
Turbomolecular Rotary 	 1 	Drying 	t 
Pumps 	Pump Exhaust Gas (White) Nebuliser 
Gas (Red) 
Figure 3.1: Schematic diagram of the micro-mass Platform II ESI mass spectrometer probe. Ions 
are accelerated by the counter electrode, through a series if skimmer cones into the analyser" 
Macromolecular ions of various charges are formed by a process known as field-ion 
evaporation, which leads to a rapid decrease in droplet size and desolvation. The 
mechanism of ion formation in ESI is still much debated and is affected by 
coloumbic forces in combination with the effects of the ESI interface conditions, 
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analyte charge, temperature and solvent polarity 
schematically in Figure 3.2. 
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The mechanism is shown 
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Figure 3.2: Proposed mechanism of macro ion formation in ESl-MS ° 
Below is shown a typical charge envelope for Myoglobin. 
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Figure 3.3: ESI-MS charge envelope for Horse Heart Myoglobin. 
What we can assume is that the peaks in the 'charge envelope' correspond to a single 
protein and each peak differs from the next in terms of charge by +1 and that charge 
is due to protonation. Since the X-axis corresponds to the mlz ratio, the true mass 
MR, of myoglobin can be determined by multiplying the mass M 1 (corresponding to a 
particular peak) by the charge associated with that species (1), less the mass of the 
number of protons that provide the charge (iM H): 
(I) MR = iM1 - iMH 	for a species with i charges 
and (II) MR = 0+0M1 - (i+I)MH for adjacent peak with i+1 charges 
Where MR = Molecular weight of protein R 
M i mlz of peak with i charges 
MH = mass of a proton 
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The charge state corresponding to a particular peak in the envelope can then be 
determined by rearranging I and II to eliminate MR and solving the simultaneous 
equations for charge i: 
I 	MR=iMI -iMH 
-II 	-MR = -(i+1)M 1+, +(i+l)MH 	add I and -II 
o = iM1 —jMH -(j+l)M 3 +i +(i+l)MH 
o iM 1 —iMH - iM1+ 1 - Mil 1 + iMH+ MH 	since MH 1 
o = iM —i - iM 1 + 1 - M+, + i + 1 
o = i(M 1 - M+ 1 )- M+1 ± 1 
i(M1±, - 1) = M 1+, - 
= 
M 1 —M1+, 
Once i is known then each peak can be used to determine a separate estimate of 
molecular weight MR 112 Fortunately, the platform II has software (Transform and 
Maximum entropy) capable of performing this type of analysis on proteins and 
complex mixtures of peptides almost instantaneously. Thus charge spectra are 
routinely and rapidly deconvoluted by the mass spectrometer's data management 
system (Mass-Lynx v2.3). 
3.1 Off-line LC-MS analysis of His 10-EPO samples. 
ESI spectra of Ni 2 affinity purified His 1 0-hEPO samples were initially obtained after 
the samples had been desalted using C 4 or C 18 reverse phase chromatography. The 
gradient employed was typically 10-100% acetonitrile over 15 to 20 minutes. Pooled 
HPLC fractions were lyophilised and re-dissolved in the minimum volume of 70% 
acetonitrile/water, 0.1% formic acid. These (standard ESI) conditions were very poor 
and failed to solubilise the EPO samples. A number of organic acids (HCOOH, 
AcOfi, TCA, and TFA) at varying concentrations were then screened along with 
mixtures of acids (eg. 0.1% AcOH; 0.01% TFA). TFA, at concentrations of 0.05-
0.1%, was found to be the most successful at solubilising the EPO samples and 
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protonating them sufficiently to be observed by ESI-MS. Under these conditions ES! 
spectra were still very poor (Figure 3.4). 
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Platform II N 	Sp.cfromels 
fl162 	l72 
	
: 	 : 	 - 	 )T 	'Y- 	- r 	Are 
Figure 3.4: Poorly resolved charge envelope for His 10-C38hEPO, acquired in 70% MeCN/H 20, 0.05% 
TFA. 
Additionally, ESI spectra of WI and cysteine mutants treated with an excess of 
suithydryl modifying reagents such as NTCBA (12), DTNB (Elimans reagent (13)), 
iodoacetamide (14), 5-1-AEDANS (15) showed no evidence that sulfydryl 
modification had taken place. 
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This was surprising since samples of Ni 2 affinity purified EPO had not yet been 
oxidatively refolded and theoretically had 4 or 5 free thiol groups. These findings 
indicated that perhaps the samples were expressed in an oxidised form (with formed 
disulfides). Even more surprising was that cysteine mutants, containing 5 cysteine 
residues (ie. an odd number) still failed to react. 
The reasons for this soon became clear. WT EPO samples, though providing poor 
data, could still be resolved to give masses close to the calculated whereas cysteine 
mutants had a mass approximately 300 mass units higher than expected (Figure 3.5). 
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Figure 3.5: The resolved ESI-MS for His 10-C38hEPO shows a peak at 21207 Da (some 303 Da 
larger than the expected molecular weight). 
It was hypothesised that this mass anomaly could result from the formation of an 
adduct with the tripeptide glutathione, (16)(molecular weight= 307.313a), present in 
the bacterium. If this was to be the case then it should be possible to reduce it off 
with 3-mercaptoethanoI or dithiothreitol (DTT). DTT was shown to be superior in 
this case as various intermediate EPO-mercoptoethanol species (16b) were frequently 
observed' 3 when using 3-mercaptoethanol as the reducing agent. 
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Figure 3.6: Mechanism of disulfide bond reduction by -mercaptoethano1 and DTT. 




DTT tends to be more effective than mercaptoethanol due to the rapid intramolecular 
cyclisation reaction resulting in a stable 6-membered ring. 
The effects of reduction on the ES! spectra were more dramatic than expected. The 
charge spectrum of the reduced species was far better resolved (Figure 3.7) 
facilitating accurate mass measurement of all samples. 
))3 i 	1435 	'4( 	.C•131 - 
Figure 3.7: Charge spectrum of reduced (50mM DTT) His i rC3 8hEPO. 
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This was believed to be the result of loss of any structure that the initially expressed 
protein may have had. Cleaved disulfide bonds resulted in a more open structure 
which could be protonated more readily 113 Such an effect was also observed by 
Przybylski and tO  when investigating the effect of disulfide reduction on 
the structure of hen egg-white lysozyme (HEL). Also, the presence of EPO 
oligomers or aggregates (observed by non-reducing SDS-PAGE of column purified 
material) may inhibit sufficient protonation. 
Further investigations with all protein samples provided a general rule: 
Reduced protein samples gave good MS data resulting in more accurate masses. 
Oxidised protein samples gave poor MS data resulting in less accurate masses. 
This was also later shown to be true for oxidatively refolded samples. Unlike their 
precursors, the refolded protein samples were shown to be monomeric by SDS-
PAGE conducted under non-reducing conditions. 
3.2 Typical Resolved Mass Spectra (shown below for WThEPO). 
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Figure 3.8: Typical resolved (Max Ent) spectrum of reduced His 10-WThEPO shows only one 
major species over a 5KDa-50KDa mass range. 
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From the acquired data we were able to determine that: 
Expressed proteins had their N-terminal methionine residues cleaved (this was 
verified by N-terminal sequencing. Edman degradation gave glycine as the N-
terminal amino acid). 
Proteins were obtained from E. co/i in an oxidised form —with (either correctly, 
incorrectly or as a mixture of both) formed disulfides and cysteine mutants were 
capped with glutathione suggesting that the oxidation occurs inside the cell, 
possibly as some sort of detoxification mechanism. 
Full alkylation was then observed with sulfhydryl modifying reagents such as 
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Figure 3.9: Mass spectrum of His 10-C24hEPO (pink) superimposed on the mass spectrum of 
reduced and iodoacetaxnide treated His 10-C24hEPO (green). The largest peak (in the green 
spectrum) corresponds to the addition of six (not five as expected) acetarnide units. 
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Notably, these reactions were particularly messy and data was poor unless the 
reducing agent was removed (by protein precipitation or dialysis) prior to the 
alkylation step. From these preliminary results we could begin to explain our 
previous findings: 
Our NMR spectra (Chapter 2, 2.4) of refolded WThEPO were always broad and 
looked unfolded. However, if disulfides were formed incorrectly during or soon after 
protein synthesis (locking it in a particular conformation) then the oxidative refolding 
step (Boissel et a!) would be ineffective in bringing about any change in structure. 
We cannot, however, explain the differences between our findings (2 species 
expressed, oxidised) and those of Boissel and co-workers 89 . 
Cysteine mutants were simply inert to suithydryl modifying reagents because there 
were no free thiol groups present. 
This prompted a new refolding protocol (Figure 3.10) whereby all protein samples 
were reduced prior to oxidative refolding. It has been reported that the biological 
activity of EPO is lost irreversibly when reduced and alkylated, but can be regained 
quantitatively when reduced protein samples are re-oxidised, hinting at the 
importance of correctly formed disulfides 80 . On introducing an extra cysteine into 
EPO we were particularly aware of the potential for mis-folding' 14•  However, 
proteins are generally unaffected by single mutations and we continued, utilising 
established refolding protocols 89. Protein was reduced with 10mM DTT or 
tricarboxyethyl phosphine" (TCEP) for 3h at room temperature. DTT was then 
removed by dialysis against 6M guanidine.HC1, 50mM Tris.HCI; pH8 under nitrogen 
until all DTT had been removed (monitored by Ellmans assay' 16)  Proteins were then 
oxidatively refolded according to the procedure of Boissel and co-workers 89. Pulse 
refolding (a newer refolding method) is also being pursued by new members of the 
group. In order to establish that the disulfide bonds had been correctly reformed we 
resolved to map the position of the glycosylation site after refolding and 
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Figure 3.10: Modified refo lding protocol for the renaturation of WT and cysteine mutant hEPO's. 
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From our electrospray data from reduced proteins we could then determine accurate 
masses for all EPO species: 
	
WTEPOreduced 50mMOTT 	 t24 EPO reduced 	 C3lEPOrsduc.d 50mMDTT. 
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His 1 0EPO species Calculated mass (Da) Observed mass (Da) 
Mono-isotopic Average 
WT 20903.76 20916.85 20912.6 
C24 20892.73 20905.89 20902.1 
C38 20892.73 20905.89 20902.8 
Masses are calculated for all proteins in their reduced forms. 
Table 3.1 Calculated and observed masses of reduced WThEPO and C24 and C38 cysteine mutants. 
Mass differences between calculated and observed masses are likely to have resulted from the 
instrument calibration. 
3.3 Optimisation of Mass Spectrometry Analysis Using On-Line LC-MS. 
Although with reduced protein samples we could obtain good MS data, the 
procedure: reverse phase HPLC, followed by fraction combining and lyophilisation, 
then ESI-MS was particularly time consuming and labour intensive and resulted in 
loss of sample. To minimise handling, an LC-MS method was developed, which 
combined the ability to use high salt concentrations (necessary to dissolve EPO and 
conduct modification reactions in) yet provide salt free EPO samples for MS. This 
CHAPTER 3 
was simply achieved by disconnecting the HPLC from the MS until salt and polar 
impurities had eluted from the C 4 or C 1 8 reverse phase column. This was determined 
by monitoring the UV trace (Figure 3.11). 
UV 







0 mins 	 40 mins 
Figure 3.11: The UV trace allows us to see when all guanidine and polar reagents have passed 
through the column and protein elution is observed in the UV trace and in the (total ion 
chromatograph) TIC. 
In summary, the acquired electrospray data had proven itself to be of particular use in 
helping us establish the state of our proteins as they were presented to us by the 
bacterium. Furthermore, we were able to gain inferences into the structure of the 
expressed material and problems that it may have presented to the host organism 
during expression. With refolded cysteine mutants in hand we could then attempt 
our glycosylation reactions with glycosyl iodoacetamides. 
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CHAPTER 4 
Synthesis of Activated Carbohydrates. 
The aim of this project was to develop methods for the synthesis of homogeneous 
glycoforms of recombinant human erythropoietin. Since the absence of the 0-linked 
glycan has no effect on the biological activity of EPO, the focus of the project was on 
the synthesis of analogues of the N-linked glycans. Although the biological aspect of 
this project was very time consuming, through a keen interest in gaining further 
experience in synthetic organic chemistry, synthesis of relevant, useful and more 
complex carbohydrates was attempted. The core pentasaccharide of EPO is required 
for full biological activity in vitro and the synthesis of this type of structure is a long-
term goal. Fortunately, a handful of groups have recently reported on the synthesis of 
this (Man3GlcNAc2) pentasaccharide core structure 48
.49,53,55 so one could be forgiven 
for becoming complacent about the difficulties in preparing such a molecule. From a 
total synthetic viewpoint, a brief discussion of the major issues which arise during the 
synthesis of (17) and applying known methodologies to the synthesis of the 
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Figure 4.1: Reagents for the convergent methods of glycoprotein and neoglycoprotein synthesis. 
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4.1 Otigosaccharide Synthesis. 
Oligosaccharide synthesis is still far from routine and has evaded the luxury of 
automation, contrasting with the now facile synthesis of oligopeptides and 
oligonucleotides. This is primarily due to the fact that glycosidation reactions, by 
which monosaccharides are extended to oligosaccharides are seldom quantitative and 
tend to result in anomeric mixtures which need to be separated 37 '47" 18 
Most methods of glycoside bond formation can be summarised as belonging to the 
class below:
Pe ~ OR OP 
OP 
OP 	
OP PRDMOTER Pe 
OP 	 OP 	 22 
19 20[. . 	 211 	
ROH
OP 
Figure 4.2: General mechanism for glycoside bond formation 	The intermediate carbocation is 
stabilised by the ring oxygen (21) 
In the absence of a participating group at C-2 (P=benzyl, P=azide) mixtures of 
glycosides are prepared in proportions which vary with the reaction conditions. In the 
presence of a participating group however (P=acetyl, benzoyl, pivaloyl N-phthaloyl. 
N-acetyl etc.) 1,2-trans glycosides can be prepared in high yields (Figure 4.3): 
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Figure 4.3: Neighbouring group participation at C-2 facilitates the synthesis of 1,2-trans 
glycosides" 8' 119 
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4.2 3I4 Man noside Linkages. 
This oligosaccharide linkage (Figure 4. 1, shown in red) has become infamous through 
years of carbohydrate research. It is known to be one of the most difficult glycosidic 
linkages to prepare (disfavoured by the anomeric effect and participating groups at C-
2). However a number of methods have been developed for its synthesis and wise 
synthetic methodologies introduce the Mann 1 -4GlcNAc linkage at as late a stage in 
the synthesis as possible. Below are some recent examples of the successful synthesis 
of the -mannoside linkage used in the context of constructing the pentasaccharide 
core of N-linked glycans. 
Danishefsky 's Method: 
Uses an oxidation (24)—(25)-reduction (25) - (26) sequence on the full 















Ogawa 's Method: 
Tethers the 2-position of mannose to the 4-position of N-phthalimido GlcNAc 
through a p-methoxybenzylidine acetal (27), setting up the stereochemistry for 
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Unverzagt 's Method' 2 ' (uses the method developed by Kunz 122 ) 
-The [3-mannoside was introduced from the [3-glucoside through an intramolecular 
SN2 reaction where the carbonyl oxygen of an N-phenyl urethane at C-3 (28) serves as 
nucleophile, displacing the chloroacetyl group. 
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Other recent developments include direct 12' and ultrasound assisted 
124 SN2 
displacement of triflates and chioroacetyl groups at C-2 and enzymatic methods 125 " 26 . 
4.3 N-Acetyl Groups as Neighbouring Groups for Participation in [3-glycoside 
Synthesis. 
These groups can be very problematic in syntheses as they have a removable proton, 
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Figure 4.4: N-acetyl groups can form stable I ,3-oxazolines. 
This problem is generally solved using N-protecting groups which lack this proton and 














Figure 4.5: Some alternative participating protecting groups for nitrogen: N-Phthalimido (30), PNZ 
(31), and dibenzylamino (32). 
4.4 Synthesis of More Complex Naturally Occurring Glycans. 
For oligosaccharide extension, beyond the core pentasaccharide, orthogonal 
protection is required on C-2 of the two terminal mannose residues to allow extension 
of oligosaccharide to more complex natural products 48 . This is not an issue here 
however our preliminary target would be the core pentasaccharide. 
4.5 Glycosyl Amines. 
Glycosyl amines have long been at the center of investigations into N-linked 
glycoprotein chemistry as they have many desirable properties. They have a cyclic 
structure and tend to adopt the 3-anomeric configuration, which is found in the 
natural sugar-protein linkage. A good synthesis of glycosyl amines has consequently 
been the focus of much research over the past two decades but generally, one of two 
methods are used. 
4.5.1 Glycosyl amines from naturally occuring mono and oligosaccharides. 
In the absence of protecting groups, saccharides from natural sources can be 
converted to the corresponding glycosyl amine by direct condensation of the aldehydo 
form of the reducing monosaccharide with ammonia 
 50,57,12 9  (formed through the 
decomposition of ammonium bicarbonate. NI-14HCO3 in saturated aqueous solutions): 
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These reactions proceed in near quantitative yield and the products are usually used 
without further purification as the starting material does not react significantly in the 
following step (coupling to synthetic peptide). The major problem with this reaction 
is that all traces of ammonium bicarbonate must be removed (lyophilised) as it may 
also take part in the following reactions. 
4.5.2 Glycosyl Amines from Reduction of Glyco.syl Azides 
Glycosyl azides (37) have proved very useful in the synthesis of glycosyl amines, they 
are more stable and can be incorporated at early stages in the synthesis and remain 
intact throughout. They are generally introduced by direct SN2 displacement of cc-
halides (36) with inversion at the anomeric centre under phase transfer catalysis 
conditions' 30 . Alternatively, through Lewis acid mediated cleavage of 3-acetates in 
the presence of homogeneous sources of azide (trimethyl silyl azide)'3 . 
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NHPC 
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Figure 4.6: Common syntheses of glycosyl azides (37) include SN2 displacement of glycosyl halides 
(36) under phase transfer catalysis conditions and exchange of anomeric acetates with azide ion in 
the presence of lewis acids. 
Azides can then be reduced using a number of methods, catalytic hydrogenation (112 
and Pd/C. Pt02 or Raney nickel), thioacetic acid. thiols 48 ' 55". Problems are that the 
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synthesis of u-chlorides is poor and even worse for large saccharides, as is the 
synthesis of beta acetates. 
One recently reported example, which demonstrates the versatility of the glycosyl 
azide and latent functionality, prepared the glycoamino acid (39) in high yield, directly 






N3 	 Bu3P 
NHPc 	 N HAc 	
r!lHFmoc 
4.6 Strategic Problems. 
Synthetic glycosyl amines are usually fully protected when coupled to fully protected 
synthetic peptides with activated aspartate residues-global deprotection then follows. 
Our glycosyl iodoacetamides are usually deprotected and water soluble prior to 
reaction with unprotected recombinant proteins. 
Potential caveats that should be noted are: 
I. Glycosyl amines are generally unstable and the amino group is readily eliminated. 
If we chose to deprotect the oligosaccharide fully and then treat with iodoacetic 
anhydride, the amine, or precursor (usually azide) must withstand the deprotection 
conditions. 
2. If the fully protected oligosaccharide is coupled to activated iodoacetic acid (using 
standard peptide coupling reagents) the resulting iodoacetamide must withstand 
the deprotection conditions. 
The issues detailed above cause significant problems when attempting the synthesis of 
this class of compounds and must be considered prior to attempting their synthesis. 
For our preliminary glycosylation studies we would be considering simpler synthetic 
targets such as the lodoacetamide derivatives of N-acetyl glucosamine (G1cNAc, (40)) 















Retrosynthetic analysis of these compounds is very simple, resulting in glycosyl 
amines and activated versions of iodo acetic acid (anhydrides, acid chlorides, active 
esters etc.) 
4.7 Synthesis of p-N-Glycosyl lodoacetamides. 
The direct synthesis of the glycosylamine (34), R=H, from the parent hemi-acetal 
(33), R=H, was achieved50 ' 57" 29" 33  by dissolving N-acetyl glucosamine in the minimum 
volume of saturated aqueous ammonium bicarbonate, the reaction mixture was then 
stirred at room temperature for five days. Further NH 4HCO3 was added throughout 
to ensure that the solution remained saturated. The excess N}LHCO3 was removed by 
lyophilisation of the reaction mixture to afford the crude product as a pale yellow 
solid. No attempt was made to purify the product further. The 'H NIVIIR spectrum of 
this amine contained other non-integral anomeric resonances corresponding to 
unreacted starting material but generally the product is used directly as the starting 
material should not react in subsequent steps. The product was then dissolved in the 
minimum volume of 1 M NaHCO3 and portions of iodoacetic anhydride were added at 
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Figure 4.7: Selective iodoacetylation of the glycosyl amine in aqueous solution. 
The product was purified by passing the reaction mixture over a column of acidic ion 
exchange resin, then basic ion-exchange resin and lyophilised' °4 . This reaction was 
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also used to prepare the glycosyl iodoacetamides of lactose (42), maltose (43) and 
chitobiose (41): 
OH 	OH OH 
HO 










We hoped to use this synthesis of glycosyl amines as a route to more complex sugars. 
The amino group could be trapped with FmocOSu 134  and purified in yields of 80% but 
the Fmoc group was generally unstable to further reactions. 
We then chose to attempt the synthesis of larger saccharide-3-iodoacetamides using 
glycosyl azides. In the simplest case, for N-acetyl glucosamine, the iodoacetamide 
(40) could be prepared in 5 steps (Figure 4.8): 
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Figure 4.8: 1) AcCI, 16h, RT, 50%, (II) NaN 3, TBAHS, DCM, Sat. aq. NaHCO3, RT, lh, 97%, (III) 




The procedure included the use of Horton's synthesis of the per-acetylated-a-
chloride' 37. This reaction proceeded in only 50% yield with the other major product 
being the fully acetylated G1cNAc. The halide was then displaced with azide ion 
under phase transfer catalysis conditions as previously described (Figure 4.6) in 
excellent yield. After reduction of the azide, we chose to use the acid chloride (45) of 
iodoacetic acid since attempts at coupling the per-acetylated glycosyl amine (44) with 
iodoacetic acid using peptide coupling reagents (pyBOP, EEDQ, DCC)' 35 were low 
yielding (0%, 20% and 40% respectively). The acid chloride was prepared in near 
quantitative yield using a slight excess of thionyl chloride: 
soci2 	I,,,—YCI ,,,—,,roH 
The synthesis of the glycosyl amine (44) was later simplified and optimised further 
using the commercially available a-acetate (38)''. 
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Figure 4.9: (I)TMS-N3, SnC14, CH202, RT, 16h, 97%, (II), H2 , 50/oPdJC, MeOH, 3h, quantitative. 
This meant that the low yielding synthesis of the a-chloride (36) 136138 was no longer 
required and the protected glycosyl amine (44) was prepared in 97% yield over the 
two steps"' compared with 36% over three steps (Figure 4.8). With our N-acetyl 
glucosamine derived glycosyl iodoacetamide in hand we conducted some test 
reactions with a suitably protected cysteine residue 
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Figure 4.10: (1) Et3N, (Ac)20, CHCI3, RT, lh, 88%, (II) Zn, HCI, MeOH, 0°C, 2.5h, 42%, (III) 
50mM (NH4)2CO3 (pH8), RT, lh, 98%. 
And then the same reaction was conducted with the tripeptide glutathione: 
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Throughout these experiments we also noted that the chemical shift of the cc-
methylene carbon (of the iodoacetamide, (40)) changed significantly from —3.58 to 
+35.2 in (50) and (52)(Table 4.1): 
Compound 13C Chemical shift of a-methylene carbon 
lodoacetic acid -6.59 
lodoacetic acid chloride (45) +4.12 
Deprotected glycosyl iodoacetamide (40) -3.58 
Cysteine derivative (50) 35.17 
Glutathione derivative (52) 35.18 
Table 4.1: 13C chemical shifts of the ct-methylene carbon in glycosyl iodoacetamides and reaction 
products. 
We then considered whether a 100% 13C label in this position may function as a useful 
indicator of protein glycosylation. The 13C labelled G1cNAc iodoacetamide (53) was 
then prepared. from 13C labelled iodoacetic acid chloride as in Figure 4.9 as only a 
slight excess of the acid chloride would be required. The use of 13 C labelled 
iodoacetic anhydride in a reaction with the deprotected glycosyl amine (Figure 4.8) 
would result in loss of 50% (as iodoacetic acid) of the extremely expensive 13C 
labelled material and this was therefore not considered viable. 
HO * Position of 13C label 
HO 
Ay I 
NHAc 0 53 
We used our 13C labelled iodoacetanude in a test reaction with glutatione and 
glycosylation on cysteine was clearly observed (Figure 4.11) as we saw the shift in 13C 
label from -3.58 to +35.2ppm. 
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Figure 4.11: (a) shows the ' 3C NMR spectrum of the 13C labelled iodoacetamide (53) and (b) shows 
the ' 3C NMR spectrum of the corresponding glutathione deirivative (52). 
We then hoped to use this technique to analyse protein glycosylation at a later stage. 
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4.8 More Complex Oligosaccharides. 
Investigations into the synthesis of the pentasaccharide core tend to favour the 
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Figure 4.12: Common retrosynthetic analysis of the pentasaccharide of N-linked glycans, P=Ac, 
P'=Bn, R=SEt. 
Key features are the syntheses of the building blocks (57), (58), (59) and (60) or 
analogs thereof. For example, (57) is ultimately transformed into (58) (R=SEt) by the 
action of dimethyl dioxirane (DMI)O) and ethane thiol 48  and finally serves as an 
acceptor for two mannose residues. Building block (57) was chosen as a key 
intermediate since it is capable of being transformed in GIcNAc, mannose, or 
glucose39'47, maximising the possibilities for diversity, which may be useful in 
structure-function glycoprotein studies. 
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Synthesis of Building Blocks: 4-p-Methoxybenzyl-D-Glucal (57). 
This work was carried out according to procedures of Danishefsky and co-workers 48 
(Figure 4.13). 3,4,6-tri-O-acetyl-D-gluCal (61) was deacetylated with sodium 
methoxide in methanol. The crude product was treated with p-anisaldehyde and 
anhydrous ZnC12  to afford the 4,6-p-methoxybenzylidifle acetal (62) in 20% yield. 
The tButyldimethylsilyl group (TBDMS) was efficiently installed using standard 
conditions and then the benzylidine acetal was regioselectively opened onto the 4-
position of the glycal using diisobutyl aluminium hydride (DIBAL-H). The TBDMS 
group was then removed using tetrabutyl ammonium fluoride in high yield to afford 
(57). The standard method for introducing benzylidine acetals (trans acetalation with 
p-methoxybenzaldehyde dimethyl acetal and p-toluene suffonic acid) was not 
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Figure 4.13 (1) NaOMe, MeOFL,pMeO(C6144)CHO, ZnCl2, 16h, 20%, (II) TBDMS-C1, imidazole, 
DCM, I.5h, 75% , (111) DIBAL-H, DCM, -20°C, 3h, 80%, (IV) TBAF, THF, 16h, 100% 
Further building blocks (59) and (60) (Figure 4.12) were also prepared using a similar 
strategy, generally involving the use of benzylidine or p-methoxybenzylidine acetals 
(prepared from the aryl aldehydes dimethyl acetals (65)) which could be 
regioselectively opened, but this time onto the 6-position 1443 . 
OMe 
MeO OMe 	 OMe 
TsOH 
 Meo--C—\  65 OMe 
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Synthesis of an Analog of Building Block (57) (Figure 4.14). 
The peracetylated glycosyl azide (37) was deacetylated and the 4,6-p-
methoxybenzylidine acetal was introduced using p-methoxybenzaldehyde dimethyl 
acetal and p-toluene sulfonic acid (TsOH) in 80% yield 141 . The remaining C-3 
hydroxyl group was then benzylated' 41 . The low yield of this reaction was accounted 
for by partial hydrolysis of the benzylidine acetal under the reaction conditions. The p-
methoxybenzylidine acetal was then reductively opened onto C-6 in 85% yield based 
on recovered starting material (actual yield was 58%). 
N3 	 N3 	
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Figure 4.14: (1) NaOMe, MeOH, 2h, then pMeO(C 6H4)CH(OMe)2, pTsOH, DMF, 2h, 50°C, 
80%, 
(II) BnBr, Ba(OH)2, 3A mol sieves, DMF, 83%, (III) Na(CN)BH3 , TFA, DINT, 16h, 85% 
Synthesis of Building Block (59) (Figure 4.15). 
For this building block, we chose N-phthalamido protection on C-2 to see whether the 
yield of reactions (particularly benzylation at C-3 and reductive acetal opening onto 
C-6) could be improved. Benzylidine acetals (not p-methoxy) which are cleaved 
under more strongly reducing conditions can be used in this case as the thioglyco side 
is stable to reducing conditions (unlike azide) and, if need be, this building block can 
also be transformed into a glycosyl azide or further glycosyl donors 41 " 23" 44 ' 145 : 
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The N-phthalimido group was introduced using a well established procedure and the 
thioethyl glycoside (71) was prepared in good yield (73%) via the Lewis acid 
mediated exchange of the anomeric acetyl group with ethane thiol' 44 . Introduction of 
the benzylidine acetal was carried out essentially as before (Figure 4.15). 
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Figure 4.15: (I) NaOMe, MeOW Phthalic anhydride, Et3N/ Ac20, Pyridine, 50%, (II) EtSH, 
BF3 .OEt2,16h, 72%, (III) PhCH(OMe)2, pTsOH,, DMF, 50°C, 2h, 85%, (IV) NaH, BnBr (V) TsOH, 
(Bu3 Sn)20, BnBr. 
Unfortunately there was no time to complete the synthesis of the pentasaccharide core 
but we had managed to prepare smaller model compounds (such as G1cNAc 
iodoacetamide) and the GlcNAc derived 13C labelled iodoacetamide. These were 
taken forward to attempt protein glycosylation and the results are disclosed in the 
following chapter. We expect that there should be no particular problem in 
assembling the pentasaccharide core considering that many routes have now been 
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CHAPTER 5  
Protein Glycosylation and 
Determination of the 
Glycosylation Site. 
CHAPTER 5 
Protein Glycosylation and Determination of the Glycosylation Site 
With refolded proteins in hand, and the ability to observe reactions at the molecular 
level, we went on to investigate whether or not it would be possible to alkylate the 
free thiol group. For the first time, we hoped to be able to address some issues in 
more detail than previously possible: 
The extent of glycosylation: Is the glycosylation or alkylation reaction 
quantitative? 
The specificity of the iodoacetamide group: Are any other amino acid side chains 
modified? 
The identity of the glycosylation site: Is the correct cysteine residue modified? 
(this also tells us whether the correct disulfides were formed during the oxidative 
refolding step). 
In order to achieve these goals a general method for the analysis of glycosylated or 
alkylated proteins was devised and this is described schematically in Figure 5.1. The 




















Figure 5.1: Schematic representation of our glycosylation and peptide mapping strategy. Refolded 
protein is glycosylated (green triangle), reduced and then cleaved into smaller peptide fragments. 
Analysis of the peptides reveals the position of the glycosylation site as only the modified peptide 
will be shifted in molecular weight and have an increased mass corresponding to the alkylating agent. 
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5.1 Identification of the Glycosylation Site: Peptide Mapping. 
Given that we could determine that glycosylation had taken place, how would we 
establish the position of the glycosylation site? In order to determine the nature of 
the glycosylation site we needed to employ reliable methods for the cleavage of the 
peptide backbone. Fragmentation of the glycoprotein into peptide fragments would 
allow us to map the position of the modified amino acid residue. Classical methods 
for the chemical and enzymatic cleavage of proteins have been extensively 
reviewed 14953 . In the following section, only the most frequently employed 
enzymatic methods for protein cleavage (associated with peptide mapping) will be 
discussed. Additionally, only the most relevant chemical methods for peptide 
cleavage (at amino acid residues containing sulfur) will be discussed. 
5.2 Enzymatic Methods for Peptide Fragmentation. 
The most commonly employed proteolytic enzymes in peptide mapping are trypsin, 
a-chymotrypsin and V8 protease from Staphylococcus aureus 152 . All three are serine 
proteases and cleave peptide bonds using a conserved active site motif known as the 
catalytic triad (Figure 5.2), named as such because the peptide hydrolysis is catalysed 
by conserved aspartate, histidine and senile side chains. The second fragment is 


















Figure 5.2: Mechanism of hydrolysis of peptides by chymotrypsi&' 9 
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These proteases however tend not to hydrolyse the peptide indiscriminately and 
instead cleave the peptide backbone adjacent to specific amino acid residues. This 
selectivity is dictated by the 3D shape, size, and surface charge within the active site: 
Enzyme Selective for Structural requirement Residues cleaved 
Trypsin Basic side-chains Protonated amino group Arg/ Lys 
(positive charge) 
a-Chymotrypsin Hydrophobic Aromatics Trp/ Tyr/ Phe 
side-chains 
V8 (Glu-C) Acidic Deprotonated acids Glu! Asp 
side-chains (negative charge) 
Table 5.1: Common serine proteases and their specificities. 
Generally, the protease is used in 10:1-100:1 protein/protease ratios at 37°C 
5.3 Chemical Methods for Peptide Mapping. 
The nucleophilicity of sulfur, which results from it's ability to be easily polarised 
through it's weakly held outer electrons, makes it an ideal target for selective 
chemistry amongst the plethora of functional groups presented by proteins. 
Performed usually at pH8, where amines are protonated and less nucleophillic, it is 
relatively simple to conduct selective chemical reactions at amino acids containing 
sulfur. Since cysteine and methionine residues are also relatively rare, the number of 
fragments is low. 
5.3.1 2-Nitro-5-thiocyanatobenzoic Acid (NTCBA). 
NTCBA (12, see chapter 3) works by providing a source of CN and once protein 
cyanlation occurs (selectively on cysteine residues). Cyanylation of the thiol group 
induces an intramolecular cyclisation reaction under basic conditions (pH 10) aided 
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Figure 5.3: Proposed mechanism of NTCBA induced peptide backbone cleavage. 
The C-terminal fragment is modified at its N-terminus where the nitrile group is 
incorporated as part of the iminothiazolidine (ITZ) heterocycle. 
5.3.2 Cyanogen Bromide (CNBr): Cleavage at Methionine. 
Cyanogen bromide has for a long time been considered the most reliable chemical 
method protein fragmentation with cleavage occurring quantitaviely at methionine 
residues. As above, cleavage occurs through neighbouring group participation 
(Figure 5.4). As methionine is a relatively rarely occurring amino acid, it is effective 
in providing few peptide fragments and has been utilised in some cases to remove 
histidine tags from recombinant proteins, a procedure normally employing the use of 
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5.4 Glycosylation of His 10-EPO Samples 
With refolded EPO samples in hand we went on to study site specific glycosylation. 
OH 	 OH 
HO 	
H H0C38 
NI-tAc 	II NHAc 
0 	 o 
5.4.1 Analysis of Glycoprotein Products. 
As a result of developing an on-line LC-MS method for glycoprotein analysis, we 
aimed to use this to monitor the progress of the glycosylation reaction by removing 
aliquots at timed intervals. As with previous samples, good MS data was only 
acquired when the protein samples were reduced prior to on-line LC-MS, and 
complimenting previous reactions with alkylating reagents, the reaction products 
were only 'clean' when the alkylating reagent was removed prior to reduction. 
For analytical purposes, aliquots were precipitated by the addition of 10 volumes of 
1:1 acetone/methanol (where buffer salts and alkylating reagents remain in solution) 
and stored at -20°C for at least ten minutes. Precipitated protein was then collected 
by centrifugation and redissolved in 1 0-20jiL of 6M guanidine.HC1, 50mM tris.HC1; 
pH8 and treated with DTT to a final concentration of 10mM. Reduced samples 
were then analysed using on-line LC-MS as described in chapter 3. 
5.4.2 The Glycosylation Reaction. 
In an effort to rapidly assess the refolding process (described in chapter 3) for it's 
ability to reform the disulfide bonds the first glycosylation reactions were crude and 
designed purely to assess the number of free thiol groups (predicted to be one). 
Refolded protein samples were concentrated by passing the dilute refolded protein 
solution over a 1 .Oml bed of His-bind resin (Novagen). Immobilised protein samples 
were eluted in the minimum volume (3.0ml) of refolding buffer containing 500mM 




Figure 5.6: deconvoluted 
charge spectrum. 
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previously described and redissolved in 100L of alkylation buffer (6M 
guanidine.HC1, 500mM Tris;pH8, 20mM EDTA). G1cNAc iodoacetamide was then 
added from a lOOmIvI stock solution (in water, alkylation buffer, or DMF) to a final 
concentration of 10mM. Aliquots were removed from the reaction mixture at 24h 
intervals and analysed by on-line LC-MS (Figure 5.5) as described in chapter 3. 
Scan ES. 
1-. 	 1040.45. 	 6.07.5 
( 
ZI 
C38G 	 Scan ES, 
1101.29 	 2.655 
YZ 
Figure 5.5: Glycosylation of refolded His 10-C38hEPO at t=lh (a) and t-24h (b). At tlh, the charge 
envelope is typical of the purified protein. At t- 24h the ESI spectrum has changed and each peak 
associated with a particular charge state is a doublet, indicating that the reaction is proceeding as two 
species are now visible. 
After 24h, the deconvoluted charge envelopes showed 
clearly (Figure 5.6) how the glycosylation reaction had 
proceeded. The results are summarised below in Table 
5.2: 
Peak Calculated Average Mass Observed mass 
Ml (His i o-C38EPO) 20905.89 20903.5 
M2 (Ml+ G1cNAc) 21166.89 21163.0 
M3 (M2+ 2G1cNAc) 21427.89 21424.5 




The analysis of the MS data showed that the reaction proceeded in approximately 
30% yield. Surprisingly, it was also clear that a second G1cNAc residue was binding. 
Logically, we would have predicted the addition of a single G1cNAc residue resulting 
from one free thiol (and 2 formed disulfides) or the addition of three G1cNAc 
residues resulting from three free thiols (and one formed disulfide) and so forth, so 
the addition of two G1cNAc residues was quite unpredicted (compare Figure 3.9 
however). Furthermore, the longer the reaction proceeded (72h), the more 
diglycosylation was observed. These results were highly reproducible on C38 and 
C24 EPO mutants but glycosylation reactions conducted on His 10-C38EPO were 
generally higher yielding (more glycosylated product was observed) than those 
conducted on the C24 mutant. 
5.4.3 NTCBA Analysis of Glycoproteins. 
The addition of two GlcNAc residues was clearly puzzling and we resolved to 
analyse the reduced, glycosylated protein with NTCBA. We analysed all proteins 
(non-glycosylated and glycosylated) and found that they were cleaved quantitatively 
to give MS data in good agreement with calculated values. This also proved a good 
general method (non-molecular biological) for proving the identity of the protein or 
position of the mutation by simply observing the sizes of the fragments. 
Fragment NTCBA Fragments 
masses 	for 
His 1 0-C38 
G(-21)-16 C7-G28 C29-H32 C33-E37 C38-A160 C161-End 
Calculated 3186.5 2535.8 483.49 589.62 13593.76 731.78 
Observed 3186.0 2534.5 - n/o 13592.5 nb 
Table 5.3: Calculated and observed masses for the peptide fragments resulting from NTCBA 
cleavage of His 10-C38hEPO. Masses under 500Da were not observed as they lay outwith the 
acquisition range (500-2000Da). n/o = not observed 
The partially glycosylated C38-mutant was reduced and gave fragments in good 
agreement with the calculated values (Table 5.3). If the protein had however been 
glycosylated on C38, the resulting sulfide would not have been cleaved allowing a 
larger peptide (C33-A160+GlcNAc, Mwt=14412.313a) fragment to be observed and 
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Figure 5.7: NTCBA 




this was the case (Figure 5.7). This fragment (14249.0 
Da) did not correspond to the mass of our glycosylated 
fragment (expected molecular weight of 14412.3) and 
was in fact some 163 mass units smaller. Neither did it 
correspond to peptides resulting from incomplete 
cleavage which would be expected at 14282.56Da (from 
missed cleavage at C161), and 14140.36Da (missed 
cleavage at C33). 
We considered a number of potential mechanisms 
whereby the glycoprotein linkage may be modified or 
destroyed. Although the larger fragment was not 
observed when NTCBA treated unglycosylated protein 
was analysed, it was observed when iodoacetamide 
treated C38 was NTCBA treated and analysed. 
Alternatively, it may be possible that the sulfide was 
cyanylated and eliminated under the basic reaction 
conditions (below). Such 13-elimination would not be possible for homocysteine or 
methionine due to the increased chain length and even if they were to become 
cyanylated under the reaction conditions, the cyano group is likely to be hydrolysed 
and lost in the following step (pH 10; 37°C). The observed fragment size may well 
turn out to be independent of the glycosylating reagent under these conditions. 
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From NTCBA analysis of the partially glycosylated 
C38 mutant we did however see the mass corresponding 
to the addition of G1cNAc, but to the N terminal region 
of the protein (from the beginning of the his-tag (G-2 1) 
to EPO residue 6). This was unexpected and may have 
arisen from modification of the a-amino group (N-
terminus) or the polyhistidine tag. Additionally, when 
the reaction was carried out in the presence of 5mM L-
histidine there was no observable difference in the 
product distribution. Although glycosylation of the his-
tag was undesirable in that it made it difficult to assess 
the degree of cysteine modification, this was not 
considered to be too problematic as our long term goal 
was to remove the entire his-tag at the end of the 
synthesis. 
Figure 5.8: N-terminal 
modification of the C38 
mutant by G1cNAc 
iodoacetamide. 
5.4.4 'H-' 3C HSQC NMR Spectrum of Partially Glycosylated His 10-C38hEPO. 
The carbon- 13 labelled glycosyl iodoacetamide (53) prepared in the previous chapter 
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Figure 5.9: The 'H-' 3C HSQC spectrum shows glycosylation on both nitrogen and sulfur. 
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This spectrum clearly demonstrated that glycosylation was also occurring on cysteine 
( 13C chemical shift of approximately 35ppm). 
From NTCBA analysis of the C38 mutant (glycosylation of the C24 mutant was so 
poor that we thought it of no use in NTCBA analysis) we could see that perhaps 
glycosylation of C38 was occurring but glycosylation of the N-terminus or 
polyhistidine tag was occurring also. We could not assign the mass of the larger 
peptide observed when the partially glycosylated C38 mutant was digested with 
NTCBA and this method may have caused destruction of the sugar-peptide linkage. 
NTCBA, and consequently CNBr analysis were considered too harsh for our 
glycoproteins. We could clearly observe that the reaction was also not proceeding to 
completion and hypothesized that perhaps rapid protein dimerisation (resulting from 
the relatively high protein concentration in the reaction) may be competing with slow 
(relative to acetamidation) glycosylation (Figure 5.10): 
S—G1cNc 
ckNAc-iodoacetanide 	
+ H2 	 H2 
Figure 5.10: Protein dimerisation may possibly compete with sluggish proten glycosylation. 
21164,00 This would help explain our observations as 
dimerisation rapidly quenches thiol groups leaving 
them unreactive to G1cNAc iodoacetamide and 
leaving only N-terminal amino groups free to react. 
Of course, dimers were not observed in the mass 
spectrum as a result of sample reduction prior to LC-
MS to allow us to acquire the best data. Dimers and 
higher oligomers could however be observed by non-
reducing SDS-PAGE. We decided to repeat this 
reaction but this time with a high initial concentration 
Figure 5.11: incubation ofC38EPO with 




of the iodoacetamide, adding G1cNAc iodoacetamide to a final concentration of 
50mM (Figure 5.11). On this occasion we saw far greater consumption of the 
starting material but also di and tri glycosylation. This result was inconclusive since 
although more EPO had been consumed we could not be sure that this increased 
glycosylation was on cysteine with concomitant increased glycosylation of the N-
terminus or on the N-terminus alone. Glycosylation of the N-terminus results in an 
amine, potentially more reactive than the offending N-terminus which could react 
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Figure 5.12: Potentially, three G1cNAc residues could add to the amino terminus. 
5.4.5 Proteolytic Digests of Glycoprotein. 
In order to investigate the glycosylation further and under mild conditions we then 
digested the glycosylated proteins with trypsin, x-chymotrypsin and V8 protease. A 
complication was that concentrated EPO samples were only soluble in guanidine.HC1 
at concentrations no lower than 3M and one concern was that these conditions would 
be too denaturing to allow the proteases to function properly. Glycoprotein samples 
were precipitated from reaction mixtures and redissolved in 25.tL of 6M 
guanidine.HC1, 100mM tnis; pH8.0 and then diluted to 50jtL with water. The 
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enzymes were added to concentrations of 10% from 10mgml stock solutions and 
incubated at 37°C for 1-16h. 
5.4.6 Analysing the Digestion Reaction. 
1) MALDI-TOF Analysis of Protease Digestion. 
The simplest method for observing digestion was to desalt the reaction using C4 
reverse phase HPLC and analyse by MALDI-TOF MS since MALDI allows us to see 
all fragments as singly charged species on the same spectrum. 10 minute fractions 
(at 50tLmin 1 =0.5ml) were collected, lyophilised, and redissolved in 70% 
acetonitrile/water, 0.1% TFA and analysed. All fractions, except the first five 
minutes, were analysed since the first five minutes allowed for the elution of the salts 
and could not be fed into the mass spectrometer. Test reactions were carried out on 
unglycosylated protein samples. Trypsin was best at cutting EPO (Figure 5.13) 
followed by chymotrypsin (leaving much of the sample uncut) and finally V8 
protease which failed to cut the protein in 3M guanidine.HC1. 
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Figure 5.13: MALDI-TOF mass spectrum of tzypsin cleaved His 10-WThEPO. These peptides are all 
in one lyophilised fraction. 
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Mass (obs) Peptide 
sequence 
1 1314.73 1315.53 162-171 8 3729.32 3728.77 98-131 
2 1442.83 1444.29 161-171 9 4099.75 4100.71 153-187 
3 2349.74 2351.22 153-171 10 4270.97 4272.38 125-164 
4 2820.26 2821.96 125-152 11 4366.03 4367.16 132-171 
5 2942.59 2944.19 98-124 12 6116.04 6118.82 132-187 
6 3191.73 3195.73 161-187 13 6900.99 6899.09 125-187 
7 3483.91 3486.53 132-164 
Table 5.4 : Calculated and observed masses of tryptically digested WThEPO. The numbering of the 
peptide sequences includes amino acids I to 21 of the his-tag. 
From the results for trypsin above, only half of the protein could be observed 
(residues 98 onwards, EPO residues 77-end) and at no stage with either trypsin or 
chymotrypsin could the N-terminal half of the protein be observed. 
ii) LC-ESI Analysis of Protease Digestion. 
Using the on-line LC-MS method developed in chapter 3 we also analysed the 
trypsin and chymotrypsin digested protein but again only fragments corresponding to 
the C-terminal end of the gene could be observed 
From the results with His 1 0-WThEPO and the partially glycosylated C38 mutant we 
could also see that glycosylation was not occurring on this portion of the protein. No 
glycosylation was observed on C7 or C161. We assumed that, due to the high 
polarity (Figure 5.14) of the N-terminus and the small size of the proteolytic 
fragments (proteolytic sites tend to be clustered around this end of the protein), the 
N-terminal fragments may have been eluting from the C18 reverse phase column with 
the salt and any highly polar impurities (within the first five minutes) and were not 
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Figure 5.14 : Hydrophilicity profile of the ammo acid side chains along the His 10-EPO backbone 
shows the greater polarity of the N-terminus. 
iii) On Column Protease Digestion. 
Since we could not observe the N-terminal region of the protein by direct proteolysis 
of the reduced protein we decided to sequester this region by first immobilising the 
protein on a metal affinity column. Reduced protein samples were separated from 
the reducing agent by precipitation and redissolved in 6M guanidine and loaded onto 
the column. The immobilised protein was then equilibrated with 3M guanidine, 
50mM tris; pH8.0 for tryptic digests (pH7.3 for chymotryptic digests) and exposed to 
solutions (O.lmg-ml 1 -1.Omgml') of the required protease for lh. Elution of the 
protease solution was prevented by plugging the end of the column. After one hour 
the plug was removed and unbound fragments were washed from the column and 
bound fragments were eluted as in Figure 5.15. 
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Figure 5.15: General protocol for on column protease digestion of His10-EPO samples. 
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Eluted fractions were lyophilised and taken up in DCM (500j.xL) to dissolve 
imidazole and the precipitated peptide was collected by centrifugation. This process 
was repeated and the peptide was dissolved in 1:1 acetonitrile/water prior to on-line 
LC-MS. 
5.4.7 On-Line LCMS Analysis of on Column Proteolytic Digests. 
i)Trypsin. 
With trypsin as the protease, and His 10-WThEP0 as the test protein, we could see 
that only one fragment had remained bound to the resin, the his-tag 
(sequence=GHHHHHHHHHHSSGHIEGR, Figure 5.16). Even when the enzyme 
solution (0. lmgmr') was allowed to flow through the column uninhibited, this was 
the only isolated fragment and perhaps indicates that this arginine residue (-2R) is 
relatively exposed. 
DHCHWTT 48(3.306) Sm (Mn, 2x0.80); Sb' (5,30.00); Cm (45:'50-(50:68+38:44)) 
	
757.86 	 1 .88e5 
100, 	 1 
568.84 J93 	1136.10 
.1 	I ._1164.95 
Figure 5.16: The charge envelope of the only isolable species from an on column tryptic digest shows 
the 2+, 3+ and 4+ ions of the his-tag (Mwt=2272). 
ii) Chymotrypsin. 
Pkl 
The on-column cleavage was then attempted 
with chymotrypsin as this had been less 
efficient at cutting EPO samples in solution. 
This time two fragments were shown to 
remain bound to the column after washing 
(Figure 5.17). As above, the first fragment 
(retention time=24mins) was resolved and 
__ was the N-terminal fragment once again 
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cleaving at the first possible cleavage site from the N-terminus (Peak 1, -21G-Y15). 
The second fragment (Peak 2, -21 G-Y49) was larger and was cleaved at the next 
tyrosine residue along, containing cysteine residues 29,33 and 38 (Figure 5.18). This 
isolable fragment was ideal for further study: 
• Leu Leu Glu Ala LysGlu Ala Glu Asn lie 
-Mr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu Asn lie Thr Val Pro Asp Thr Lys 
Val Asn Phe 
Ii 
, 	 Mwt = 8058.95 
WT1 1C 348 (23.812) Sm (Mn. 2x0.80); Sb (5,30.00 ); Cm (342:353) 
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Figure 5.18: (a) the charge spectrum of peak I (Fig. 5.17) and (b) charge spectrum of peak 2. 
As we could now observe and purify the N-terminal region we went on conduct the 
same procedure on the glycosylated C38 mutant. Again we could see that this 
section of the protein had been mono and di-glycosylated (Figure 5.19). 
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	 M- 2 Peak Average Mass Observed A 
mlz 
Ml 8047.9 8042.6 5.3 
M2 8308.9 8301.3 7.6 
(Ml +G1cNAC) 
M3 8569.9 8560.5 9.4 
(Ml +2G1cNAC) 
Table 5.5: Calculated and observed masses for partially 
glycosylated His 10-C38EPO, digested on Ni 2 affinity 
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Figure 5.19: Glycosylation of the sequestered 
N-terminal region. 
Furthermore, these N-terminal fragments were significantly more soluble than the 
intact protein and could be dissolved in 50mM NH 4HCO3; pH8 and digested further 
with trypsin or V8 protease to cause further fragmentation (Figure 5.20). 
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Figure 5.20: Evidence for mono, and a small portion of di-glycosylation on the N-terminal fragment 
of His 10-C38hEPO after further digestion with V8 protease. 
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The fragment mixture was then digested further with V8 protease and we could see 
the N-terminus and could also observe the addition of as many as two GIcNAc 
residues (Figure 5.20) to the N-terminal fragment. Additionally we could observe 
further fragments (Figure 5.21) and see that glycosylat ion was also occurring on the 
fragment which incorporated C38. 
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* The smaller equidistant peaks are +23 Na adducts. 
Peak Observed Corresponding sequence Calculated Calculated 
m/z average based on 
m/z observed 
1 2112.3 NITTGC AEH(SLNIC1TVPD 2121.38 — 
2 2316.6 AEN1TTG AH( SLNICITVPD 2321.57 — 
3 2374.0 1 + GlcNAc 2382.38 2373.3 
4 2577.0 2+ G1cNAc 2582.57 2577.6 
Figure 5.21: Glycosylated C38EPO fragments. Peaks 3 and 4 correspond to glycosylated I and 2 
respectively 
Unfortunately however, the fragments also contained two further cysteine residues 
from the native C29-C33 disulfide bond (red). The enzyme had failed to cleave at 
the glutamate residues (underlined) between cysteine residues. This proved that 
glycosylation was occurring on the correct fragment. 
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5.4.8 Q-TOF Analysis of Tryptic Digest of Chymotryptic (8KDa) Fragments. 
A further approach was to digest the immobilised 8KDa chymotryptic fragments 
(Figure 5.19) with trypsin. This gave smaller fragments and, as with the V8 protease 
digestion, the fragment of interest was also home to the two cysteine residues of the 
native disulfide bond. We could then attempt to sequence this peptide in the 
collision cell of the Q-TOF mass spectrometer. This work was carried out in 
collaboration with Dr Adam Gouldsworthy. 
Trypd. dI.t or. obymoIrypol. thg.ot frq.001 23pTIp d4*.IIod. 	 II.JAN.1909, 12119140 
Mkro.s... Q-Tor ..00ko3ro.p,oy 
	
dmlSOla 46 (2 187) Sb (5.8.00): Sm (SO. 2*2.00): Cm (5:7526 	 TOF MS ES- 





S 	 3371 	 13 79.19 	 434 991 
1 . 11 	
230.63 	 i 
7 22
23677 	 I 272162771367 	323.26
0 	
U 	
40925 00699 	 36144 
423.30 	 470.61 ('96.57 
1.33626 
77922 
331.11 134199 590.79 
.1. Lr.. i, . 	 ,i, 0. ..- 	rM 
200 	25 	....... 30 	315 	4 	45 	4 	45 	500 	525 	560 
o1 2 
177364 
79735 	 605.03 
67607 	 31 
k7717 	 I 
67664 	 I 
61*2 
167141 	 13670 
6332* 	
.4*6.29 	673.26 	 70 	7I0 	 7 	II 	. 	 000.03 
60334 77 M 	 ~111
3l 	
U3649349 2 05359 	




1127 Ij 32007 
8 	 300.36 
112111 16003! 1111.00 
1071.06 	 113500 	
IIII9 




1050 	1076 	1100 	1125 	1150 	1 1'75 	120	1225 	1250 	1275 	1300 	1325 	1350 	13175 	1400 
Figure 5.22: Q-TOF-MS of tryptic digest of 8KDa chymotryptic digest fragment. The ions of interest 
are indicated as I and 2. 
From the digested mixture we could see that the proteolysis had occurred (Figure 
5.22). Through MS-MS we were able to transmit a single ion into the collision cell. 
Ions transmitted (892.66 and 979.68) were the 3+ ions corresponding to the peptide 
below and its glycosylated peptide analog respectively: 
Glu Ala Glu Asn lie Thr Thr Gly 29Cys Ala Glu His 33 Cys Ser Leu Asn Glu 38Cys lie 
Thr Val Pro Asp Thr Lys 
We then aimed to sequence this fragment by collision induced fragmentation in the 
collision cell. Although the original 3+ ion peaks were small, it did not imply that 
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they were only fractionally present. More intense peaks were also sequenced and 
were shown to be from the same peptide indicating that this peptide may only ionise 
poorly. 
When both ions were fragmented they could be partially sequenced. 
Trypdo dip.I .1. 	 dt1I frq..L ZtpTIp d.Jud (MS/MS 	 I$-JAN.I99, 14 34 ai 
Nk... Q-Te(N.I.fr.p.,y 
dml8Olj 142 (6 267) Sn, (SG. 2x2.QO); Sb (5800); Cm (50:150) 	 I: TOF MSMS 893.86ES+ 
Figure 5.23: Collision induced fragmentation of the glycosylated and non-glycosylated small tryptic 
peptides. 
Considering that the fragmentation was induced from two ions thought to have the 
same sequence it was not surprising, that on fragmentation, many of the same ions 
were observed (Figure 5.23). Unfortunately either peptide could only be sequenced 
as far along as the isoleucine residue adjacent to the cysteine residue of interest 
(sequence obtainedIle Thr Val Pro Asp Thr Lys). In the case of the glycosylated 
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Interestingly, there was also a mass difference observed when transmitting masses 
into the collision cell. The observed masses differed from the theoretical isotope 
distribution by two to three mass units (Figure 5.24) indicating that perhaps a 
disulfide bond had been reformed during the proteolytic digest (perhaps the native 
C29-C33). 
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Figure 5.24: Theoretical and observed isotope profiles for the 980(+3) ion for the glycosylated tryptic 
fragment. 
5.5 Optimisation of the Glycosylation Reaction. 
Throughout our previous crude glycosylation reactions we noted that the protein was 
not being glycosylated quantitatively and considered that it was unlikely that 
dimerisation may be occurring solely as a result of the high protein concentrations. 
Believing that the precipitation step prior to previous glycosylation reactions may be 
having a detrimental effect on the reaction we devised a new protocol (Figure 5.25) 
which avoided this step. 
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Oxidative refolding of' dilute. 
reduced protein 
Concentrate 	refolded 
protein on His-Bind 
resin (1 .Oml) 
Elute from column with 6M 
guanidine.HCI, 50mM tris; 
pH 8. 500mM imidazole 
(3.0m1), followed with 6M 
guanidine.HC1. 50mM tris; 
pH 8 (2.0m1) 
OH 







Add G1cNAc iodoacetamide 
to 10mM and incubate at 
room temperature (24-48h) 
on blood rotator. 
Figure 5.25 : Optimised protocol for protein glycosylation. 
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This dramatically changed the glycosylation profile 
(Figure 5.26) with mono-glycosylation proceeding 
to approximately 60%. Surprisingly there was little 
di-glycosylation observed after as much as 48h. 
Reactions conducted under these conditions were 
again highly reproducible. Unfortunately no 
considerable improvement in the yield of the 
reaction of refolded His- 1 0C24EP0 with G1cNAc 
iodoacetamide was observed under these conditions. 
Non-reducing SDS-PAGE showed that after the 
refolding of His10-C24bEPO some soluble 
aggregates were still present but it was difficult to 
establish whether reactions proceeded in poor yield 
due to aggregation as a result of mis-folding, as a 
result of competitive dimerisation or whether the 
Figure 5.26: ESI-MS of 
glycosylated His 10-C38hEPO 
under optimised conditions. 
thiol group was less accessible. Interestingly, in the case of His10-C38hEPO, when 
the protein was eluted from the column in refolding buffer (2% N-lauroyl sarcosine, 
50mM Tris; pH8.0, 40j.tM CuSO4, 400mM imidazole) instead of 6M guanidine 
hydrochloride and treated with G1cNAc iodoacetamide, the degree of glycosylation 
was very poor. Glycosylation was also not observed when a 10mM solution of 
GlcNAc iodoacetamide was passed over the affinity column immobilised His10-
C38hEPO. 
This clearly demonstrated that sample preparation played a key role in the efficiency 
of the subsequent glycosylation and that the more dilute the protein sample was, the 
less likely it was to aggregate and the higher the yield of the glycosylation. 
Following on from this, it would be logical to assume that conducting the reaction at 
even lower protein concentrations may result in even higher yields of glycosylated 
product and preliminary results show that this is the case. At lower protein 
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Figure 5.27: ESI-MS of 
reaction of His 10-C38hEPO 
with maltosyl iodoacetamide 
after 16h. 
CHAPTER 5 
concentrations however, it becomes more difficult to recover the protein from the 
reaction mixture for monitoring as it tends not to precipitate and LC-MS data is 
presently poor. One drawback from this is that more glycosyl iodoacetamide is 
required to achieve the same concentration and this may not be trivial for more 
complex saccharides. 
20902.0 	
It was also possible to react the glycosyl iodoacetamide 
derived from maltose with refolded His 10-C38hEPO 
(Figure 5.27). Glycosylation of the C38 mutant 
afforded a product with a molecular weight of 212821)a 
(+380) which corresponded to the addition of maltose. 
Additionally, a peak at 20958 was observed. This may 
have resulted from reaction of a small percentage of 
iodoacetic acid or iodoacetamide (emphasising the need 
for complete removal of ammonium bicarbonate prior to 
treatment with iodoacetic anhydride). 
Clearly there are still significant obstacles to overcome 
if we are to unambiguously assign the position of the 
glycosylation site when working with the C24 and C38 
mutants. In order to fully determine the position of the 
G1cNAc residue on the glycosylated fragment. These 
preliminary experiments should be scaled up so that we 
can obtain sufficient quantities of smaller peptide 
fragments (from on-column chymotryptic digests or after further digests with V8 
protease or trypsin). If we could isolate sufficient quantities of each fragment using 
metal affinity, lectin affinity, or reverse phase chromatography then we may be able 
to sequence them or look at them by NMR spectroscopy. This will allow 
unambiguous assignment of the glycosylation site. 
Perhaps, for initial studies, the pETl6b-N83ChEPO construct should be prepared. 
Standard tryptic digests of the whole glycoprotein in solutions of 3M guanidine have 
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always been capable of revealing peptides relating to this end of the protein (Figure 
5.13, Table 5.4) and glycopeptides resulting from glycosylation on C83 should be far 
simpler to observe than those derived from the C24 or C38hEPO mutants by online 
LC-MS or MALDI-TOF MS. 
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Preparation of the pETI 6b- 
C83hEPO(COPT) Vector, 
Expression and Purification 
of Hislo-C83hEPO. 
CHAPTER 6 
Construction ofpETl6b-C83hEPO(COFI) and expression of Hisir 
C83hEPO. 
6.1 Preparation of pET16b-C83EPO, Using the Megaprimer PCR Method. 
Due to difficulties with the unambiguous determination of the C24 and C38 EPO 
mutant glycosylation site we chose to synthesise the C83 mutant hoping that 
glycosylation at this position would be more readily observed. The C83 mutant was 
prepared using a Polymerase chain reaction (PCR) based method. 
The Polymerase Chain Reaction was invented by K.B. Mu11is 155  and it revolutionised 
genetics by providing a simple method for the amplification of predetermined DNA 
sequences using thermostable DNA polymerases isolated from organisms thriving in 
the harsh conditions of hot-springs (Thermus aquaticus) and deep hydrothermal 
vents (Pyroccoccus species for example) 156" 57 . 
Since its invention, many variants have been reported which allow for the 
introduction of mutagenic sequences at predetermined sites (site directed 
mutagenesis) as well as DNA amplification. For the synthesis of the pET16b-
C83EPO mutant we chose the 'megaprimer' PCR method (Figure 6 . 1) 15859 .  Using 
this technique the C83 mutant could be prepared in two (or three) rounds of PCR. A 
third step is only usually employed if the yield of the desired PCR product is low and 
it needs to be amplified further. 
NS3C 
PCR 1 	::::: 
M13 
NR 
PCR2 	 I 	 I 
MP 
-1- 
I 	x 	I 
PCR3 
M13 
Figure 6.1: The megaprimer PCR method. A mutagenic primer and flanking reverse primer are 
initially employed to amplify part of the desired gene. Next, the megaprimer (bearing the mutation) 
and another flanking primer synthesise the remainder of the gene (PCR2). The whole sequence may 
then be amplified using both flanking primers. 
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First, pET 1 6b-WThEPO(COPT) prepared in chapter 2 was cut NcoI/Hin DIII and 
ligated into NcoI/ HinDlil cut pUC18-RBS-BioB (a high copy number plasmid) 
which was kindly provided by Dr. Dominic Campopiano (University of Edinburgh). 
This new plasmid termed pUC18-RBS-WThEPO would be our template for the PCR 
reactions and was cloned and the DNA was purified. 
A synthetic mutagenic primer (termed N83C), containing a TGC (Cys) mis-matched 
codon in place of AAC (Asn) was then obtained desalted and deprotected: 
GCC CTG TTG GTC TGC TCT TCC CAG CCG T (N83C) 
This primer was chosen as it had already proved successful in the previous (though 
unintentional) synthesis of the C38/83EP0 double mutant 103 . 
The three rounds of PCR were conducted using both Taq DNA polymerase 
(Pharmacia) and deep vent DNA polymerase (New England Biolabs). Using Taq 
polymerase, the PCR step (synthesis of the megaprimer) was successful but 
subsequent steps were messy. With Deep Vent polymerase, all steps worked 
extremely well. This may have been due to the higher fidelity of Deep Vent 
polymerase, it is known to have proof reading capabilities and does not label the 3' 
end of genes with 'A' as Taq frequently does. Consequently, only the Deep Vent 
- 	derived results are discussed here. In the 
J
first round of PCR (Figure 6.2), the 
inegaprimer was prepared using N83C as 
the forward primer and M13 (pUC reverse 
sequencing primer) as the reverse primer. 
_______ 	 The PCR product was purified by 
horizontal agarose electrophoresis (Figure 
6.2) which gave and an intense band at 
approximately 500base pairs (expected 
size was 550 base pairs). 
Figure 6.2: Nlegapri:ner synthesis using 
N83C and M13 primers. 
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This megaprimer was then purified from the excised gel slice and used as the reverse 
primer in the second round of PCR. Again pUCI8-RBS-WThEPO was used as the 
template DNA and NR (pUC forward sequencing primer) was employed as the 
forward primer. In this step we would prepare the remainder of the gene (Figure 
6.1). 
The second PCR reaction afforded another intense 
band (Figure 6.3) at approximately 1000 base pairs in  
size (another, smaller and less intense band was also 
observed at ca. 750 base pairs). The intense band was 
40 _.__JlIt 	ivain excised and purified from the agarose gel. 
Next, 5% of this PCR product was used in the third 
ound of PCR (Figure 6.1) using NR as the forward 
primer and M13 as the reverse to amplify the target 
DNA further. The remainder was cut with NcoI and 
HinDill so that it could be re-ligated back into NcoI 
and HinDill cut pUC18-RBS-BioB (Figure 6.4). Figure 6.3: The 
2nd  round of 
PCR. The agarose gel shows 
(from left), mega primer, 
round 2 PCR product, 
markers. 
.. 	After the overnight endonuclease digestion with NcoI 
L. 	 and HinDu! a clear and intense band was observed 
between 750 and 1000 base pairs (Figure 6.4, left). We 
expected the size of our fragment to be approximately 
10 base pairs. Additionally, amplification of the gene 
(product from 2 nd  round of PCR) using NR and M13 
-. primers also gave an intense band (Figure 6.4, right) 
Figure 	.4: 	Agarose 
	which was purified. 
electrophoresis of NcoI/ 
HinDilI cut PCR product 
(left) 
HWO 
The purified NcoII HinDu1 cut gene (Figure 6.4, left) was then ligated into pUC18-
RBS and transformed into competent TOP 10 (Pharmacia) cells and selected on LB-
ampicillin plates. Six single transformants were then picked and grown overnight at 
37°C. The plasmid DNA from each was then purified and screened to see whether or 
not the PCR fragment had been incorporated into pUC18-RBS. Positives were 
determined using a simple procedure. Plasmid DNA was cut with HinD III (to 
linearise), and with NcoI/ HinDu! ( to cut our PCR derived insert back out) and HinC 
II (should not cut as the mutation had destroyed this unique site). All six colonies 
were screened and all six were shown to be positives by restriction endonuclease 
digestion (Interestingly, when Taq DNA polymerase was used, only 2 of the six 
colonies screened were positives). Deep vent derived DNA samples 1 and 2 were 
then taken forward and sequenced using the M13/NR primers. Both could be fully 
sequenced and both contained the desired AAC->TGC mutation and no PCR derived 
errors. 
Genes 	encoding 	His 10- 
C83hEPO were then cut 
NcoI/BamHI out of pUC 18-
RBS (Figure 6.5) and ligated 
into NcoIIBamHI cut 
pET16b. 	The ligation 
mixture was used to 
transform competent TOP 10 
cells as before and positives 
were determined by cutting 
the product with NcoI and 
BamHI to excise the gene 
from the plasmid. 
Figure 6.5: Agarose gel shows (from left) Ncol/BamHI cut 
pUC18-RBS-C83hEPO sample 1, sample 2 (fully 
sequenced), markers, sample 3, NcoL/BarnHI cut pETl6b 
and further markers. 
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6.2 Expression and Purification of His 10-C83hEPO. 
With the newly synthesised pET16b-C83hEPO(COPT) vector in hand we went on to 
express and purify the gene product from B834(DE3) cells as before (chapter 2). 
The gene product was purified on a Ni 2 affinity column as a single band (Figure 6.6) 
,- 
., 	 dos %daAftwo o 
' 
Figure 6.6: Column fractions from Ni 2 affinity purified His 10-C83hEPO. 
We hope that this protein may prove particularly useful in further developing the 
cysteine mutant/glycosyl iodoacetamide neoglycoprotein synthesis methodology. 
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General Conclusion and Future Perspectives. 
In B834(DE3) cells, the pET expression system facilitated the efficient expression 
and purification of His 10-WThEPO, His io-C24hEPO, H1s 10-C38hEPO, and His 1 0-
C38/83hEPO in similar yields of approximately 13mgL". In addition to providing us 
with sufficient quantities of protein, pure enough for further study, there are 
properties of the His-tag which are particularly suited to our needs. The His-tag 
provided a handle with which we could manipulate EPO with ease and it did not 
undergo proteolytic processing allowing us to look at proteolytic digests on resin 
bound EPO samples. Consequently, it should remain in place until the glycoproteins 
have been fully characterised. 
MALDI-TOF and ESI-MS were invaluable (and essential) techniques for protein 
characterisation and the study of protein glycosylation allowing us, for the first time, 
to formulate and test hypotheses regarding protein structure and glycosylation at the 
molecular level. Through ESI-MS and non-reducing SDS-PAGE we were able to 
establish that proteins were presented to us by B834(DE3) cells in an oxidised form 
with formed disulfides. Cysteine mutants, containing an additional thiol, were also 
obtained as glutathione adducts and were unreactive towards sulfhydryl selective 
reagents. While His10-WThEPO was highly monomeric after expression, the cysteine 
mutants were highly aggregated, forming aggregates with masses greater than 
I OOKDa. These aggregates could however be broken down by the action of reducing 
agents such as DTT or TCEP, giving us the opportunity to refold our samples under 
conditions known to re-establish the correct tertiary structure. After refolding, non-
reducing SDS-PAGE indicated that all proteins were mainly monomeric with a small 
percentage of soluble aggregated material remaining. Protein was recovered from 
the refolding step in >80% yield. 
We chose to assess the efficacy of the refolding step after protein glycosylation 
(through peptide mapping) inferring that the correctly folded structure was obtained 
if the correct cysteine residue was glycosylated. It was encouraging that per-
glycosylation was rarely observed and, if so, only to a small extent. 
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Protein glycosylation was readily monitored by ESI-MS and was never quantitative. 
Initially we believed that this resulted from competitive quenching of thiol groups 
through fast protein dimerisation relative to slow protein glycosylation. It is equally 
likely that soluble aggregates resulting from a small percentage of mis-folded (and 
incapable of being glycosylated) samples were carried through and this material was 
broken down by sample reduction prior to on-line LC-MS and displayed as 
unglycosylated material. This explained why the addition of huge excesses of 
glycosylating reagent still failed to consume all the unglycosylated EPO. 
Consequently, it may be true that size exclusion chromatography will be as useful in 
separating glycosylated EPO from non-glycosylated EPO as techniques such as 
lectin-affmity chromatography. 
A persistent problem was glycosylation of the N-terminal region of our His 10-tagged 
proteins. Ultimately, we aimed to remove the His-tag after our glycoproteins were 
prepared so the fact that that it was occurring was actually less problematic than the 
fact that it made it difficult to quantify the degree of glycosylation on cysteine. N-
terminal modification could however be partially inhibited under our optimised 
protein glycosylation conditions. The reasons for this are unclear. 
Generally, glycosylation of the C38 mutant was far more successful and proceeded in 
higher yield (approx. 60%) than on the C24 mutant (approx. 20%). The correct 
fragment was clearly glycosylated (cysteine glycosylation was also intimated by 
NMR spectroscopy) but unfortunately it also housed the cysteine residues of the 
C29-C33 disulfide thus unquestionable assignment of the glycosylation site was 
hindered. From MS data we could also determine that glycosylation had not 
occurred on C7 or C161 of EPO (the cysteine residues which make up the disulfide 
which connect the C and N termini of EPO). 
As a general rule: The more dilute the protein samples were prior to the 
glycosylation reaction, the higher the yield of glycosylation. Glycosylation 
reactions carried out at very high dilutions (1 iM protein) appeared to proceed 
quantitatively or near quantitatively by on-line LC-MS analysis. Unfortunately, the 
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lower the protein concentration was, the harder it was to recover it from the reaction 
mixture (for reaction monitoring) by precipitation and the mass spectral data were 
poor. Other methods of sample concentration for analysis may need to be employed 
here. The drawback of this is method is that more glycosyl iodoacetamide is 
required to establish the same concentration and may be more costly for larger 
glycans. 
We were also able to glycosylate C38hEPO with maltosyl iodoacetamide and the 
glycosyl iodoacetamide of chitobiose (results not shown). When the glycosyl 
iodoacetamides were prepared from the amines obtained from the saturated 
ammonium bicabonate reaction, the complete removal of the salt was key to it's 
success 
As more reliable methods for the total synthesis of N-linked glycans become 
available, the more attractive total synthesis becomes as a realistic method for 
neoglycoprotein preparation. The products are usually crystalline ana easier LI) 
characterise and provide further scope for conducting structure activity relationships 
as unnatural saccharides may be incorporated. 
Importantly, the protein glycosylation studies are preliminary and there is much 
scope for further optimisation. One factor which may need to be addressed further is 
the protein refolding step. It tends to require huge volumes of buffer (this problem 
may be solved by pulse refolding) and its efficacy is difficult to assess as the 
refolding buffers are not compatible with NMR or CD spectroscopy. All steps 
should be scaled up so that we may be able to isolate large enough quantities of 
glycosylated proteins and peptide fragments for further sequence analysis or NMR 
spectroscopy. Then it may be possible to unambiguously assign the position of the 
glycosylation site. This may also be achieved through the synthesis of the N83C 
mutant which has a potential glycosylation site where enzymatic proteolysis tends to 
produce fragments which are more readily observed by on-line LC-MS and the 





7.1 Experimental Details For Chapter 2. 
General Experimental Details: 
pET 1 6b-WThEPO, pET 1 6b-C24hEPO, pET 1 6b-C3 8hEPO, and pET 1 6b-C3 8/83hEPO 
were the gifts of Dr. Karen Sage (formerly of the Dyson Perrins Laboratory, University 
of Oxford, UK). All E. coli bacterial strains for cloning (JM1O9, JM1O1) and expression 
(B834(DE3), BL21(DE3) and BL21(DE3)PlysS) were the gift of Dr. Dominic 
Campopiano (University of Edinburgh). 
All restriction endonucleases (except Bpu 1102 I) and DNA modifying enzymes were 
obtained from New England Biolabs and were used according to the suppliers 
instructions. Bpul 102 was obtained from Stratagene. Murine anti-human EPO 
monoclonal antibody was obtained from Genzyme diagnostics. HRP-conjugated rabbit 
IgG to mouse IgG was from DAKO. IPTG was from Europa. Guanidine.HC1 was 
obtained from Fluka and 6M solutions were filtered through a 0.45 p.m filter (from 
Millipore) prior to use. All other routine laboratory reagents were from Sigma. 
Centrifugation of small samples in Eppendorf tubes was carried out at maximum speed 
in an Eppendorf centrifuge 5410. Larger samples (up to 15.Oml) were centrifuged in a 
Sanyo MISTRAL 2000R. Large scale (20.Oml - 0.3L) samples were centrifuged in a 
Sorvall RC SC plus centrifuge. 
Shake flask fermentations were carried out in a New Brunswick Scientific INNOVA 
4000 incubator shaker (37'C, 250rpm). Large scale fermentations (10L) were carried 
out in a New Brunswick Scientific BioFlow 1000 fermenter at 37°C, stirred at 250rpm 
with an air flow of 2Lmin'. 
Sonication was performed using a Sanyo Soniprep 150 at 50% of maximum power. 
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Cloned plasmid DNA was purified from 10.Oml overnight cultures using WIZARD TM 
mini-prep kits (Promega) according to the manufacturer's instructions. 
DNA was purified from excised agarose gel slices using a Prep-A-Gene DNA 
purification kit (Bio-Rad) according to the manufacturer's instructions. 
PCR reactions were carried out on a Techne cyclogene thermal cycler. 
Horizontal agarose electrophoresis was carried out in ANACHEM model H3-SET 
apparatus at lOOV according to the manufacturer's instructions. lOOmi Agarose gels 
were generally 1% agarose in TAE (0.04M Tris-Acetate, 0.001M EDTA; pH8) buffer 
containing 4p.L of 5mgml' ethidium bromide. 
Protein electrophoresis was carried out using Bio-Rad PROTEAN II (preparative) and 
Mini-PROTEAN II (analytical) vertical gel electrophoresis apparatus. Acrylamide 
resolving gels (15-18%) were generally prepared from 30% acrylamide/ Bis acrylamide 
stocks and prepared according to the manufacturers instructions. Samples were loaded 
and gels were ran for approximately 1.5h at 200V, 60mA. SDS-PAGE gels were stained 
(0.1% w/v Coomassie blue R-250, 40% v/v methanol, 10% v/v acetic acid) for 0.5-1h 
and destained with several washings of 40% v/v methanol, 10% v/v acetic acid. 
Destained gels were stored in water prior to drying. 
Protein purified via elution from excised slices of SDS-Polyacrylamide gel, were eluted 
using a BIO-RAD model 422 Electro-Eluter according to the manufacturers instructions. 
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Bacterial Growth Media. 
LB (Luria - Bertani) medium M9 (minimal) medium A: 
Per Litre: Per Litre: 
Bacto tryptone Bacto yeast 	10.5g Na2HPO4 6g 
Bacto yeast extract 	 5g KH2PO4 3g 
NaCl 	 lOg NaCl 0.5g 
N}LC1 ig 
Adjust pH to 7.5 with NaOH Adjust pH to 7.4 
AUTOCLAVE AUTOCLAVE and add: 
1M MgSO4 2m1 
20% glucose lOmi 
1MCaC12 0.lml 
For ' 5N labelling Minimal media was prepared as follows: 
M9 (minimal) medium B: 
Per Litre: 
Na2HPO4 	 6g 
KH2PO4 	 3g 
NaCl 	 0.5g 





Standard techniques were performed as described in Molecular Cloning - A Laboratory 
Manual (Sambrook, Fritsch and Maniatis, 2'' Edition, 1989, Cold Spring Harbour Press, 
USA). Standard sterile technique was maintained during all microbiological routine 
work. Media, glassware and equipment were sterilised by autoclaving at 121'C for 
15mins. in an Astell Scientific autoclave. Thermolabile solutions were sterilised by 
filtration through Sartorious minisart 0.22prn filters. Plates were prepared and media 
innoculated either on ethanol swabbed surfaces or in a Class II environmental cabinet. 
Antibiotic stock solutions were stored at -20°C and were used at the following 
concentrations: iOOtgmF' ampicillin, 50tgrni' carbenicillin, or 34.tgml*l 
chloramphenicol. 
Preparation of E. coli Competent Cells. 
LB medium (10.0ml) was seeded with lOj.il of the bacterial host cell line. This was 
grown at 37°C overnight with shaking (250rpm). An aliquot (1001.11) of the overnight 
culture was used to seed lOml of fresh LB medium containing 200i.tl of 1M MgCl2. This 
was grown as above until A600 = 0.2. The cells were then collected by centrifugation for 
15mm. at 3000rpm (2700G) at 4°C. The supernatant was then discarded and the cells 
were resuspended in 4.Oml of fresh, ice-cold transformation buffer (50mM CaCl2, 
10mM Tris; pH8.0). The cells were left on ice for 30min with occasional agitation. The 
cells were then collected by centrifugation for 15mm. at 3000rpm (2700G) at 4°C. The 
supernatant was then discarded and the cells were resuspended in 4001.tl of ice-cold 
transformation buffer (50mM CaCl2, 10mM Tris; pH8.0) and kept on ice until required. 
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Transformation of DNA into Competent Cells. 
A lOOj.il aliquot of competent cells was transferred to a sterile 1 .5m1 eppendorf tube and 
left on ice for 0.5h. 5tl of the DNA sample was then added, the tube was tapped gently, 
and then left on ice for a further 0.5h. The sample was then heat shocked for 5min at 
37°C. L.B. Medium (1.Oml) was then added and the sample was incubated at 37°C for 
lh. The cells were then collected by centrifugation for 1 5mm. at 3000rpm (2700G) at 
4°C. The supernatant was then discarded and the cells were resuspended in 100tl of 
fresh L.B. medium. The cells were then spread to dryness on selective (containing 
100 jigml' ampicillin or 50tgml' carbenicillin) L-agar plates and the plates were grown 
inverted at 37°C overnight. 
Cloning of Plasmid DNA. 
A single colony, transformed with one of the pET 16b-WT or cysteine mutant containing 
plasmids was used to seed 10.0ml of fresh LB medium containing the required anti-
biotic. The culture was then incubated at 37°C with shaking overnight. The cells were 
then collected by centrifugation at 3000rpm (2700G) at 4°C. Cloned plasmid DNA was 
then purified using Wizard (Promega) or Quiagen spin column DNA purification kits 
according to the manufacturers instructions. 
MOLECULAR BIOLOGY. 
Endonuclease Digestions. 
General analytical restriction endonuclease digestion. 
Plasmid DNA * 	51.IL 
Restriction enzyme 	0.5p.L 
1OxNEB buffer 	2tL 
dH20 	 12.5pL (to a final volume of 20p.L) 
* plasmid DNA prepared from 10.Oml overnight culture. 
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Reactions were then incubated at the required temperature (variable depending on 
enzyme) for I  and linearized DNA was observed by horizontal agarose electrophoresis. 
Preparative restriction endonuclease digestion. 
Plasmid DNA * 	30tL 
Restriction enzyme 	1 tL 
1 OxNEB buffer 	5p.L 
dH20 	 14L (to a final volume of 50tL) 
Reactions were then incubated at the required temperature (variable depending on 
enzyme) for 2-3h and linearized DNA was separated from restriction endonuclease by 
horizontal agarose electrophoresis. The band containing the required DNA was excised 
and the DNA was purifed from the gel slice using a BlO-RAD Prep-A-Gene kit 
according to the manufacturer's instructions. 
Optimisation of Expression by the Incorporation of a New C-Terminal Sequence. 
Oligonucleotides (below) were prepared by GIBCO BRL and were obtained fully 
deprotected and desalted. 
Oligonucleotide Orientation Sequence 5' - 	3' Restriction Site 
EPOCOPT 1 Sense C !GC CGT ACC GGT GAC BamH I / Stu I 
COT TAA TGA G 
EPOCOPT 2 Antisense GA TCC TCA TTA ACG GTC BamH I / Stu I 
ACC GOT ACG GCA GG 
Annealing Oligonucleotides. 
Equimolar amounts of oligonucleotide EPOCOPT 1 and EPOCOPT 2 were mixed and 
diluted to 200tL with sterile water (final concentration = 19.1 tM) The mixture was then 
heated in a boiling water bath for 5mm. and allowed to cool to room temperature 
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Ligation of annealed oligonucleotides into linearisedplasmid DNA. 
Ligation reactions were prepared as follows: 
Cut DNA Synthetic Duplex lOxligase buffer 14 ligase dH20 
Reaction 5pL 1l.tL 2tL 2jL - 
Control 5jtL - 2tL 2tL 1lL 
The reaction mixtures were allowed to stand at room temperature overnight and then 
used to transform competent JM109 cells. The transformed cells were plated out onto 
selective LB-agar plates containing lOOtgmF' ampicillin. The purified plasmid DNA 
from individual colonies was screened to confirm the presence of the oligonucleotide 
insert and positives were sequenced across the insert region using the pET system 
reverse primer (NOVAGEN). 
DNA Sequencing. 
Sequencing of DNA was accomplished using the ABI PRISMTM  Dye Terminator Cycle 
Sequencing Ready Reaction Kit (with Amplilaq®DNA polymerase, FS) according to 
the manufacturers instructions. 
The sequencing mix used was as follows: 
Terminator ready Reaction mix 	 8jiL 




dH20 	 6.tL (to a final volume of 20tL) 
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The reaction mixture was overlain with 50.tL of oil and subject to the following 
sequencing conditions: 
96°C for 5mm 	(1 cycle) 
96°C for 30 seconds 
45°C for 15 seconds 
60°C for 4 minutes (30 cycles) 
4°C hold 
The sequencing reaction mixture was then submitted to the automated fluorescent 
sequencing service (Nicola Preston, ICMB, University of Edinburgh) for analysis. 
PROTEIN EXPRESSION. 
Production of His-10 Tagged Erythropoietin. 
Expression of His io-tagged proteins was carried out according to manufacturer's 
instructions (pET systems Manual, Novagen). A single colony of E. coli (Strain 
B834(DE3)) transformed with the cDNA encoding WT or mutant EPO (BamH I / Nde I 
inserted into pET 16b) was used to inoculate a lOml culture of LB medium containing 
either carbenicillin (50j.igmF') or ampicillin (lOOp.gml'). The culture was incubated at 
37°C with shaking (250rpm) overnight. This culture was then use to inoculate 4x250ml 
of fresh LB medium containing the required antibiotic and incubated at 37°C with 
shaking until A6000.6. IPTG was then added to a concentration of 1mM and the 
incubation was continued with shaking at 37°C for a further 3h. The cells were then 
harvested by centrifugation at 8000rpm (l0000xG) at 4°C for 10mm. The pellet could 
then be stored at —20°C prior to purification. 
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Preparation of a Cell-Free Extract. 
[Quantities given are for a pellet derived from 500ml induced culture] 
The pellet was thawed on ice and resuspended in 25.Oml binding buffer (5mM 
imidazole, 500mM NaCl, 20m1v1 Tris-HC1; pH8) containing 0.005% PMSF. The cells 
were then sonicated on ice for 10 periods of 30s separated by 30s intervals. Inclusion 
bodies and cellular debris was collected by centrifugation at 10000rpm (12000xG) for 
15min at 4°C. The resulting pellet was then suspended in binding buffer (20.Oml) 
containing 0.005% PMSF. M902 and DNAse I were then added to final concentrations 
of 10mM and 20tgml 1 respectively and the suspension incubated at 20°C for 20mm. 
The sample was then sonicated on ice for 5 periods of 30s separated by 30s intervals and 
centrifuged at 10000rpm (12000xG) for 15min at 4°C. The resulting pellet was then 
resuspended in 20.Oml of binding buffer containing 6M guanidinium hydrochloride and 
0.005% PMSF. The sample was then shaken vigorously and stirred magnetically on ice 
for 0.5h to completely solubilise the protein. Any remaining insoluble material was 
collected by centrifugation at 20000rpm (48000xG). The supernatant was then stored at 
—20°C prior to affinity chromatography. 
Column Chromatography of His 10-EPO's Under Denaturing Conditions. 
[All buffers contain 6M guanidinium hydrochloride and 0.005% PMSF] 
The solubilised inclusion bodies in binding buffer were purified under denaturing 
conditions using Ni2 immobilised on a metal chelation resin as described in the pET 
system manual (Novagen) The column (5.Oml column bed volume) was charged with 
15.Oml aqueous NiSO4 and equilibrated with 25.Oml binding buffer. The cell extract 
was then loaded onto the column and unbound proteins were washed from the column 
with 50.Oml binding buffer and then 25.Oml wash buffer (50mM imidazole, 500mM 
NaCl, 20mM Tris-HC1; pH8). The target protein was then eluted in 1.Oml fractions 
using elution buffer (500mM imidazole, 500mM NaCl, 20mM Tris-HC1; pH8). The 
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fractions were then analysed by SDS-PAGE: 10tL aliquots were precipitated by the 
addition of 1 00L of 1:1 acetone / methanol and placed in the freezer (-2 0°C) for 5 mm. 
The protein was collected by centrifugation at maximum speed in a microcentrifuge and 
taken up 15i.tL of SDS loading buffer. 
Western Blotting Analysis of Purified EPO Samples. 
[For western blots, 1150 - 1/100 of the protein loaded for coomassie blue staining was 
sufficient to give a good response with the following detection method] 
Following SDS-PAGE, resolved proteins were transferred to PVDF membrane 
in a BlO-RAD Trans-Blot cell at 40V for 2.5h in transfer buffer (25mM Tris.HC1; pH 8, 
192mM glycine, 15% v/v methanol). The membrane was then incubated overnight at 
room temperature with shaking in blocking buffer (20mM Tris.HC1; pH 8, 37mM NaCl, 
0.1% v/v Tween-20, 5% w/v non-fat milk powder) and then incubated with the primary 
antibody (Monoclonal murine anti-hEPO) at a dilution of 1:2000 in blocking buffer for 
lh. The membrane was then washed with fresh blocking buffer (3xl5minutes) and then 
incubated for a further lh with the secondary antibody (Horse radish peroxidase labelled 
rabbit anti-mouse IgG) at a dilution of 1:1000. The membrane was then washed with 









Membranes were incubated in this solution until clear strong bands were observed (5-
15mins). When stained bands were observed the reaction was quenched by washing the 
membrane with water (3x 1 5 mins). 
Large Scale Production of His io-Tagged Erythropoietin. 
A single colony of E. coli transformed with one of the pET- 1 6b EPO clones was used to 
inoculate 5.0-1O.Oml of LB medium containing the required antibiotic. This culture was 
then grown at 37°C with shaking for approx. 8h. This culture was then used to 
inoculate 500m1 of fresh LB medium containing the required antibiotic and this culture 
was grown at 37°C with shaking overnight. The following day this culture was used to 
inoculate 8.01, of fresh LB medium and this was then grown in the fermenter and 
induced as described above for small scale work (see also general experimental details 
for fermenter settings). 
' 5N Labelling of His 10-WThEPO (1L scale). 
A single colony of E. coli transformed with one of the pET- 1 6b EPO clones was used to 
inoculate 40.0m1 of LB medium containing the required antibiotic. This culture was 
then grown at 37°C with shaking overnight. The cells were then collected by 
centrifugation at 3000rpm (2700G) and the supernatant was discarded. The cells were 
then resuspended in 20.Oml minimal media B (see general experimental details). This 
solution was then used to innoculate 1L of minimal media B containing MgSO4 (2.Oml 
from a 1 M stock solution), glucose (1 Oml form a 20% w/v stock solution), CaC12 (0.1 ml 
from a 1M stock solution), ( 15NH42SO4 (0.66g, a final concentration of 5mM) and L-
methionine (added to a final concentaration of 50tgmF 1 ; B834(DE3) is a methionine 
auxotroph. The culture was then incubated at 37°C with shaking and induced as 
described above for non 15N labelled material. 
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Renaturation of His 10-EPO Samples (PROTOCOL I). 
EPO samples expressed in E. coli were found to be expressed in an oxidised form with 
formed disulfides. In the case of the cysteine mutants the proteins were found to contain 
an additional glutathione so prior to oxidative refolding the samples were reduced. 
Ni2 affinity purified protein samples (30-6OpM) were reduced with 10mM DTT for 3h 
at 37°C to afford a pale orange / brown solution. The reducing agent was then removed 
by dialysis against 6M guanidine.HC1, 50mM tris.HC1; pH8 under Nitrogen. The 
dialysis procedure was monitored using Ellmans reagent: A 1 .Oml sample of the dialysis 
buffer was treated with lOpL 0.1M Elimans reagent and A412nm  was measured. Dialysis 
was complete when A412nm = 0. 
The resulting colourless solution was then diluted 1:50 (0.6-1.2pM) and dialysed 
overnight at 4°C against refolding buffer (2% w/v N-lauroyl sarcosine, 50mM Tris.HC1; 
pH 8, 40.iM CuSO4) and then against 2% wlv N-lauroyl sarcosine, 50mM Tris.HC1; pH 
8 for a further 5h. The protein samples could then be concentrated by loading (via a 
0.45 pm syringe filter) onto a Ni 2 affinity column (equilibrated with 5 column volumes 
of refolding buffer) and eluted with refolding buffer containing 500mM imidazole. 
Yields for the refolding step were determined by UV A280 and found to be in excess of 
80%. 
Renaturation of His 10-EPO Samples (PROTOCOL II: Pulsed Refolding 
Technique). 
EPO samples expressed in E. coli were found to be expressed in an oxidised form with 
formed disulfides. In the case of the cysteine mutants the proteins were found to contain 
an additional glutathione so prior to oxidative refolding the samples were reduced. 
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Ni2 affinity purified protein samples (4.Oml, 30-6O.iM) were reduced with 1mM 
Tricarboxyethyl phosphine (TCEP) for lh at 37°C to afford a pale yellow solution. The 
reducing agent was then removed by dialysis against 6M guanidine.HC1, 50mM 
tris.HC1; pH8 under Nitrogen. The dialysis procedure was monitored using Elimans 
reagent: A 1 .Oml sample of the dialysis buffer was treated with 1 OtL 0. 1M elimans 
reagent and A412nm was measured. Dialysis was complete when A412nm = 0. 
The resulting colourless solution was then added at a rate of 500 PL per hour to 400m1 of 
refolding buffer (2% wlv N-lauroyl sarcosine, 50mM Tris.HC1; pH 8, 40.iM CuSO4) 
with stirring and then stirred overnight at 4°C. The protein solution was then 
concentrated by loading (via a 0.45pm syringe filter) onto a Ni 2 affinity column 
(equilibrated with 5 column volumes of refolding buffer) and eluted with refolding 
buffer containing 500mM imidazole. Yields for the refolding step were determined by 
UV A280 and found again to be in excess of 80%. 
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6.2 Experimental Details For Chapter 3. 
Protein Electrospray Mass Spectrometry. 
General Experimental Details: 
Mass spectrometry of protein samples and modified protein samples was carried out on a 
Micro-Mass Platform ESI mass spectrometer. Data was analysed using mass lynx v2.3 
software. 
For off-line LC-MS, HPLC was carried out on a WATERS HPLC system (Waters 600 
controller connected to a WatersTM tuneable absorbance detector set at 280nm. Flow 
rate = l.Omlmin'. 
Samples were lyophilised on a savant speed vac plus SC  1OA 
For on-line LC-MS, HPLC was carried out on a Waters 2690 microbore separations 
module connected to a WatersTM tuneable absorbance detector set at 280nm. Flow rate 
= 0.05mlmin 1 . 
Solvents for HPLC were filtered before use. 
Off-Line LC-MS 
Sample preparation: 
1) Samples to be analysed were precipitated out of solutions by the addition of 10 
volumes of 1:1 acetone / methanol. The mixture was then placed in the freezer (-20'C) 
for 5 mins and the precipitate was then collected by centrifugation. The precipitate was 
then dissolved in 70% MeCN, 0.05%TFA (50.tL). 
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All samples were then purified using a PHENOMENEX ATLANTIS C4 (4.6 x 
250mm) reverse phase HPLC column to remove trace amounts of salt and small 
molecules prior to injection into the mass spectrometer. 
HPLC conditions: A = 100% H20, 0.05% TFA B = 100% MeCN, 0.05% TFA 
0-5 mins. 90% A, 10% B - 70% A, 30% B 
5-20mins. 70%A, 30%B - 100%B 
20-30mm 100%B 
30-35mm 100%B - 90%A, 10%B 
35-40min 90%A, 10%B 
1 .Oml fractions were collected and those containing protein were lyophilised. The 
lyophilised protein samples were then dissolved in 75% MeCN, 0.1% AcOH, 0.025 - 
0.05% TFA or 75% iPrOH, 0.5% AcOH, 0.025 - 0.05% TFA (100tL) and injected into 
the mass spectrometer by means of an automatic infusion pump (15Lmin 1 ). 
ESI spectra were recorded at a cone voltage of 70V (full experimental details are in 
appendix I) 
On-Line LC-MS 
Alternatively, and to minimize handling samples were analysed by on-line LC-MS: 
Analysis of Intact or Unmodified WT, C24, C38 and C38/83 EPO Samples. 
Unmodified His 10-WT and Mutant EPO's were analysed directly after Ni 2 affinity 
chromatography after reduction with 10-50mM DTT at 37°C for 0.5h (although LC-MS 
can be carried out on unreduced samples, unreduced samples give very poor, often 
unresolvable charge spectra) 
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Samples were then purified using a PHENOMENEX Jupiter, microbore, C4 (1 x 
1 50mm) reverse phase HPLC column (to remove trace amounts of salt and small 
molecules) coupled to ESI-MS. 
Acetamidation and Glycosylation of Fully Reduced Protein Samples. 
Column purified protein samples (typically 100 jtL; 60tM, —0.1mg) were reduced by the 
addition of DTT to a final concentration of 10mM. The samples were then incubated at 
37°C for 0.5h. The fully reduced protein samples were then separated from excess 
reducing agent by precipitation, using 10 volumes of 1:1 Acetone! Methanol as 
previously described. The resulting precipitate was then redissolved in alkylation buffer 
(6M guanidinium hydrochloride, 0.5M Tris.HC1; pH 8, 20mM EDTA). lodoacetamide 
or glycosyl iodoacetamide was then added to a final concentration of 10mM and the 
reaction mixture was allowed to stand at room temperature for 16h with the exclusion of 
light. The reaction was monitored by removing 10tL aliquots from the reaction mixture 
and the modified protein samples were analysed directly using On-line LC-MS. 
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Experimental Details For Chapter 4. 
General Experimental Details. 
Infrared spectra were recorded for Nujol suspensions or chloroform solutions using a 
Bio-Rad FTS 7 Interferometer coupled to a Bio-Rad SPC 3200 Processor, and a Perkin-
Elmer FT Spectrophotometer. In bands were strong and sharp unless specified as w 
(weak), br (broad) or vs (very strong). 
'H N.M.R. spectra were measured from the stated solvents on Brucker WP 200 SY, WP 
250 SY, WP 360 SY and Varian 200MHzGemini2000 spectrometers. Signals were 
sharp unless specified as br(broad); and s = singlet, d = doublet, t = triplet, q = quartet 
and m = multiplet. ' 3C NMR spectra were obtained at 62.9MIHz (250MHz spectrometer) 
and 90.6MHz (360MHz spectrometer) 
Mass spectral data was obtained using A.E.I. MS-902 and Kratos MS-50TC instruments. 
Fast atom bombardment (FAB) spectra were measured from matrices in thioglycerol - 
acetonitrile or nitrobenzyl alcohol - acetonitrile. 
C, H, N, Analyses were obtained using a Carlo-Erba Elemental analyser model 1106. 
Unless otherwise stated melting points of samples were determined on Griffin melting 
point apparatus and are uncorrected. 
Where necessary, atmospheric moisture was excluded by connecting a drying tube filled 
with fused calcium chloride to a water condenser. 
All organic extracts were dried over anhydrous magnesium sulfate or sodium sulfate 
prior to evaporation under reduced pressure. Solvents used were of technical grade 
unless otherwise specified. 
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Wet column flash-chromatography was carried out over silica (Merck Grade 60). TLC. 
was carried out using Polygram SIL F! UV 254 pre-coated aluminium sheets 
General Synthesis of Glycopyranosyl Amines (19)129 






HO 	 HO 
NHAc 	 NHAc 
OH 
A solution of N-acetyl-a-D-glucosamine in the minimum volume of saturated aqueous 
NH4HCO3 and was stirred at room temperature for 5 days. Further additions of 
NH4HCO3  were made throughout this period to ensure that the solution remained 
saturated. 
The reaction mixture was then diluted with water and frozen in a bath of liquid nitrogen 
while spinning on a rotary evaporator (to give the maximum surface area) and freeze 
dried. This procedure was repeated (usually three times) until the flask reached constant 
weight affording a pale yellow solid which was used without further purification, 
Rf0.22(ethyl acetate: methanol 1:1) m1z222. 1 196(M+2 2 ,l00%), C8H18N205 requires 
222.1216. 
General Synthesis of G1ycosyl--N-Iodoacetamides. 
To a solution of the glycosyl amine (15mg, 6.8x10 5) in 1M NaHCO3 (300tL) was 
added iodoacetic anhydride (120mg, 3.4x10 4). The reaction was then stirred at room 
temperature in the absence of light. After 2h TLC indicated that the reaction was 
complete. The reaction mixture was then diluted with water (1cm 3) and then passed 
over a short column of AG50W-X8 resin (hydrogen form) and the eluent was then 
passed through a short column of AG l-X2 resin (hydroxide form). The eluent was then 
lyophilised to obtain the product (24mg, 91%) as a colourless solid. 
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2-Acetamido-2-Deoxy-3, 4, 6-Tri-O-Acetyl-a-D-Glucopyranosyl Chloride (36)136 




HO 	 AcO- 
NHAc 	 JHAc 
OH CI 
N-Acetyl glucosamine (5.00g; 22.6mmol) was added to stirring acetyl chloride 
(10.0cm3) and the resulting suspension was stirred magnetically for 16h. Chloroform 
(40.0cm) was then added to the amber solution and the resulting solution was poured 
into ice (40.0g) and water (10.0cm 3) with stirring. The organic layer was immediately 
separated and run into saturated aqueous NaHCO 3 (40.0cm3) and ice with stirring, the 
neutralisation being completed in a separating funnel. The organic layer was then 
separated and dried for 1 Omins. The organic layer was then filtered with suction and the 
residue washed thoroughly with dichioromethane. The resulting orange solution was 
concentrated to approximately 10cm 3 under vacuum. Anhydrous ether (50.0cm 3) was 
then added and the product crystallised out immediately. The product was stoppered 
and left to stand at room temperature for 16h. The pale yellow solid was then filtered 
with suction, washed with anhydrous ether (2x 15.0cm 3) and allowed to dry for 5 
minutes to afford the crude product which was subsequently purified by flash 
chromatography over silica (100% ethylacetate) to afford the product (4.17g; 50%) as a 
colourless crystalline solid, mpt. 124-125°C (lit. 127128°C), Umax 3239(NH), 1742 and 
1642(CO) cm', oH (250MHz; CDC1 3) 6.17(1H, d, J3.8Hz, H-i), 5.86(1H, d, J=8.7Hz, 
NH), 5.31(1H, dd, J=9.8Hz, H-3), 5.19(lH, dd, J=9.6Hz, H-4), 4.57-4.46(1H, m, H-2), 
4.31-4.06(3H, m, H-6b, H6a and H-5), 2.09(3H, s, COCH3), 2.04(6H, s, 2xCOCH3) and 
1.97(3H, s, COCH3), Found: mlz (FAB-MS), 366(M, 90%), 330(M-Cl, 100%), 
C 141120N08C1 requires mlz, 366 (Mt). 
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To a solution of the glucosyl chloride (36) (1.00g; 2.7mmol), TBAHS (0.92g; 2.7mmol) 
and sodium azide (0.53g; 8.1 mmol) in dichioromethane (10.0cm 3) was added saturated 
aqueous NaHCO3 (10.0cm3). The resulting biphasic solution was stirred vigorously at 
room temperature for lh. 
Ethyl acetate (100.0cm 3) was then added and the organic layer was separated and 
washed with saturated aqueous NaHCO 3 (1 x20.Ocm 3), water (2x20.Ocm 3) and saturated 
aqueous NaCl (lx 10.0cm 3). The organic phase was then dried over Na 2SO4 and the 
solvent removed under vacuum to afford the pure (by TLC) azide (0.91g ; 91%) as a 
white solid mpt. 158161°C (lit. 166-167°C), Umax 3622 (NH), 2118 (N 3), 1747 and 1642 
(CO) cm', oH (250MHz; CDC1 3) 5.84(1H, d, J8.9Hz , NH), 5.24(1H, dd, J=9.7Hz, H-
3), 5.08(1H, dd, J=9.7Hz, H-4), 4.76(1H, d, J=9.3Hz, HI), 4.26(1H, dd,JH6 a H6b =12.5Hz 
JH6b-H5 =4.8Hz, H-6b), 4. 14(1H, dd, JH6aH5 =2.4Hz, H6 a), 3.90(1H, m, H-2), 3.82-3.75(1H, 
m, H-5) and 2.09, 2.02, 2.01, and 1.96(12H, 4s, COCH 3 )ppm, Found: mlz (FAB-MS), 
373 (MW), C 14H20N408 requires mlz, 372.3 (M). 














To a solution of the per-acetate (1.0g, 2. 57rnmol), in freshly distilled DCM (15.0cm 3) 
containing SnCL (1.OM in anhydrous DCM, 0.93mmol, 932tL) under nitrogen was 
added azido trimethylsilane (800tL, 6.04mmol) and the reaction mixture was stirred at 
room temperature. 
After 20h the reaction mixture was diluted to 50cm 3 with DCM and washed with 10% 
K2CO3 (3x20.Ocm 3) and brine (2x20.Ocm 3). The organic layer was then dried and the 
solvent was removed under vacuum to afford the product (homogeneous by TLC) as a 
white solid (954mg, 99%). Analytical data as above. 











A solution of the glycosyl azide (17) (1.50g; 4.Ommol) in anhydrous THF (27.0cm 3) was 
catalytically hydrogenated at atmospheric pressure with Pt0 2 for lh. 
The catalyst was then removed by filtration through Celite and the filtrate was 
evaporated to dryness under vacuum to afford the pure (by TLC) amine (1.03g; 74%) as 
a pale grey solid mpt.=159°C Umax 1744 and 1682 (CO) cm' ,SH (250MHz; CDC1 3) 
5.72(1H, d, J=8.9Hz ,NH), 5.10-5.00(2H, m ,H-3 and H-4), 4.20(1H, dd, JHH6b =12.3Hz 
JH6b-H5 = 4.8Hz, H-6b), 4.13-3.97(2H, m, H-6 3 and H-2), 3.99(1H, d, J=9.5, H-i) 3.66-
3.60(1H, m, H-5) and 2.08, 2.02, 2.0 1, and 1.96(12H, 4s, 4xCOCH 3), Found: m/z (FAB-
MS), 347(MW , 44%), 330(M-NIH2, 66%), C 14H22N208 requires mlz, 346.3 (W). 
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2-lodo-Acetyl Chloride (45). 
Thionyl chloride (0.1cm3 ; 1 .3Ommol) was added dropwise over 5 mins. with stirring to 
iodoacetic acid (200mg; 1 .O8mmol) and the resulting pink suspension was stirred at 
room temperature with the exclusion of atmospheric moisture and light. 
After 24h the excess thionyl chloride was removed under vacuum to afford the acid 
chloride (214 mg, 97.2%) as a pink oil. 8H  (250MHz; CDC13) 4.23(s, CH 2I), ö (CDC13) 
167. 12(COC1) and 4. 12(CH2I), Found: mlz (EI-MS), 203.9 (Mt), C 21-1200I requires 









NHAc 	 -40°C 
OAc 
H 




A solution of the protected glucopyranosylamine (44) (187mg; 0.54mrnol) in anhydrous 
DCM (4.0cm) was treated with pyridine (0.044cm 3 ; 0.54mmol) and cooled to -40°C 
with the exclusion of light under Nitrogen. This solution was then treated dropwise with 
stirring with 2-iodo-acetyl-chloride (110mg; 0.54mmol) and the reaction mixture was 
stirred at -40°C. 
After 0.5h the reaction was quenched with chloroform (40.0cm 3) and the resulting 
yellow solution was washed with saturated aqueous NaHCO3 (2x15.Ocm 3) water 
(lx 15.0cm3). The organic phase was then dried, filtered, concentrated under vacuum to 
approx. 2cm3 and then co-evaporated with toluene (2x5.Ocm 3) to afford the 
iodoacetamide (264mg; 95%) as a yellow solid mpt.=200-202°C(decomp.), u 1745 
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and 1684(CO) cm' , 6 (250MHz; CDC13) 7.65(1H , d, J=8.lHz, NH), 6.57(1H, d, 
J=8.4Hz, NH), 5.15-4.98(3H, m, H-i, H-3 and H-4), 4.29(iH, dd, JH6bH6a =12 . 5HZ, JH6b-
H5=4.3HZ, H-6b), 4.22-4.12(1H, m, H-2), 4.08(1H, dd, J 65 =2.1Hz, H6a), 3.793.73(1H, 
m, H-5), 3.62(2H, s, CH2I) and 2.07, 2.06, 2.03 and 1.99(12H, 4xs, 4xCOCH3 ), Found: 
36.5%C;4.3%H;5.2%N, mlz (FAB-MS), 515(MH, 63%), 389(M-I, 41%) C 16H23N2091 
requires 37.4%C;4.5%H;5.5%N, m,/z, 515 (MW). 
2_Acetamido-2-Deoxy-1-N-L1-(2-Iodo)Acetyl]-13-D-GlucopyraflOSe (40).' 
–OAc 	 OH 
NaOMe 




N  NHAc 
0 	 0 
The iodoacatamide (46) (65.0mg; 0. l3mmol) as a solution in anhydrous methanol 
(10.0cm3) was treated with a solution of sodium methoxide in methanol (0.5M; 
0.078cm3) under nitrogen with the exclusion of light and the resulting solution was 
stirred at room temperature for A. 
The solution was then treated with a solution of N11 4C1 (0.5M; 0.078cm3) and the 
solvent was removed under vacuum. The residue was dissolved in water (14.0cm 3), 
extracted with ethyl acetate (2x3.5cm 3) and the aqueous layer was evaporated to dryness 
to afford the pure (by TLC) deprotected product (56.4mg; 100%) as an orange solid. 
Rf=0.68 (CHC13: MeOH:H20, 12:12:3), H  (250MHz; D20) 5.33(1H , d, J=9.7Hz ,H-1), 
3.82(iH, dd, JH6a H6b12.3HZ JH6b4I52.1Hz, H-6b), 3.76(1H, dd, J 2 ,3 =9.8Hz, H-2), 
3.69(1H, dd, J6 =4.8Hz, H-6a), 3.67(2H, q, JAB =10.0Hz, CH2I), 3.55(1H, dd, J34 
=9.5Hz, H-3), 3.45(1H, m, H-5), 3.42(1H, dd, J4 ,5 =10.111z, H-4) and 1.98(3H, s, 
COCH3), 6 (D20) 174.7 and 173.1 (CO), 78.6(C(1)H), 77.7 (C(5)H), 74.1(C(3)H), 
69.4(C(4)H), 60.4 (C(6)H 2 ), 54.3 (C(2)H), 22.4(COH 3) and -3.6(CH2I), Found: mlz 
(FAB-MS), 389.019 (MB'), C 1014 17N2061 requires mlz, 389.020 (MH). 
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N-N-Diacetyl-L-Cystine Dimethyl Ester (48) 139 
Triethylamine (0.58g; 5.8mmol) was added to L-cystine dimethyl ester dihydrochioride 
(47) (1.0g; 2.9mmol) as a suspension in chloroform (15.0cm 3). Acetic anhydride 
(3.0cm3) was then added and the resulting solution was stirred at room temperature for 
1 h. 
The reaction mixture was then washed with water (2x5.Ocm 3) and then separated and the 
organic layer was dried and the solvent was removed under vacuum to afford the 
product (0.89g; 87.6%) as a white crystalline solid mpt. 118-122°C, Um,, 3425 (NH) and 
1742 and 1674 (CO) cm', oH (250MHz; CDC1 3) 6.62(2H, d, J=7.4Hz, 2xNH), 4.88-
4.80(2H, m, 2xCH), 3.75(6H, s, 2xCO 2CH3), 3.18(4H, dd, J=5.lHz J=2.9Hz, 2xCH 2 S) 
and 2.04(6H, s, 2xCOCH3), 8 (CDC13) 170.8 and 170.1(CO), 52.6(aCH), 51.5 
(COH3 ), 40.4 (CH2S) and 22.9(COcH3). 
N-Acetyl-L-Cysteine Methyl Ester (49) 140 
A solution of N-N-diacetyl-L-cystine dimethyl ester (48) (200mg; 0.57mmol) in 
methanol (10.0cm 3) was stirred and zinc powder (0.37g; 5.7mmol) was added. The 
resulting suspension was cooled to 0°C and treated dropwise with concentrated HC1 
until TLC indicated no starting material was present (0.1cm 3 of HC1 added in total). 
After 2.5h.the reaction mixture was diluted with DCM (30.0cm 3) and the colourless 
solution was washed with water (lxlO.Ocm 3), dilute NaHCO 3 (lxlO.Ocm3) and then 
water (lx 10.0cm 3). The solution was then dried and the solvent was removed under 
vacuum to afford the product (84.5mg, 42%) as white crystalline solid mpt. 76-80°C, 
Umax 3432 (NH), 1741 and 1672 (CO) cm', OH (200MEIz; CDC13) 6.80(1H, s(br), NH), 
4.86-4.80(1H, m , CH), 3.72(3H, s, CO 2CH3 ), 2.93(2H, dd, J=9.2Hz J=4.4Hz, CH 2S), 
2.01(3H, s, COCH3), and 1.39(1H, t, J=9.OHz, SH), O (CDC1 3) 170.5 and 169.7 (CO), 
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53.4(CH), 52.7 (COH 3 ), 26.7 (CH2 S) and 23.0(COcH3), Found: mlz (FAB-MS), 
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A solution of N-acetyl-L-cysteine-methyl ester (20mg; 0.11mmol) and the deprotected 
iodoacetamide (40)(43mg; 0.1 immol) in ammonium carbonate (50mM, 20.0cm3) was 
stirred at room temperature with the exclusion of light. 
After lh the solvent was removed under vacuum to afford the crude product as a yellow 
solid which was taken up in water (3.0cm 3), co-concentrated with methanol (3x3.Ocm 3) 
and lyophilised to again obtain a yellow solid. This solid was then dissolved in 
methanol, filtered and the solvent was removed under vacuum to afford the crude 
product which was purified by flash chromatography over silica (EtOAc:MeOH, 1:1) to 
obtain the pure cysteine derivative (47. ling, 97.9%) as a pale yellow solid mpt. 59-65°C, 
H (360M}Iz; D20) 5.13(1H, d, J=9.8Hz, H-i), 4.71(1H, dd, J=8.lHz J=5.OHz, 
CIICH2S), 3.94(1H, dd, JH6aH6b =12.3Hz JH6H52.0HZ, H-6b), 3.90(1H, dd, J 23 =9.9Hz, H-
2), 3.83(3H, 5, CO2CH3), 3.80(1H, dd, JH6a-H5 =4.8Hz, H6 a), 3.69(1H, dd, Ji =10.1, 
J2=8.5Hz, H-3), 3.59-3.57(1H, m, H-5), 3.54(1H, dd, J=9.8Hz, H-4), 3.38(2H, q, JIB  
=15.3Hz, COCH2S), 3.15(1H, dd, JHa.fTh  =14.1Hz J cH5.0Hz, CHCU2S), 3.00(1H, dd, 
JHa CH8.2HZ, CHCJI2S) and 2.11 and 2.07(6H, 2xs, 2xCOCH 3)ppm. 8c (D20) 174.6, 
174.2, 172.8 and 172.3(CO) , 78.6(C(l)H), 77.6(C(5)H), 73.9(C(3)H), 69.4(C(4)H), 60.5 
(C(6)H2), 54.2(C(2)H), 53.2(COH 3), 52.4(HCH2S), 35.2(COCH2S), 32.9(CH2S) and 
22.0 and 21.6(2xCOCH 3), Found: m!z (FAB-MS), 438(MW, 73%) and 460(MINa, 
100%), C 16H27N309S requires mlz, 438 (MW). 
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Glutathione Derivative (52) 1 . 
The iodoacetamide (40) (43mg; 0.1 immol) was added to a solution of glutathione 
(34.4mg; 0.1 immol) in 50mM ammonium carbonate (50.0cm 3 , pH8). The resulting 
solution was stirred at room temperature with the exclusion of light and monitored using 
Elimans reagent to detect the free thiol groups. Ellmans reagent (0.01M; 0.0 1cm 3) was 
added to an aliquot (0.0 1cm 3) in ammonium carbonate solution (50mM, 1.0cm3) and the 
absorption peak at 412nm was measured using UV spectroscopy. The reference cell 
contained the initial glutathione solution (0.0 1cm) in ammonium carbonate solution 
(50mM; 1.0cm). 
After 2.5h the the reaction mixture was lyophilised and the crude product was dissolved 
in water (2.0cm 3) and co-concentrated with MeOH (3x10.Ocm 3) and the water was 
removed under vacuum to afford the product (65mg; 104.2%) as a pale yellow solid (1 
spot by TLC),H (360MHz; D 20) 5.15(1H, d, J=9.7Hz, H-i), 4.65(1H, dd, J 1 8.6Hz 
J2=5.OHz, (xCffCH2S), 3.94(l H, dd, JH6a.H6b 10.6Hz JH6H5=1.8Hz, H-6b), 3.90(1H, t, J 23 
=9.9Hz, H-2), 3.85-3.78 (411, m, H6 a, CU2CO2H and cxCH), 3.70(1H, t, J9.3Hz, H-3), 
3.62-3.58(1H, m, H-5), 3.54(1H, t, J=9.lHz, H-4), 3.39(2H, s, COCH 2S), 3.13(1H, dd, 
JHa-Hb =14.0Hz J cH5.0HZ, CHCILS), 2.96(iH, dd, JH a.CH8.8HZ, CHCII2S), 2.63 
2.54(2H, m, COCCH2), 2.24-2.18(2H, m, CthCH) and 2.05(3H, s, COCH3), öc (DO) 
174.6, 174.2, 172.8 and 172.3(CO), 78.6(C(1)H), 77.6(C(5)H), 74.0(C(3)H), 69.4 
(C(4)H), 60.5(C(6)H 2), 54.2(C(2)H), 54.0(cHCH2), 52.9(HCH2S), 43 .3(H2CO2H) 
35.2(COCH2S), 33 .5(CH2S), 31 .3(cH2CONH), 26.1 (aCHH2CH2) and 22.1 (COH 3), 
Found: mlz (FAB-MS), 568 (MH), C20F133N5012S requires mlz, 567 (MW). 
Control Experiment for the Derivatisation of Glutathione. 
This experiment was run exactly as above except that no glycosyl iodoacetamide was 
added to the glutathione in solution. The number of free thiol groups were monitored 
over three hours. 
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2-Acetamido-2-Deoxy-1-N- [l-(2,2-Iodo, 13C)AcetylJ43-D-Glucopyranose(53). 
The 13C labelled, deprotected glycosyl iodoacetamide (53) was prepared as above for 2-
acetamido-2-deoxy- 1 -N-[ 1 -(2-iodo)acetyl]-3-D-glucopyranose from 2-acetamido-2-
deoxy-3,4,6-tri-O-acetyl--D-glucopyranosy1 amine and the 13C labelled 2-iodo acetyl 
chloride in 86% yield over all three steps from the 13C labelled iodoacetic acid. The 13C 
labelled iodoacetamide was obtained as a yellow solid. The 13C NMR spectrum of the 
labelled material affords an intense 13C peak at -3.14ppm, Found: m/z (FAB-MS), 390 
(MH, 11%). 
'3C Labelled Glutathione Derivative (52). 
This experiment run exactly as above for (52) except that the 13C labelled glycosyl 
iodoacetamide (53) was used. 
After 5.25h the solvent was removed under vacuum to afford the crude product as a 
yellow solid which was dissolved in water (5.0cm 3) and co-concentrated with MeOH 
(5x5.Ocm 3). On the addition of methanol (10.0cm3) the product precipitated out of 
solution and the white glutathione derivative (38mg; 61%) was collected by filtration 
and dried under vacuum. The ' 3C NMR spectrum of the glutathione derivative afforded 
a very intense peak at 35.18ppm, Found: mlz (FAB-MS), 569.19475(MW, 73%), 
C20H34N5012S requires m/z, 569.19528 (MW). 
4,6-0-p-Methoxybenzylidine-D-Glucal (62)48. 
Oft 





Zn C 12 
To a solution of tri-O-acetyl-D-glucal (61) (2.0g) in anhydrous methanol (10.0cm 3), 
under nitrogen, was added a solution of NaOMe in methanol (0.5M, 200tl, lxi 0mol). 
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After 1.5h the reaction was quenched by the addition of NH 4C1 (0.5M, 200.tL, 1x10). 
The solvent was removed under vacuum and the deacetylated product (1.0g, 6.8mmol), 
and anhydrous ZnC1 2 (0.6g, 4.4mmol) were taken up in p-anisaldehyde (2.0cm 3 , 
16.4nimol) and stirred at room temperature. 
After 1 6h the green reaction mixture was treated with a solution of Na2CO3 (10% w/v, 
10.0cm3) with stirring. The precipitated Zn(OH)2 was then filtered off with suction and 
the precipitate was washed with water (20.0cm 3) and ether (50.0cm 3). The organic 
phase was separated and the aqueous phase was extracted with ether (5x50.Ocm 3). The 
combined organic extracts were dried [Na2SO4], filtered, and the solvent was removed 
under vacuum to afford the crude product as an orange oil which was purified by flash 
chromatography over silica (100% CHC1 3 , then 3:2 EtOAc / Pet. Ether 40-60°C) to 
afford the pure product (0.33g, 20%) as a white solid. R=0.53 (3:2 EtOAc / Pet. Ether 
40-60°C), oH (200MHz; CDC13) 7.42(2H, d, J=8.9Hz, 2xArff),  6.89(2H, d, J=8.9Hz, 
2xArfl ), 6.32(1H, d, J=6.2Hz, H-i), 5.54(1H, s, ArCij), 4.76(1H, dd, J 1 ,2=6.2Hz, 
J2,3=2.OHz, H-2), 4.51-4.46(1H, m, CH), 4,37-4.31(1H, m, CH), 3.95-3.73(5H, m, OCH3 
and CH and CH) and 2.31(1H, d, J=5.3Hz, OH)ppm. O (CDC1 3) 160.2(qC, (OMe)), 
144.0(CH), 129.4(qC), 127.4(2CxH, rn-ArCH), 113.6 (2xCH, o-ArCH), 103 .4(CH, 










To a stirred solution of the glycal (62) (0.25g, 0.95mmol )in anhydrous DCM (5.0cm 3) 
was added imidazole (0.16g, 2.4mmol) and TBDMS-chloride (0.18g, 1 .2mmol). The 
resulting suspension was stirred at room temperature. 
After 1 .5h water (30.0cm3) was added and the organic phase was separated. The 
aqueous phase was then extracted with CH2C12 (3x10.Ocm 3) and the combined organic 
extracts were dried [Na2SO4], filtered, and the solvent was removed under vacuum to 
afford the crude product as a yellow oil. The oil was purified by flash chromatography 
over silica (95:5 Pet. Ether 40-60°C / EtOAc) to afford the pure product (267mg, 75%) 
as a colourless oil. R=0.47 (9:1 Pet. Ether 40-60°C / EtOAc), 6H (250MHz; CDC13) 
7.42(2H, d, J=8.9Hz, 2xArfl), 6.89(2H, d, J=8.9Hz, 2xArfl), 6.29(1H, d, J=6.2Hz, H-
1), 5.54(1H, s, ArCU), 4.67-4.64(1H, m, CH), 4.51-4.47(1H, m, CH), 4.34-4.31(1H, m, 
CH), 3.88-3.73(5H, m, OCH 3 and CH and CH), 0.89 (9H, s, 'Bu) and 0.09 and 0.07(6H, 
2xs, 2xCH3)ppm. ö (CDC1 3) 159.8(qC, (OMe)), 143.2(CH), 129.8(qC), 127.1(2CxH, 
rn-ArCH), 1 13.4(2xCH, o-ArCH), 105.3(CH, CHAr), 1 10.1(CH,C-1), 80.4(CH), 
68.7(CH), 68.2(CH2, C-6), 67.2(CH), 55.(CH 3 , OCH3) 25.7(3xCH 3, tBu), 18.1(qC, tBu) 
and —4.5 and —4.9(2xCH3, TBMS). C20H3005Si requires mlz=378.54, found mlz (ESI-
MS), 378.5(M, 100%). 
4-p-Methoxybenzyl-3-tButyldimethylsilyl-D-Glucal (64)48. 
0 	 0 
0 
TBDMSO 
HO 	 0 
DIBAL-H 	 PMBO \ 
IM 	
TBDP$O 
A solution of the protected glycal (63) (200mg, 5.28x 10mol) in anhydrous DCM 
(5.0cm3) cooled to -20°C was stirred under nitrogen. A solution of DIBAL-H (1M in 
toluene, 2.11cm3 ; 2.1 1x10 3mol) was then added dropwise. 
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After 3h the reaction was quenched by the addition of methanol (0.25cm 3). The reaction 
mixture was then diluted with EtOAc (5.0cm3) and then a solution of K-Na tartrate 
(20%w/v, 2.5cm 3) was added. The resulting solution was stirred at room temperature 
for lh. The mixture was separated and the aqueous phase was extracted with EtOAc 
(3x5.Ocm 3). The combined organic extracts were dried [Na2SO4], filtered, and the 
solvent was removed under vacuum to afford the crude product as a colourless oil. The 
oil was purified by flash chromatography over silica (Pet. Ether 40-60°C / EtOAc) to 
afford the pure product (162mg, 81%) as a colourless oil. R=0.5 (70:30 Pet. Ether 40-
60°C / EtOAc), 6H (200MHz; CDC13) 7.27(2H, d, J=8.9Hz, 2xArU), 6.87(2H, d, 
J=8.9Hz, 2xArki), 6.31(1H, d, J=6.lHz, H-i), 4.68(2H, q, J=11.3Hz, ArCH2), 
4.66(iH, dd, J 1 26.1Hz, J23=2.9Hz, H2), 4.35-4.31(1H, in, CH), 3.96-3.91 (1H, m, CH), 
3.89-3.79(5H, m, OCH3 and CH and CH), 3.63-3.57, (1H, m, CH), 2.03(1H, s(br), OH), 
0.90(9H, s, 'Bu) and 0.1(6H, s, 2xCH3)ppm. 6 (CDC13) 159.2(qC, (OMe)), 
143.4(CH), 129.9(qC), 129.5(2CxH, rn-ArCH), 1 13.8(2xCH, o-ArCH), 103.4(CH), 
76.2(CH), 73.4(CH2), 68.5(CH), 61.8(CH2, C-6), 55.2(CH3, OCH3) 25.7(3xCH3, tBu), 
17.9(qC, tBu) and —4.5 and —4.7(2xCH3, TBMS). C20H3305Si requires m/z=380.56, 
found mlz (FAB-MS), 3 79.2 174(M, 100%). 
4-p-Methoxybenzyl-D-GIucal (57)48k 
HO 	0 	 HO\ Q 
p o c \ TaN: 	 po" \ 
__, TBDMSO 	 HO 
TBAF (1M in THF, 0.55m1; 5.52x10mol) was added to a solution of the glycal (64) 
(140mg, 3.68x 10mol) in anhydrous THF (4.0cm3). The resulting pale yellow solution 
was stirred at room temperature. 
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After 16h the solvent was removed under vacuum and the product was purified form the 
pale yellow residue via flash chromatography over silica (Pet. Ether 40-60°C / EtOAc) 
to afford the pure product (98mg, 100%) as a waxy white solid. R=0.43 (80:20 Pet. 
Ether 40-60°C / EtOAc), mpt. 90-92°C, 8. (200MHz; CDC13) 7.39(2H, d, J=8.8Hz, 
2xArfl), 6.97(2H, d, J=8.8Hz, 2xArkf), 6.45(1H, d, J=6.0Hz, H-i), 4.95-4.71(m.(br), 
3H), 4.39-4.35(1H, m, CH), 3.95-3.83(5H, m, OCH3 and CH and CH), 3.70-3.63(1H, m, 
CH) and 3.40(1H, s(br), H)ppm. ö (CDC1 3) 151.3(qC, (OMe)), 135.4(CH), 
122.4(qC), 121.3(2xCH, rn-ArCH), 105.2(2xCH, 0-ArCH), 95.3(CH), 69.9(CH), 
68.3(CH), 65.2(CH2), 60.8(CH), 52.5(CH2), 46.2(CH 3 , OCH3). 
4-p-Methoxybenzaldehyde dimethyl acetal 141 . 
A solution of p-anisaldehyde (30cm 3, 0.25mo1), trimethyl orthoformate (30.2cm 3 , 
0.275mo1) and toluene p-sulfonic acid monohydrate (0.24g, 1 .25mmol) was stirred at 
room temperature for 18h. 
After 18h, sodium carbonate (0.265g, 2.5mmol) was added and the mixture was stirred 
for a further lh. The residue was filtered and the methyl formate was removed on a 
rotary evaporator. The remaining pink solution was distilled to give the acetal (32.28g, 
71%) as colourless oil, bpt=49°C at 0.03nimHg (100°C at 7mmHg 141 ), E (200MHz; 
CDC13) 7.37(2H, d, J=8.8Hz, 2xArH), 6.89(2H, d, J8.8Hz, 2xArH), 5.36(1H, s, CH), 
3.81(3H, s,p-CH30) and 3.31(6H, s, 2xCH 3O)ppm. 
2-Acetamido-2-Deoxy-4,6-O-p-Methoxybenzylidine--D-G1ucopyranosy1 
Azide(66) 141 . 
OAc 
AcO 	 N3 	
NaOW 	
0 	 N3 
NHAc 	 TsOH 	Wo 	 NI-lAc 
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The per-acetylated glycosyl azide was dissolved in anhydrous methanol (10.0cm 3) and 
NaOMe (200tL, 0.5M solution in anhydrous methanol) was added. After 2h the 
reaction was treated with NH4C1 and the solvent was removed under vacuum. The 
residue (125mg, 5.03x10mo1) was dried under high vacuum and dissolved in 
anhydrous DMF (5.0cm 3). p-Methoxy benzaldehyde dimethyl acetal (275mg, 1 .5x 10 
3mol) and p-tosic acid (20mg, 1.21 xl 0mol) were then added and the reaction mixture 
was stirred at room temperature. After 2h the reaction mixture was connected to a rotary 
evaporator and the reaction was continued at 30°C and 30mbar for a further 7h. 
The reaction mixture was concentrated under high-vacuum and then poured into an ice-
cold mixture of DCM (5.0cm3) and sat. aqueous NaHCO3 (5.0cm3) with stirring. The 
precipitate was filtered off with suction and washed with water and DCM. The solid 
was dried under vacuum and crystallised from ethyl acetate to afford the pure p-methoxy 
benzylidine acetal (147mg, 80%) as white crystals Rf=0.38 (100% EtOAc). 
The product was very insoluble and a portion was acetylated in an attempt to increase its 
solubility for analysis. The product was dissolved in pyridine (2.0cm 3). Acetic 
anhydride (1.0cm 3) was added and the reaction was stirred at room temperature.. After 
5h the solution was evaporated under high vacuum. The solid was taken up in water 
(10.0cm3) and DCM (20cm3). The organic layer was separated and washed with 
saturated aqueous NaHCO3 (lx 10cm 3) and again with water (lx 10cm), dried and the 
solvent was removed under vacuum to afford the acetylated product in quantitative 
yield. Rf=0.59(100% EtOAc), 8. (250MHz; CDC1 3/ CD30D) 7.24(2H, d, J=8.9Hz, 
NAM), 6.77(2H, d, J=8.9Hz, 2xArH), 5.37(1H, s, ArCj), 5.08(1H, dd, J3,4=9.3Hz, 
113), 4.55(1H, d, J 1 ,2=9.3Hz, Hi), 4.21(1H, dd, JH6a-H6b 1 0.4, JH6bH5 4.8Hz, H6b), 
3.92(1H, dd, J2,310.211z, H2), 3.69(iH, dd, H6a), 3.68(3H, s, OCH3), 3.60(1H, dd, 
J4,5=9.3Hz, H4), 3.50(1H, m, H5) and 1.95 and 1.85(6H, 2xCOCH3)ppm. 8c, 171.4, 
170.9, 159.8 and 128.8(qC), 127.1(2xArCH), 1 13.2(2xArCH), 101.2(CH), 88.8(CH), 
78.1(CH), 71.4(CH), 68.1(CH), 67.9(CH 2), 54.9(OcH3), 53.3(CH) and 22.2 and 
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20.3(COH3), Found: mlz (FAB-MS), 407(MH, 74%), C 18H22N407 requires mlz, 407.4 
(+) 
2-Acetamido-2-Deoxy-3-Benzyl-4,6-O-p-Methoxybenzylidine-f3-D-Glucopyranosyl 
Azide (67) 11 . 
N3 	




WO 	 NI-lAc 	 NHAc 
The alcohol 0(125mg, 3.43x104mo1), Ba(OH)2.8H20 (250mg, 7.89x10mol) and 3A 
molecular seives were stirred in anhydrous DMF (3.0cm 3) under nitrogen. Benzyl 
bromide (147mg, 8.58x10mo1, 102p.L) was then added dropwise and stirring was 
continued at room temperature. 
After 4h the reaction mixture was diluted with DCM (5.0cm 3) and filtered. The 
precipitate was washed with further DCM (10.0cm 3). The filtrate was washed with 
water (2x 10.0cm 3) and the organic phase was dried [Na2S041, filtered, and evaporated to 
afford the product (129mg, 83%) as a white solid, mpt=175-178(decomp), 8. (250M}Iz; 
CDC13/ CD30D) 7.35(2H, d, J=8.9Hz, 2xArH), 7.25(5H, s(br), 5xArH), 6.86(2H, d, 
J=8.9Hz, 2xArH), 5.48(1H, s, ArCH), 4.86(1H, d, J=9.lHz, H-i), 4.78(2H, q, JAB 
=11.8Hz, CH2), 4.39(1H, dd, JH6a-H6b 1 0.3, JH6bH5 4.8HZ, H6b), 3.98-3.80(7H, m, CH3, 
CH2, 2xCH), 3.97-3.71(1H, m, CH), 3.67-3.55(1H, m, CH) and 1.96(3H, s, 
COCH3)ppm, ö, 170.0, 158.3, 136.4 and 127.8(qC), 126.5(2xArCH), 126.3(2xArCH), 
125.9(ArCH), 125.6(2xArCH), 111.8(2xArCH), 99.5 (CH), 87.1(CH), 80.1(CH), 
75.7(CH), 72.6(CH2), 66.6(d 2), 66.4(CH), 53.6(CH), 53.5(OcH3) and 20.9(COH3), 
Found: mlz (FAB-MS), 455.(MH), C 23H26N406 requires mlz, 455.5(MW). 
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2-Acetamido-2-Deoxy-3-Benzy1-6-p-Methoxybenzy1--D-GIucopyranosy1 
Azide(68)' 41 . 
Na(CN)B143 	PMBO 
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BnO BnO 
NHAc 	 N}-IAc 
Wo"'O 0~ 
A solution of the glycosyl azide (480mg, 1.lxlO 3mol) and Na(CN)BH3(332mg, 
5.28x10 3mo1) in anhydrous DMF (10cm 3) containing 3A molecular sieves was stirred in 
an ice-bath under nitrogen. An ice cold solution of trifluoroacetic acid (81 7L, 10.6x 10 
3mol) in anhydrous DMF (5.0cm3) was then added dropwise and then the reaction 
mixture was allowed to come to room temperature by removal of the ice bath and stirred 
at room temperature for a further 16h under nitrogen. 
The reaction mixture was then filtered with suction and poured into ice-cold saturated 
aqueous NaHCO3 (30.Oml) with stirring. The aqueous phase was then extracted 
chloroform (3x60.0m1), and the combined organic extracts were dried (Na2SO4) and the 
solvent was removed under vacuum to afford the crude product which was purified by 
Rash column chromatography over silica to regain unreacted starting material (129mg, 
27%) and afford the pure product(291mg, 58%) as a white solid. 8 H (250MHz; CDC13) 
7.37-7.21(5H, m, ArH), 7.25(2H, d, J=8.8Hz, 2xArH), 6.87(2H, d, J=8.8Hz, 2xArH), 
5.54(1H, d, J=7.8Hz, NH), 4.90(1H, d, J=9.lHz, H-i), 4.73(2H, q, J =11.7Hz, CH2), 
4.50(2H, q, J =11.6Hz, CH2), 3.82(1H, dd, J=10.2, J=8.6Hz, H3), 3.79(3H, s, OCH3), 
3.76-3.64(3H, m, H-4 and 2xH6), 3.58-3.80(1H, m, H5), 3.43-3.32(1H, m, H2), 
2.94(1H, s(br), OH) and 188(3H, s, COCH 3), & , 170.0, 159.0, and 138.1 (qC), 
129.4(2xArCH), 128.5(2xArCH), 128. 1(2xArCH), 127.9(ArCH), 1 13.8(2xArCH), 
87.7(CH), 79.9(CH), 75 .7(CH), 74.1 (CH2), 73.3(CH2), 72. 8(CH), 69.6(CH 2), 55 .8(CH), 
















To a stirred solution of sodium methoxide (3.0g; 46.3mmol) in anyhdrous methanol 
(75.0cm3) was added glucosamine hydrochloride (10.0g; 46.3mmol). The reaction 
mixture was stirred for 10min at room temperature and then filtered with suction. 
Phthalic anhydride (3.5g; 23mmol) was then added to the filtrate and stirring was 
continued for a further 20mins. A further portion of phthalic anhydride (3.5g; 23mmol) 
was then added followed by triethylamine (7.6m1; 55.6rnmol). The reaction mixture was 
stirred at room temperature for 10 mins and then at 50°C for 0.5h. The resulting mixture 
(containing a thick white precipitate) was cooled for lh in an ice bath and then filtered 
with suction. The precipitate was washed with cold methanol (2x20.Ocm 3) and dried 
under high vacuum. The dry white solid was then suspended in acetic anhydride 
(44.5cm 3), cooled to ice bath temperature and then pyridine (22.7cm 3) was added 
carefully with stirring. The reaction was then stirred at room temperature for 16h. 
After 16h the reaction mixture was poured into ice/water (200cm 3) and extracted with 
chloroform (3x200cm 3). The combined organic extracts were washed with 5% HC1 
(lxi 20cm), saturated NaHCO3 (ix 120cm 3), water (1 x 120cm 3) and brine (lxi 00cm). 
The organic phase was then dried (Na2SO4), filtered and the solvent was removed under 
vacuum to afford the crude product as an orange oil which was purified by flash column 
chromatography over silica (hexane/Ethyl acetate 1:1) to afford the product (8.65g, 
40%) as a white foam. 8. (250MHz; CDC13) 7.86-7.75(4H, m, 4xArfl),  6.50(1H, d, 
J 1 ,210.0Hz, H-i), 5.86(1H, dd, J 3 ,4=9.5Hz, H-3), 5.20(1H, dd, J4 ,5=9.9Hz, H-4), 
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4.45(1H, dd, J2,3=lOHz, H2), 4.37(1H, dd, JH6b-H6a1 1.4Hz, JH6bH54.1Hz,  H-6b), 
4.12(1H, dd, JH6a.H52.911Z, H6a), 4.03(1H, ddd, H-5), 2.11, 2.05 and 2.00 and 1.87(12H, 
4xs, 4xCOCf)ppm. 
2-Phthalamido-2-Deoxy-3,4,6-tri-O-Acetyl-l-Thioethyl-p-D-glucopyranoside(71) 1 44 
OAc 	 OAc 
EtSH 
AcO 0AC SEt 
AcO 	 BF3.OEt2 	AcO 
 AcO'-::)~~
NPhth 	 NPhth 
To a stirred solution of 2-phthalamido-2-deoxy-1, 3, 4, 6-tetra-0-acetyl-3-D-
glucopyranoside (1.0g, 2.09mmol), ethane thiol (263tL, 3.56mmol) and 3A molecular 
sieves in anhydrous chloroform (2.Oml) under nitrogen was added boron trifluoride 
diethyl etherate (464tL, 3.77mmol) and the reaction mixture was stirred at room 
temperature. 
After 16h the reaction mixture was diluted with chloroform (20.Oml) and washed with 
sat. aqueous NaHCO3 (2x20.Oml) and water (1x20.Oml). The organic phase was dried 
[Na2SO4], filtered and the solvent was removed under vacuum to afford the crude 
product as a pale yellow foam which was subsequently purified by flash 
chromatography over silica (Pet. Ether 40-60°C! EtOAc, 3:2) to afford the pure product 
(716mg, 71 %) as a white foam. R=0.26(Pet.ether/EtOAc, 3:2), 6H (250MHz; CDC13) 
7.86-7.71(4H, m, 4xArff 
), 
5.81(1H, dd, J3,4=9.lHz, H-3), 5.47(1H, d, J1,2=10.6Hz, H-i), 
5.160H, dd, J4,5=10.2Hz, H-4), 4.38(1H, dd, J 2,3 10.3Hz, H-2), 4.29(1H, dd, JH6b-
H6a 12.4HZ, JH6bH54.911Z,  H'6b), 4.15(1H, dd, JH6a-H5 =2.3Hz, H-6a), 3.91 -3.85(1H, m, 
H-5), 2.70 and 2.62(2H, 2xdq, J=15Hz, JcH2cH3=7.5Hz), 2.09, 2.02 and 1.84(9H, 3xs, 
3xCOCj) and 1.20 (3H, t, J=7.4Hz, CH3)ppm, 6 (CDC13) 170.6, 169.9, 169.4, 167.6 
and 167.0 (6xqC, 6xCO), 134.3 and 134.2 (2xCH, 2xArCH), 131.5 and 131.0 (2xqC) 
123.6 (2xCH, 2xArCH), 81.1(CH), 75.8(CH), 71.4(CH), 68.7(CH), 62.2(CH2), 
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53.5(CH), 24.2(CE2-CH3), 20.6, 20.5 and 20.3(3xCO-CE and 14.8(CH2-U)ppm. 






AcO 	 P-WO(C6H4)CH(OKAe) 	 HO 
NPhth 	 TsOH MeO 	 NPhth 
Sodium methoxide (0.5M, 0.2cm 3, 1x10) was added to a stirred solution of 2-
phthalamido-2-deoxy-3, 4, 6-tri-O-acetyl- 1 -thioethy1--D-glucopyranoside (0.5g, 
1.04mmol) in anhydrous methanol (10.0cm 3) under nitrogen and the reaction mixture 
was stirred at room temperature 
After lh the reaction was quenched by the addition of glacial acetic acid (10tL). The 
solvent was removed under vacuum and toluene (10.0cm 3) was evaporated from the 
residue. 
The residue was then dissolved in anhydrous DMF (5.0cm 3) and p-methoxy 
benzaldehyde dimethyl acetal (436mg, 2.39mmol) and p-toluene sulfonic acid (45mg, 
0.25mmol) were added. The reaction mixture was then stirred at 50°C. 
After lh the reaction mixture was diluted with toluene (20.Oml) and washed with sat. 
aqueous NaHCO3 (1 x20.Oml). The aqueous phase was separated and extracted with 
further toluene (2x20.Oml). The combined organic extracts were washed with water 
(1x20.Oml), dried [Na2SO4], filtered and treated with silica gel (0.5g) for 5mm. The 
silica was filtered off and the solvent was removed under vacuum to afford the crude 
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product as a yellow oil which was purified by flash chromatography over silica to afford 
the pure product (354mg, 72%) as a white solid. Rf0.41 (3:2 Pet. Ether 40-60°C! 
EtOAc), 8. (250MHz; CDC13) 7.85-7.66(4H, m, 4xArff), 7.39(2H, d, J8.614z, 2xm-
CH), 6.87(211, d, J8.6Hz, 2xo-CH), 5.39(1H, s, CH), 5.37(1H, dd, J 1 ,10.6Hz H-i), 
4.61(1H, dt, J3 ,4=12.2Hz, JH30H3.514Z, W3), 4.35(1H, dd, JH6H6a 9. 91 , JH6b-
H52''4 H-6b), 4.28(1H, dd, J 2 ,3=10.lHz, H-2), 3.813.76(1H, m, H6a), 3.78(3H, 
s(br), OCH3), 3.64(IH, ddd, 11-5), 3.54(1H, dd, J4 ,5 12.2Hz, 14-4) 2.83(IH, d, J=3.514z, 
OH), 2.74-2.59(2H, m, cijzCH3), and 1.71 (3H, t, J7.5Hz, CH 3)ppm. 8c (CDC13) 168.1 
and 167.6(2xqC, 2xCO), 160.1(qC), 134.0(2xCH, 2xArCH), 131.5 and 131.4 (2xqC, 
ArC), 129.2(qC), 127.5(2xCH, 2xArCH), 123.7 and 123.2(2xCH, 2xArCH), 113.6 
(2xCH, 2xArCH), 101.7(CH, CH(0)2), 81.9(d), 81.7(CH), 70.2(CH), 69.3(CH), 
68.4(CH2, C6), 55.3(CH), 55.2(CH3, OCH3), 24.0(ScH2) and 14.7(CH2cH3). 
C24H25N07S requires m/z47 1.5, found mlz (FAB-MS), 472(MH, 59%). 
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Experimental Details For Chapter 5. 
General Method for Refolded Protein Glycosylation with Glycosyl lodoacetamides. 
Ni2 affinity purified EPO samples (3.Oml, 60tM, approximately 3.7mg) were reduced 
and refolded as previously described. The dilute refolded protein was then passed 
through a 0.45p.m syringe filter (50.Oml syringe) onto a column of charged His-bind 
resin (1 .Oml bed volume). After the refolding buffer had drained the immobilised 
protein was eluted (6M guanidine.HC1, 50mM Tris; pH8,400mM imidazole, 2.5m1) and 
the column was washed with further 6M guanidine.HC1, 50mM Tris; pH8 (2.5ml). The 
protein solution (approximately 20tM by UV) was then treated with the glycosyl 
iodoacetamide to a final concentration of 10mM (SOOxexcess). The reaction was then 
mixed on a blood rotator for 24h with the exclusion of light. The reaction was 
monitored by the removal of 0.5m1 aliquots, which were precipitated using 10 volumes 
of 1:1 Acetone! Methanol as previously described. The precipitate was dissolved in 6M 
guanidine.HC1, 50mM Tris; pH8 (20p.L), reduced by the addition of DTT to a final 
concentration of 10mM and heating at 37°C (0.5h), and analysed using on-line LC-MS 
as described previously. The reactions when were complete when no further protein 
modification was observed in the ESI-MS spectrum. 
General Method for 2-Nitro-5-Thiocyanato-Benzoic Acid (NTCBA) Analysis of 
His10-WT and Cysteine Mutant EPO's. 
Column purified protein samples (typically 200p.L; 50tM, 200p.g) were precipitated 
using 10 volumes of 1:1 Acetone! Methanol as previously described and redissolved in 
lOOp.L alkylation buffer (6M guanidinium hydrochloride, 0.5M Tris.HC1; pH 8, 20mM 
EDTA). DTT was then added to a final concentration of 10mM and the samples were 
incubated at 37°C for at least 3h. NTCBA was then added to a final concentration of 
30mM and the resulting bright yellow/orange solution was allowed to stand at room 
temperature for 0.5h. The solution was then acidified to pH 4 with 30% TCA (60p.L) 
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and the modified protein was precipitated from the now colourless solution as above. 
The precipitate was then taken up in 50.tL cleavage buffer (3-6M guanidinium 
hydrochloride, 50mM Tris.HC1; pHI0) and incubated at 37°C for 16h. The reaction 
mixture was then analysed directly using on-line LC-MS. 
Tryptic Digest Analysis of WThEPO. 
50pL of denatured protein samples in (Ni 2  affinity column) elution buffer at 
concentrations of typically 55pM (1 .2mgmt') were diluted with 50pL dH20 and then 
treated with 0.4p.L of 15mgniI 1  trypsin (final protein:trypsin ratio of 20:1) and the 
resulting solution was incubated at 37°C for 16h. After 16h the cleavage was observed 
by LCMS 
Alternatively, fractions were collected from the LC-MS microbore HPLC system (every 
lOmins), lyophilised and the peptide mixtures were submitted for MALDI-TOF analysis. 
Tryptic Digest Analysis of Reduced WThEPO. 
As above except that the EPO sample was reduced with DTT to a final concentration of 
10mM for 0.5 h and then the reducing agent was removed by precipitation of the protein 
sample,prior to incubation with trypsin 
Tryptic/ChymotrYPtic Digest Analysis of Reduced and Immobilised EPO Samples. 
EPO samples were initially reduced with 10mM DTT for lh at room temperature and 
the protein was separated from the reducing agent by protein precipitation as previously 
described. The protein samples were then redissolved in 6M guanidine.HC1 or the 
minimum volume of 3M Guanidine.HC1 and loaded onto a Ni 2 charged His-bind 
column (0.5 ml column bed). Any unbound material was removed by washing with 4 
column volumes (2.Oml) of 3M guanidine.HC1, 50mM TrisHCl; p118 (pH 7.3 for 
chymotrypsin). A solution of TCPK treated trypsin/chymotrypsin (0.1-1.Omgmi 1 ) in 
3M guanidine.HCl 50mM TrisHCl; pH8/pH7.3 (3.Oml) was applied to the column and 
I .Oml of this solution was allowed to drain from the column. The column was then 
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plugged and the immobilised protein samples were exposed to the protease solution for a 
further lh. The protease solution was then allowed to drain from the column and the 
resin was washed with 3M guanidine.HC1, 50mM TrisHCl; pH8 (10.Oml), 6M guanidine 
(1 .Oml) and water (2.0ml). Hydrophillic fragments were then eluted from the column 
with 400mM imidazole and 0.25m1 fractions were collected. 2.5p1 of each fraction was 
spotted onto nitrocellulose membrane for western 'dot-blotting'. Once dry the fractions 
were probed for N-terminal fragments using monoclonal murine anti human EPO 
antibody. Positive fractions were lyophillised. The lyophillised sampled were taken up 
in DCM (0.5m1) to dissolve the imidazole and the peptide fragments were collected by 
centrifugation. The supernatant was discarded and the remaining material was dissolved 
in 1 0tL of 1:1 acetonitrile/Water, 0.1% TFA and 5mM DTT and submitted for MALDI- 
TOF analysis. 
NeoglycoprOteifi Purification. 
Lectin affinity chromatography: 
Glycosylated His io-EPO samples were purified using Bandeiraea simplicfolia II 
lectin 
(Grifffonia simplicifolia II lectin; BS I) immobilised on 4% beaded agarose (0.5m1 
packed column bed volume). The column was initially equilibrated with 50mM sodium 
phosphate buffer; pH 7.2, 150mM NaCl. The sample to be purified was dialysed out of 
the glycosylating reaction mixture and into 50mM sodium phosphate buffer; pH 7.2, 
150mM NaCl overnight at 4°C. This solution was then applied to the column using a 
syringe fitted with a 0.45 tM filter and was allowed to stand at room temperature for 2h. 
The unbound material was then eluted and the column was washed with 50mM sodium 
phosphate buffer; pH 7.2, 150mM NaCl (3x 1 .Oml) to remove unglycosylated protein. 
The glycoprotein was then eluted using the same phosphate buffer containing 500mM 




Experimental Details For Chapter 6. 
General Experimental Details as for Chapter 2 except: 
Deep VentTM DNA polmerase was obtained from New England Biolabs. 
1"  round of PCR (synthesis of the megaprimer). 
Template (double stranded pUC1 8 WThEPO) I .LL 
Primer (N83C) 	 5tL 
Primer (M13) 
IOmMdNTP's 	 5p.L 
ThermopolTM (lOx buffer) 	 5pL 
Deep Vent DNA Polymerase 	 1 tL 
dH20 	
28pL (to a final volume of 50tL) 
The reaction mixture was overlain with 50.tL of oil and subject to the following PCR 
cycling conditions: 
96°C for 5mm 
	 (1 cycle) 
96°C for 30 seconds 
54°C for 15 seconds 
60°C for 1 minute, 15 seconds 	(30 cycles) 
4°C hold 
The PCR product (ca 500 base pairs) was purified by horizontal agarose electrophoresis, 
further purified from the excised gel slice using the Quia-QuickTM DNA purification kit 
and used as a megaprimer for the 2' round of PCR. 
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2H1 Round of PCR. 
Template double stranded pUC 18 WThEPO) 
Primer (N83C megaprimer) 
Primer (NR) 
10mM dNTP's 
ThermopolTM (I Ox buffer) 








20pL (to a final volume of 50 jtL) 
The PCR was then carried out as for the 1 st round of PCR. 
The PCR product (Ca 1000 base pairs) was purified by horizontal agarose 
electrophoresis and further purified from the excised gel slice using the Quia Quick 
DNA purification kit (Quiagen) as before. 
Deep Vent DNA polymerase gave enough of this product to used directly but the PCR 
product (from the 2m1  round of PCR) could be amplified further as follows: 




ThermopolTM  (I Ox buffer) 








28tL (to a final volume of 50pL) 
The PCR products from the second or third round of PCR were digested with Nco I and 
HinDIII to afford a sharp and intense band (Ca 750 
base pairs) corresponding to our 
165 
CHAPTEK2 
amplified fragment. This fragment was purified as before and ligated (as described in 
experimental details for chapter 2) into Nco I! HinDifi cut pUC 1 
8-RBS. 
Single transformants were chosen and screened HinD III (to linearise), 
Nco I and 
HinDIII (to excise the fragment) and HinC II 
(to prove mutation was incorporated) and 
positive clones were fully sequenced as described in experimental details for chapter 2. 
This DNA was then excised form pUC I 8-RBS with 
Nco I and BamH I and ligated Nco 
I! BamH I cut pET 1 6b to reintroduce our new C83 mutant into the expression vector. 
This new construct, pET 16bC83hEPO(C0PT), was then expressed and purified from E. 
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